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Abstract 
RELEVANCE OF FGFR1 AND ITS ISOFORMS IN PROSTATE CANCER BONE 
METASTASES 
  
Estefania Labanca, B.S. 
 
Advisory Professor: Nora Navone, M.D., Ph.D. 
 
 
 
The fibroblast growth factor receptor (FGFR) 1 is implicated in prostate cancer 
(PCa) progression. Various FGFR1 isoforms have been described and we demonstrate 
here that the well-characterized FGFR1 a and b isoforms are correlated with the 
expression of different genes and pathways in human PCa. Direct injection of PC3 PCa 
cells overexpressing FGFR1 isoforms into the femur of mice resulted in enhanced tumor 
growth and reduction in bone volume when compared with PC3 expressing empty vector. 
However, only PC3 overexpressing FGFR1 b was associated with increased osteoclast 
parameters, suggesting that each isoform may mediate diverse biological effects (similar 
findings were obtained when using C4-2B PCa cell line). Also, PC3 PCa cells 
overexpressing FGFR1 a injected intracardially significantly reduced mouse survival (P = 
0.0001) and PCa cells overexpressing FGFR1 a and b increased the incidence of bone 
metastases (P = 0.00005 and P = 0.025 compared to controls). Accordingly, 
immunohistochemical analysis of castration-resistant human PCa bone metastases 
revealed a significant enrichment of FGFR1 expression compared with treatment-naïve, 
non-metastatic primary tumors (P = 0.0007). Importantly, we demonstrate by RPPA 
analysis that FGFR1 induces expression of the anchoring filament protein ladinin 1 
 viii 
(LAD1) in PC3 cells. Furthermore, LAD1 gene amplification and LAD1 expression were 
significantly enriched in castration-resistant human PCa bone metastases (P < 0.0001 
and P = 0.0048 respectively) suggesting that LAD1 is implicated in FGFR1-mediated 
metastases.  
In summary, our studies indicate that FGFR1 drives the PCa metastatic 
phenotype, thus further supporting the development of FGFR blockade as a therapy for 
metastatic PCa. Our results also suggest that new FGFR1 signatures define pathway 
activation and this knowledge will help identify markers of pathway inhibition in human 
PCa. Finally, our findings implicate, for the first time, LAD1 in the metastatic phenotype of 
a subpopulation of men with PCa. 
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Chapter 1: INTRODUCTION  
 2 
This chapter is partly based upon “Navone N.M. and E. Labanca, 2017. Modeling Cancer 
Metastasis. In: Patient-Derived Xenograft Models of Human Cancer. Molecular and 
Translational Medicine. Humana Press, Cham. Y. Wang, D. Lin, and P.W. Gout, editors. 
pp. 93-114”, with permission from Springer International Publishing AG 2017, Springer 
Nature. License number: 4654420161143. 
 
Overview of prostate gland and prostate cancer 
Located below the bladder and surrounding the prostatic urethra, the prostate 
is a small accessory gland of the male reproductive system (Fig. 1A). Its main role is to 
secret fluids that protect the sperm.  
Male sex hormones, androgens, including testosterone and 
dihydrotestosterone (DHT), contribute to prostate growth, in particular, by regulating 
survival and proliferation of prostate cells. Size increases of this gland can be associated 
to several prostate conditions: inflammation, benign prostatic hyperplasia, or cancer 
(Hodson, 2015).  
Prostate cancer (PCa) is the second leading cause of cancer deaths in men in 
the United States (Siegel et al., 2018) and among the most commonly diagnosed cancer 
worldwide (Bray et al., 2018). Genetic and non-genetic components can be associated to 
this disease; the major risk factors being age and ethnicity (Cuzick et al., 2014). 
Among the secretion products of the prostate is the prostate-specific antigen 
(PSA), whose serum levels are currently used as a marker for PCa or other prostate 
abnormalities, since PSA blood levels vary specifically with perturbations of the gland 
(Balk et al., 2003). PSA expression is also androgen-regulated (Kim and Coetzee, 2004).  
Different anatomic regions, or zones, can be distinguished in the prostate: 
central, transition and peripheral (Fig. 1B). Most PCa begin in the peripheral zone. 
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Histologically, the normal human prostate is composed 
of prostatic glands embedded in a non-glandular stroma (Fig. 2A). The glandular 
component is comprised by ducts and acini. Each glandular lumen of the ducts and acini 
is surrounded by an epithelium layer of secretory cells. These cells express androgen 
receptor (AR), are androgen-dependent and produce the molecules that are secreted as 
part of the seminal fluids (e.g. PSA). 
A layer of basal cells encloses these secretory luminal cells. Neuroendocrine 
cells, androgen-independent, and rarely, stem cells, that are AR-negative, can be found 
intercalated in the stratum of basal cells. A basement membrane surrounding the basal 
cells delimits them from the stroma. The non-glandular stroma is mainly fibromuscular 
stroma, and includes nerves, blood vessels and other components. 
Figure 1. Diagram of human male anatomy illustrating 
prostate and surrounding organs (A) and prostate zones (B). 
Adapted with permission from  Hodson, R., 2015. Small organ, 
big reach. Nature. 528:S118. Springer Nature. License number: 
4680960211217 (A) and reproduced with permission from 
Toivanen, R. and M.M. Shen, 2017. Prostate organogenesis: 
tissue induction, hormonal regulation and cell type specification. 
Development. 144:1382.  Company of Biologists. License 
number: 468096084778 (B). 
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A pre-malignant lesion may present as dysplasia, or abnormal growth of cells. 
In PCa, the prostatic intraepithelial neoplasia (PIN) is the most accepted presumed 
precursor of PCa (De Marzo et al., 2016; Haffner et al., 2016; Zhou, 2018). However, it is 
the high-grade PIN (characterized by cells that share many genetic and molecular 
similarities with cancer cells) which is believed to have clonal, temporal, and spatial 
relationships with invasive PCa. The transition between high-grade PIN and invasive PCa 
is believed to result from invasion through the basement membrane into the stroma 
(localized and locally advanced PCa), which can eventually disseminate to other organs 
resulting in metastasis (Wang et al., 2018) (Fig. 2B).  
In most cases, PCa is an indolent, or slow-growing disease that does not 
spread; thus, the survival rate is high for the early stages. However, the 5-year survival 
rate drops from nearly 100% to 29% when the disease has disseminated beyond the local 
Figure 2. Types of cells within human prostatic ducts and acini (A) and stages 
in PCa progression (B). Adapted with permission from Rane, J.K., D. Pellacani, 
and N.J. Maitland, 2012. Advanced prostate cancer--a case for adjuvant 
differentiation therapy. Nature reviews. Urology. 9:595-602. Springer Nature. 
License number: 4680961190809 (A) and Witte, J.S., 2009. Prostate cancer 
genomics: towards a new understanding. Nature Reviews Genetics. 10:77-82. 
Springer Nature. License number: 4680961423948 (B). 
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site (Siegel et al., 2017). Metastatic PCa cells spread through the blood and lymph to 
lymph nodes and bone primarily (Fig. 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Heterogeneity and classification of PCa 
Solid tumors are typically heterogeneous. The existence of a wide variety of clinical 
scenarios, from indolent to lethal, evidence the characteristic heterogeneity of PCa.  
Morphologically, most PCa are adenocarcinomas, and they are classified using 
the Gleason score (Union for International Cancer Control, UICC), which is based on the 
appearance of the tumor under the microscope (Gleason, 1966) (Fig. 4). Because 
Figure 3. A model of PCa progression. PCa starts as a localized 
tumor. In its natural progression, it typically metastasizes to the lymph 
nodes and then bone, producing bone-forming metastases. Most PCa 
respond to androgen ablation therapy (see section “The clinical 
challenge of PCa treatment-resistance”), but relapse usually occurs, 
and bone is the primary site of progression. Reproduced with 
permission from Navone N.M. and E. Labanca, 2017. Modeling Cancer 
Metastasis. In: Patient-Derived Xenograft Models of Human Cancer. Y. 
Wang, D. Lin, and P.W. Gout, editors. Humana Press, Cham. 93-114. 
License number: 4654420161143. 
 
 6 
different areas within a tumor typically have a different Gleason score, which outlines a 
spatial heterogeneity, the pathologists report the Gleason sum score which considers the 
two more prevalent scores within the tumor. 
 
 
Clinically, the progression from localized and hormone-naive PCa to castration-
resistant PCa (CRPC) may be accompanied by phenotypic divergence. In addition to the 
classic CRPC metastatic phenotype consisting of osteoblastic bone metastases, high 
levels of PSA, and responsiveness to androgen deprivation therapy (ADT), the existence 
of clinically aggressive variants of PCa are increasingly recognized in the clinic, especially 
Figure 4. Representative diagram depicting the Gleason score. 
The Gleason score is used for determining the stage of PCa, by 
assessing the degree of tissue differentiation under a microscope. 
The sum of the Gleason grade of the most prevalent pattern and the 
Gleason grade of the second most predominant pattern will 
determine the Gleason score, ranging from 6-10; 6 being low grade 
PCa. Reproduced with permission from Deweerdt, S., 2015. 
Prognosis: Proportionate response. Nature. 528:S124. Springer 
Nature. License number: 4680970850941. 
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after the introduction of the highly potent AR pathway inhibitors, enzalutamide and 
abiraterone. Use of these inhibitors is also correlated with an increasingly prevalent 
morphology and immunohistochemical acquired neuroendocrine-like phenotype (Beltran 
et al., 2014). The clinical phenotype of these aggressive variants is characterized by the 
development of rapidly progressive disease involving visceral metastases and hormone 
refractoriness. Importantly, clinically defined aggressive variants are estimated to account 
for 40% of lethal PCa (Beltran et al., 2014).  
The clinical course of PCa from diagnosis to death has been classified as a series 
of clinical stages or treatment statuses (e.g., extent of the local disease, hormonal status, 
absence or presence of detectable metastases on an imaging study). These clinical 
stages and treatment statuses together with PSA blood levels are used to monitor disease 
progression and response to treatment. However, investigators have proposed a new 
molecular classification of PCa that incorporates AR signaling, oncogenes/tumor 
suppressors, and the tumor-bone microenvironment in the disease model (Logothetis et 
al., 2013) (Fig. 5). This proposed classification, reflecting the dynamic evolution in the 
progression of the disease, may facilitate the implementation of current and emerging 
therapies.  
Studies have suggested the existence of clonal evolution of metastases as well 
as genetic and epigenetic diversity of primary and metastatic clones (de Bruin et al., 2014; 
Turajlic and Swanton, 2016). This clonal diversity may be reduced or enhanced at both 
primary and metastatic sites by systemic treatment. The spiral model proposed by 
(Logothetis et al., 2013) (Fig. 5) reflects the temporal heterogeneity that supports the 
emergence of pre-existing subclones under selection pressures. Underlining these 
features is the molecular genetic and epigenetic heterogeneity, that will result in different 
transcription and metabolic programs (Dagogo-Jack and Shaw, 2017). 
 8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The clinical challenge of PCa treatment-resistance  
When tumor cells spread and grow in sites noncontiguous to the organ of origin, 
primary site, and become metastatic, cancer enters a treatment-resilient stage. At this 
stage, the prospects for a cure using conventional therapy (e.g., surgery, radiotherapy) 
are greatly reduced. Patients with advanced metastatic PCa have several treatment 
options, but none of them are curative. Since PCa cells use androgens as fuel to grow, 
hormone or androgen deprivation (e.g., leuprolide and bicalutamide) is the most effective 
and first-line therapy, but growth of the cancer resumes over time in most cases, and the 
disease progresses to CRPC (Watson et al., 2015). Although new-generation drugs for 
ADT are available and also effective (e.g., abiraterone and enzalutamide), resistance to 
these therapies eventually emerges. Since there is no available chemotherapy and/or 
targeted therapy that is curative, disease recurrence and death after several different 
treatment modalities occur in most cases (Loberg et al., 2005; Watson et al., 2015). 
Figure 5. Spiral model of PCa progression. Three phases are described: endocrine-
driven, i.e. DHT-dependent; paracrine-driven i.e. microenvironment-dependent, and cell-
autonomous. The dynamic evolution in the progression of the disease is represented in 
the “progression spiral”, where under a certain therapy in each turn, adaptive changes 
in tumors and tumor microenvironment results in acquired resistance. Reproduced with 
permission from Logothetis, C.J., G.E. Gallick, S.N. Maity, J. Kim, A. Aparicio, E. 
Efstathiou, and S.H. Lin., 2013. Molecular classification of prostate cancer progression: 
foundation for marker-driven treatment of prostate cancer. Cancer Discov. 3:849-861. 
American Association for Cancer Research (AACR). License number: 4680971122175.  
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Cancer progression to established metastases  
The invasive phenotype, defined by the ability to actively breach or cross tissue 
barriers, including the bone marrow (Kohrman and Matus, 2017), distinguishes benign 
from malignant neoplasms (cancer) and is manifested throughout the metastatic process.  
Metastases result from a multi-step cascade that cancer cells must undergo to 
establish tumors at distant sites. In brief, these steps include escape of cancer cells from 
the primary tumor by local invasion of the surrounding extracellular environment, 
degradation, and passage through a basement membrane, followed by intravasation into 
the blood or lymphatic system, survival in circulation (hematogenous and/or lymphatic), 
arrest at a distant organ (involving lodging in a distant capillary bed), extravasation out of 
the blood vessel, survival in the new environment, and invasion and proliferation in what 
is now a foreign cellular microenvironment (establishment of a secondary tumor at a 
distant site) (reviewed in Talmadge and Fidler, 2010 (Fig. 6)).  
The cascade of events that lead to metastatic dissemination starts long before 
a tumor is clinically detected at a distant site (Hong et al., 2015; Turajlic and Swanton, 
2016). Metastatic dissemination possibly continues throughout the progression of the 
disease. Therefore, the need for precise understanding of the molecular mechanisms 
underlying each step in the metastatic process is imperative. Longitudinal analyses of 
human cancer progression in addition to laboratory-based studies have demonstrated the 
anarchic evolution of metastases, which in some cases caused local recurrence, whereas 
others had cross-metastatic site seeding (Crockford et al., 2014; Hong et al., 2015; Turajlic 
and Swanton, 2016). In fact, one study demonstrated the presence of metastatic and 
primary tumor clones in blood even years after removal of the primary tumor, supporting 
the concept of the anarchic evolution of metastases (Hong et al., 2015). 
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The development of metastases constitutes a complex and demanding process 
cancer cells must overcome to successfully colonize remote organ sites (Massague and 
Obenauf, 2016; Sethi and Kang, 2011; Talmadge and Fidler, 2010; Turajlic and Swanton, 
2016; Valastyan and Weinberg, 2011). Tumor cells must have or acquire specific traits, 
including restructuring of the cytoskeleton along with transcriptional and epigenetic 
changes. Furthermore, invasive cells can adopt different morphogenetic programs. When 
invasive cancer cells utilize a mesenchymal invasion program, the switch from epithelial 
to mesenchymal cell phenotype is often referred to as epithelial to mesenchymal transition 
Figure 6. The metastatic cascade. Reproduced with permission from Gómez-
Cuadrado, L., N. Tracey, R. Ma, B. Qian, and V.G. Brunton, 2017. Mouse models 
of metastasis: progress and prospects. Disease Models & Mechanisms. 10:1061.  
This is an Open Access article distributed under the terms of the Creative 
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which 
permits unrestricted use, distribution and reproduction in any medium provided 
that the original work is properly attributed.  
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(EMT) (Kohrman and Matus, 2017). Recently reported evidence indicated that cells are 
in cell-cycle arrest when they enter an invasive state. This cell-cycle arrest state is 
frequently associated with the invasive phenotype acquired via EMT (Hagedorn et al., 
2013; Kohrman and Matus, 2017; Matus et al., 2010; Matus et al., 2015). The transition 
to a different morphogenetic program is influenced by the tumor microenvironment. 
Stephen Paget’s 1889 work proposed that metastasis depends on a cross-talk 
between cancer cells (the “seeds”) and specific organ microenvironments (the “soil”). This 
hypothesis has been used to account for the non-random and cancer specific distribution 
of metastases. Furthermore, the concept of the selective nature of metastasis was 
supported by experimental evidence (Hart and Fidler, 1980). A detailed analysis of 
experimental metastases in syngeneic mice indicated that mechanical arrest of tumor 
cells in the capillary bed of distant organs did indeed occur but that subsequent cell 
proliferation and growth into secondary lesions were influenced by specific organ cells 
(Hart and Fidler, 1980).  
PCa is one of the most striking examples of the selectivity of cancer cells for 
specific sites of metastasis. Indeed, as PCa progresses, greater than 80% of tumors will 
develop bone metastases, and the majority will be bone-forming (Catalona, 1994; Cook 
and Watson, 1968; Hess et al., 2006; Loberg et al., 2005). Other malignancies have a 
lower, though still significant, incidence of bone metastases, namely breast (50%-60%) 
(Hess et al., 2006), thyroid (40%), renal (35%), lung (35%), liver (13%), and rectal (10%) 
carcinoma (Freeman et al., 2015; Hess et al., 2006). Additionally, multiple myeloma, a B 
cell malignancy, is the second most common haematological malignancy and, 
characteristically, involves bone during progression (Panaroni et al., 2017). Yet, only PCa 
has bone as a single, dominant metastatic site (Hess et al., 2006). Also, it was recently 
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reported that targeting bone metastases in PCa with a bone homing a-emitting 
radiopharmaceutical lengthens survival (Parker et al., 2013). Taken together these clinical 
observations point to a central role of bone metastases in PCa progression.  
Following local progression, cancer cells will in some cases acquire traits that 
allow them to escape the local site and disseminate, eventually, via the blood stream 
(circulating tumor cells [CTCs]). Once they reach a distant site, they are known as 
disseminated tumor cells (DTCs). In this context, it is important to distinguish between 
trafficking cells (cells that are moving freely in organs’ blood vessels and capillary beds, 
not yet growing or invading) and cells that are arrested at certain sites. Currently, there 
are two lines of thought to explain the process by which a cancer cell will get arrested at 
certain organ sites but not others: active or passive arrest. Passive arrest is when cancer 
cells get mechanically trapped in the capillary beds of distant organs, and active arrest is 
when cancer cells specifically migrate and stay in certain organs by, for example, 
receptor-mediated tropism. It is worth noting that normal bone houses the hematopoietic 
stem cell (HSC) niche, which comprises hematopoietic and mesenchymal cell 
populations, which provide homing signals to HSCs and regulate HSC self-renewal 
(Taichman et al., 2010). It has been suggested that DTCs can precondition the metastatic 
niche and compete with and occupy the HSC niche to facilitate metastasis (Decker et al., 
2016; Shiozawa et al., 2011). 
Arrested cancer cells at organ sites (DTCs) will generally undergo a period of 
dormancy prior to the development of either micrometastases (metastases composed of 
small groups of cancer cells that cannot be detected by current diagnostic procedures) or 
established metastases. The mechanism that makes the cell leave the dormant state and 
start growing is ill-defined and a subject of intense study. It has been proposed that there 
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are signals and factors from the metastatic/HSC niche, including c-Myc, vascular 
endothelial growth factor (VEGF) and fibroblast growth factor (FGF) 2, that can play a role 
in exiting dormancy (Decker et al., 2016; Shiozawa et al., 2011).  
 
Overview of bone biology and bone metastasis  
The human skeleton is constituted of rigid, dense connective tissues, bones, 
and semi-rigid connective tissue, cartilage. Among its central functions are supporting the 
body, enabling locomotion, protecting soft tissues, minerals (calcium and phosphate) 
storage and hematopoiesis within the bone marrow cavity (J. Gordon Betts, 2013).  
Bone formation in the embryo involves the conversion of preexisting 
mesenchyme into bone tissue (Gilbert, 2000). Briefly, embryonic skeletogenesis starts 
with mesenchymal condensation in all prospective bones. The bone tissue is then formed 
by two different mechanisms: endochondral (axial and appendicular bones) and 
intramembranous ossification (flat bones of the face, most of the cranial bones, and the 
clavicles). During endochondral ossification, condensation leads to the formation of a 
complete cartilaginous skeleton that will eventually be replaced by bone (Rodan, 2003). 
In intramembranous ossification, mesenchymal condensation is followed directly by 
ossification centers. Cells then assume osteoblastic features and start depositing bone 
matrix (consisting of collagen fibers and calcium-derived  mineral, hydroxyapatite, mainly) 
that will go on to mineralize and form the bones (Rodan, 2003). The commitment of 
mesenchymal stem cells and differentiation into osteoblasts requires expression of Runt-
related transcription factor 2 (RUNX2) and Osterix, master transcription factors that 
regulate several genes in osteoblasts, such as type I collagen, bone sialoprotein (BSP), 
osteopontin (OPN), transforming growth factor beta (TGFβ), and osteocalcin (OC). The 
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regulation of bone formation involves several factors, including TGFβs, bone morphogenic 
proteins (BMPs), FGFs, and Wingless-related integration site (Wnt) signaling, all of which 
were shown to regulate cell differentiation and survival in a spatiotemporal manner 
(Berendsen and Olsen, 2015; Ornitz and Marie, 2015; Sims and Martin, 2014; Takarada 
et al., 2016). In summary, a network of signaling molecules governs bone morphogenesis. 
Among them, FGF and their receptors were identified as relevant players in bone 
formation (Shahi et al., 2017), and some functional redundancies and complementary 
roles between different FGFRs throughout osteogenesis have been determined 
(Karuppaiah et al., 2016).  
Two types of bone can be distinguished: compact or cortical bone, constituting 
the dense outer layer of bones, and trabecular, cancellous or spongy bone, constituting 
the internal area of the bones. The latter is porous and, given the higher remodeling 
surface, metabolically more active (J. Gordon Betts, 2013). 
Structurally, different parts can be distinguished in long bones (Fig. 7). The 
diaphysis constitutes the cylindrical shaft that runs between the two bone ends. It holds 
the medullary cavity inside, occupied by bone marrow, and surrounded by walls of 
compact bone. Towards each of the bone ends, there is the epiphysis, occupied with 
trabecular bone. Between these two parts, the metaphysis can be found, which contains 
the growth plate in actively growing bones. In developed bones, only a scar line of it is 
left. All parts are highly innervated by blood vessels and nerves (J. Gordon Betts, 2013). 
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The bone is a highly dynamic organ. During adulthood, bone undergoes 
continuous remodeling via resorption and replacement at basic multicellular units (BMUs) 
(Fig. 8). This process of bone remodeling is critical for bone homeostasis in response to 
structural and metabolic demands, and is strictly controlled through a complex cell 
communication network involving signals between cells of the osteoblastic and 
osteoclastic lineages at each BMU (Sims and Martin, 2014). Many factors mediating 
stimulatory and inhibitory signals contribute to coupling the processes of bone formation, 
mediated by osteoblasts, and resorption, mediated by osteoclasts, including oncostatin 
M, parathyroid hormone-related protein (PTHrP), sclerostin, matrix-derived TGFβ, insulin-
like growth factor-1 (IGF-1), cardiotrophin-1, Sema4D/3B, sphingosine 1-phosphate 
(S1P), ephrinB2 and ephrinB4, receptor activator for nuclear factor-κB ligand (RANKL), 
Sema3B, Wnt5a, osteoprotegerin (OPG), and T cell-derived interleukins (IL).  
Figure 7. Bone Structure. Adapted with permission from 
Proulx, H.R. and W.G. Donald, 2019. Bone. In Encyclopædia 
Britannica. Encyclopædia Britannica,Inc. Merriam-Webster, Inc. 
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More recently, evidence indicates that bone-forming mature osteoblast and 
bone-resorptive mature osteoclast functions are also regulated via direct cell–cell contact 
between these cell types (Benayahu et al., 2019; Chen et al., 2018; Furuya et al., 2018).  
These pathways and bona fide cell-to-cell interactions in bone are hijacked by 
cancer cells during the metastatic process. Indeed, it has been proposed that tumor cells 
can acquire features exclusive to cells from the microenvironment (i.e., osteomimicry) 
(Huang et al., 2005). Consequently, the arrival and growth of cancer cells in the bone will 
disrupt bone homeostasis. Depending on the specific interaction that occurs between 
cancer cells and bone cells, bone metastases can be osteoblastic (e.g., PCa) or osteolytic 
(e.g., multiple myeloma). If the balance between bone formation and bone resorption is 
shifted towards increased bone formation, the bone lesion will be seen as radiodense in 
the X-ray analyses. These are the so-called osteoblastic lesions. When the balance is 
Figure 8. The bone remodeling cycle. The process starts with resorption 
of existing bone by osteoclasts, followed by osteoblast recruitment, 
proliferation and differentiation at the remodeling site. Osteoblasts then 
secrete new bone matrix, osteoid, which will then mineralize, completing the 
cycle. Reproduced with permission from Proulx H.R. and W.G. Donald, 
2019. Bone. In Encyclopædia Britannica. Encyclopædia Britannica,Inc. 
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shifted towards bone resorption (as a consequence of osteoclast activation), the bone 
lesion will be seen as radiolucid in the X-ray analyses. These are the so-called osteolytic 
lesions. In many instances, the lesions can be mixed blastic-lytic. Nonetheless, both 
components (osteolytic and osteoblastic) are generally present at different levels in any 
type of bone metastasis.  
In this context, a positive feedback loop or “vicious cycle” mediated by soluble 
factors released by cancer cells and the bone is implicated as a means of survival and 
growth in the bone microenvironment (Fig. 9). Authors originally described this cycle in 
the interaction of breast tumor cells with bone cells (Ell and Kang, 2012; Kozlow and 
Guise, 2005). Researchers proposed that tumor cells, osteoblasts, osteoclasts, and bone 
matrices are the four components of the vicious cycle necessary for the initiation and 
development of bone metastases (Kozlow and Guise, 2005).  
Among the factors implicated in osteoclast activation by cancer cells in 
osteolytic metastases, either directly or via activation of osteoblasts, are RANKL, PTHrP, 
and IL-6. Conversely, gene expression in tumor cells is modified by factors released from 
the bone matrix by osteoclast-mediated resorption that promote tumor cell proliferation 
and survival.  
Among the factors mediating aberrant formation of new bone by osteoblasts in 
osteoblastic metastases, are IGFs, BMPs, FGF, endothelin 1 (ET1), and Wnt ligands 
secreted by tumor cells. In a reciprocal fashion, osteoblast activation is suggested to 
produce factors that favor the growth of PCa cells (Lee et al., 2015a; Lee et al., 2015b; Li 
et al., 2008; Logothetis et al., 2008; Yang et al., 2001). Since the osteolytic component is 
present as well in the osteoblastic lesions, the release of factors embedded in the bone 
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matrix (e.g., IGF, TGFβ) by the bone resorption process will, in turn, support cancer 
growth. 
 
As described above, bone is the most common and often the only site of PCa 
progression (Logothetis et al., 2013). Accordingly, bone-related complications (primarily 
bone pain, fractures, and spinal cord compression) are the main causes of morbidity and 
mortality in PCa (Ottewell et al., 2014). A consistent hallmark of PCa lethal progression to 
bone is the development of osteoblastic metastases (Bubendorf et al., 2000), indicating 
that PCa–bone interaction may mediate PCa growth in bone (Croucher et al., 2016; 
Logothetis et al., 2018). Therefore, identifying the molecular pathways involved in the 
Figure 9. The vicious cycle of bone metastasis. Briefly, PCa cells release 
paracrine factors that stimulate formation of new woven (weak) bone, and 
at the same-time, osteoblasts release factors that stimulate proliferation of 
cancer cells (e.g., FGFs). Reproduced with permission from Suominen, 
Suominen, M.I., K.M. Fagerlund, J.P. Rissanen, Y.M. Konkol, J.P. Morko, Z. 
Peng, E.J. Alhoniemi, S.K. Laine, E. Corey, D. Mumberg, K. Ziegelbauer, 
S.-M. Käkönen, J.M. Halleen, R.L. Vessella, and A. Scholz, 2017. Radium-
223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer 
Cells and Bone Microenvironment in Mouse Models. Clinical Cancer 
Research. 23:4335. AACR. License number: 4680971283953.  
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development of bone metastases and PCa growth after dissemination to and in the bone 
will lead to the development of therapeutic opportunities for secondary prevention. 
 
Models of metastasis 
In vivo studies modeling metastases in mice may involve the entire metastatic 
process when cells are injected orthotopically (in the site of origin of the cancer), and 
metastatic spread is monitored macroscopically or by labeling the input cells with a 
transgene-expressing luciferase, which enables them to be tracked in vivo (termed 
“spontaneous” metastasis). The ability of cells to reach specific organs, via the blood 
vessels, and grow can be studied with intracardiac injection of cancer cells into the left 
ventricle (termed “experimental” metastasis). In this scenario, the initial steps of 
metastasis are bypassed. Finally, the interaction of cancer cells with the host cells at the 
metastatic site can be studied using direct injection of the cancer cells into the organ 
subject of study. This strategy does not provide information about the metastatic process 
but does provide important information on tumor-microenvironment interactions that lead 
to tumor growth at the metastatic site. In particular, bone metastases of PCa are sites of 
treatment resistance; thus, this approach is useful in preclinical studies for assessment of 
impact on not only tumor volume but also PCa cell-bone interaction. Cancer-induced bone 
remodeling generates high heterogeneity of bone lesions. Histomorphometry of 
undecalcified bone provides an accurate measure of tumor-induced bone reaction and 
treatment effects on normal bone and tumor-induced bone reaction. Metastatic lesions in 
the bone are believed to grow in the medullary cavity first. These measurements are 
usually performed in the mid-cancellous region of the distal metaphysis of the femur.  
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These experimental procedures have strengths and shortcomings, and 
determining the value of each of these methods comes down to the scientific question 
that is being addressed and how well the methods for answering the question were 
selected. For example, intracardiac injection of cancer cells into the left ventricle will 
provide important evidence regarding the preferred site of metastasis of a given cell line 
and how this tropism can be altered by genetically manipulating the injected cells. 
However, the effects of genetic manipulation of the injected cells in the initial steps of 
metastasis cannot be studied using intracardiac injection. Also, the effects of genetic 
manipulation of the injected cells on tumor-stroma interaction at the metastatic site cannot 
be accurately assessed because the pattern of metastasis is unpredictable. A more 
informative method for the latter would be direct injection of a cells into the metastatic site 
because the subject of the study is controlled. For preclinical/co-clinical studies, direct 
injection of cells into the organ of interest is preferred if the purpose of the study is to 
identify means of controlling the growth of established metastases. If the goal is to prevent 
the development of metastases, either orthotopic or intracardiac injection would be 
adequate.  
 
The FGF signaling axis 
The contribution of bone metastases to the clinical morbidity of solid tumors has 
prompted efforts to better understand the mechanism of cancer metastases to bone. As 
a result, many factors implicated in bone metastases have been identified. Prominent 
among these areas of study is the FGF signaling axis, which has been shown to be central 
to the metastatic progression in bone of some tumors, including PCa. While in other 
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tumors, there is still insufficient evidence to implicate the FGF axis in its progression to 
bone metastases.  
The FGF axis is a highly conserved complex signaling pathway that typically 
mediates epithelial–stromal cell interactions and is central to prostate and bone 
development (Lin and Wang, 2010; Su et al., 2014). In humans, the axis consists of 18 
receptor-binding ligands (FGFs), 4 transmembrane receptor tyrosine kinases (FGFRs), 
and their isoforms. The various FGFs are classified in canonical (paracrine), hormone-like 
(endocrine), and intracellular (intracrine).  
The interaction in the paracrine signaling requires heparan sulfate (HS), which 
leads to activation of the FGFR kinases. Current evidence indicates that FGFR kinase 
activation is followed by phosphorylation of FGFR substrate 2a (FRS2a), recruitment of 
phospholipase Cg (PLCg), and activation of downstream cascades and networks (e.g., 
mitogen-activated protein kinase [MAPK], protein kinase B [AKT], signal transducer and 
activator of transcription [STAT]) (Ornitz and Itoh, 2015) (Fig. 10). FGFR signaling can be 
modulated by different mechanisms including negative regulators (e.g., Sprouty) and 
receptor internalization and degradation (Ornitz and Itoh, 2015). 
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In addition to the paracrine canonical FGFs, there are three FGFs, namely 
FGF19, 21, and 23, that function as endocrine factors and are believed to require protein 
co-factor aKlotho, bKlotho, or the Klotho-related protein for receptor binding and activation 
due to their lower affinity for HS (Ornitz and Itoh, 2015) (Fig. 11). Also, the intracrine FGF 
subfamily, FGF11-14, encodes intracellular FGFs, which are non-signaling proteins that 
Figure 10. Paracrine FGF signaling pathways. A ternary FGF-FGFR-HS complex 
results from the binding of canonical FGFs to FGFR with HS. This complex then activates 
the FGFR intracellular tyrosine kinase domain by phosphorylation of specific tyrosine 
residues. The FRS2!, a major FGFR kinase substrate, is phosphorylated by the activated 
FGFR kinase. Phosphorylated FRS2! then recruits the RAS/MAPK pathway. MAPK 
activates members of the ETS transcription factor family and negative regulators of the 
FGF signaling pathways. Phosphorylated FRS2! also recruits the enzyme PI3K, which 
then phosphorylates AKT. AKT has multiple activities including the activation of FOXO1 
transcription factor. Activated FGFR kinase recruits and activates the enzyme PLC" as 
well, which produces IP3 and PIP2. Also, FGFR kinase activates STAT1, 3, and 5, which 
mostly regulate gene expression in the nucleus. 
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serve as cofactors for voltage-gated sodium channels and other molecules (Ornitz and 
Itoh, 2015). 
 
  
The complexity of this axis is further increased by the possibility of FGFRs to 
undergo alternative splicing, producing isoforms with differential ligand specificity and 
spatial lineage expression, as well as the complexity of HS members (Gong, 2014; Li et 
Figure 11. FGF23 endocrine and autocrine/paracrine actions. In osteoblasts, 
activation of FGFR1 by low molecular weight (LMW)-FGF2 isoform-HS ternary complex 
formation in the membrane (or FGF23 binding to intranuclear FGFR1, not shown) 
induces FGF23 expression. FGF23 in the kidney forms a ternary FGF23-FGFR-Klotho 
complex, leading to activation of the FGFR tyrosine kinase and inhibition of phosphate 
reabsorption and reduction of circulating levels of 1,25-dihydroxyvitamin D. 1,25-
dihydroxyvitamin D in turn induces FGF23 production by osteoblasts. FGF23 is also 
thought to inhibit parathyroid hormone (PTH) production by the parathyroid gland. 
Finally, FGF23 regulates OPN secretion in osteoblastic cells, which is a potent regulator 
of the mineralization process. 
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al., 2016). Lastly, an additional member of the family is FGFR-like 1 (FGFRL1) or FGFR5, 
which lacks the cytoplasmic tyrosine kinase domain (Kahkonen et al., 2018).  
In particular, the FGFR1 extracellular, ligand-binding, region comprises two or 
three Ig-like domains which result from alternative splicing of the a exon leading to FGFR1 
a (containing the a exon)  and b (lacking the a exon) isoforms (Fig. 12). This does not 
affect ligand binding, but can lead to enhanced ligand affinity in the FGFR1 b isoform, 
possibly due to partial loss of auto-inhibition. Expression of both isoforms is detected in 
most tissues, being a predominant in general, and expressed during  embryogenesis in the 
mice, and b expressed after birth (Wan et al., 2014).  
 
 
 
Figure 12. Representation of FGFR1 isoforms. FGFR1 alpha 
(a, NM_023110.2) has 3 and beta (b, NM_023105.2) 2 immunoglobulin 
(Ig)-like domains in the extracellular region. The first Ig-loop (Ig I) is 
deleted by alternative splicing of the alpha exon. TM: transmembrane 
domain. Adapted with permission from Johnson, D.E. and L.T. 
Williams, 1993. Structural and functional diversity in the FGF receptor 
multigene family. Advances in cancer research. 60:1-41. Elsevier. 
License number: 4680980052600.  
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These isoforms are of interest in cancer as they have been associated with 
pancreatic cancer, breast cancer, bladder cancer and glioblastoma (Bruno et al., 2004; 
Luqmani et al., 1995; Tomlinson and Knowles, 2010; Vickers SM, 2002; Wendt et al., 
2014; Zhao et al., 2019). Furthermore, it has been reported that changes in the expression 
ratio of these simultaneously expressed splice variants in cancer could modulate 
responses to either autocrine or paracrine factors (Luqmani et al., 1995).  
Of note, these are only some of the many isoforms that have been identified for 
FGFR1. For instance, lack of the exon coding for the transmembrane domain can result 
in soluble receptor forms. Additionally, other isoforms can result from alternative exon 
usage of the exon coding for a region of the IgIII, generating IIIb and IIIc isoforms (Gong, 
2014). Interestingly, previous reports from our group determined that the FGFR1 IIIc 
isoform is prevalently expressed in PCa compared to IIIb (Wan et al., 2014).   
Once activated, FGF signaling regulates a plethora of cellular biological 
processes: mitogenesis, differentiation, angiogenesis, survival, and motility/invasiveness, 
among others (Li et al., 2016; Ornitz and Marie, 2015). The FGF pathway plays a central 
role in various processes that include embryonic and organ development, wound healing 
and carcinogenesis (Corn et al., 2013; Teven et al., 2014). In particular, the FGF axis is 
integral to normal bone development and function (Li et al., 2016; Ornitz and Marie, 2015). 
 
Role of FGF signaling in bone 
The discovery that FGFR mutations are associated with specific skeletal 
abnormalities in humans has established the relevance of this pathway in bone 
development and homeostasis (Ornitz and Marie, 2015). These include congenital 
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FGFR2 mutations in humans associated with craniosynostosis (Karuppaiah et al., 2016) 
and bent bone dysplasia among other skeletal disorders, implicating this receptor in bone 
development (Neben et al., 2017). However, the effects of FGF/FGFR signaling in 
osteogenesis are complex, as they depend on which FGFs and FGFRs are expressed, 
the stage of maturation of the target cells, and the microenvironment (e.g., availability of 
HS). Studies using genetically engineered mice (GEM) have provided some 
understanding of the role of the FGF axis in bone biology (Jacob et al., 2006).  
Briefly, the data resulting from conditional knockout of Fgfr1 in the 
osteoprogenitor lineage suggest that FGFR1 promotes the differentiation of mesenchymal 
progenitors into preosteoblasts, while inhibiting their proliferation (Jacob et al., 2006; Xiao 
et al., 2014; Zhang et al., 2014), and inhibits the maturation and mineralization of 
osteoblasts (Jacob et al., 2006; Su et al., 2014). Likewise, Fgfr2 inactivation in mice 
suggest that this receptor is also involved in postnatal bone growth (Karuppaiah et al., 
2016), although the underlying mechanism is not clear. Fgfr1 and Fgfr2 have considerable 
overlap in their expression patterns and their double deletion in mice resulting in severe 
postnatal growth defects and impaired longitudinal bone growth, embodies the important 
role for FGF signaling in bone formation after birth (Karuppaiah et al., 2016).  
As for FGFR3, gain-of-function mutations result in achondroplasia and related 
chondrodysplastic disorders, as a consequence of suppressing pre-pubertal skeletal 
growth. Further, in mice studies, chondrogenesis was observed as a result of an inhibitory 
activity of FGFR3, expressed on growth plate chondrocytes (Ornitz and Marie, 2015). 
Although much is known about the signals downstream of FGFR3 in chondrocytes, the 
mechanisms that regulate FGFR3 expression and activation, and that coordinate 
osteogenesis and chondrogenesis are poorly understood (Ornitz and Marie, 2015). 
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The specific roles of FGF ligands in bone biology post birth are not completely 
understood. Cell-based and GEM studies implicate FGF2 (one of the most studied FGF 
ligands) in osteogenesis (Montero et al., 2000; Su et al., 2014). However, different FGF2 
isoforms (low molecular weight [LMW] and high molecular weight [HMW]) seem to have 
opposite effects on bone mass (Xiao et al., 2018; Xiao et al., 2010). Moreover, both, LMW- 
and HMW-FGF2 induce FGF23 promoter activity (Han et al., 2015). FGF23, expressed 
mainly by osteoblasts and osteocytes (Martin et al., 2011), controls phosphate 
homeostasis and bone mineralization via endocrine actions in its main target organ, the 
kidney, after formation of the ternary FGF-FGFR-Klotho complex (Feng et al., 2013; 
Quarles, 2012). There is also evidence suggesting the existence of a PTH–bone feedback 
loop in which PTH stimulates FGF23 bone-expression and FGF23 inhibits PTH production 
by the parathyroid gland (Quarles, 2012)  (Fig. 11). Finally, FGF23 also locally regulates 
bone mineralization acting through FGFR3 in a Klotho-independent manner. In this case, 
FGF23 regulates OPN secretion in osteoblastic cells, which is a potent regulator of the 
mineralization process (Murali et al., 2016) (Fig. 11). 
Combined in vitro and in vivo studies suggest that FGF-ERK1/2 signaling 
regulates the expression of dentin matrix acidic phosphoprotein 1 (Dmp1), critical for 
proper bone mineralization in osteocytes. Once activated, the mechanism of FGFR 
signaling down-regulation involves ubiquitin ligase c-CBL and is prevalent in osteoblasts, 
thus highlighting the important role of this adaptor protein in the control of 
osteoblastogenesis (Ornitz and Marie, 2015). 
FGF signaling interacts with other pathways involved in osteogenesis most 
notably with BMPs and the Wnt canonical pathway. Briefly, in vitro and in vivo studies 
indicate that FGFs enhance canonical BMP2 signaling and induce β-catenin nuclear 
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accumulation in osteoblasts, thus regulating the fate and differentiation of mesenchymal 
stem cells (Miraoui and Marie, 2010; Ornitz and Marie, 2015).  
Furthermore, FGF2 is necessary for the positive effects of PTH on osteoblast 
proliferation and differentiation (Ornitz and Marie, 2015); and, in turn, PTH stimulates 
Fgf2, Fgfr1, and Fgfr2 in osteoblasts.  
The FGF axis regulates bone remodeling by regulating osteoclast activation and 
function, as well. FGF2 induces osteoclast precursor proliferation and stimulates bone 
resorption through the activation of FGFR1 and MAPK. FGF18 can induce RANKL and 
cyclooxygenase-2 expression in osteoblasts, which in turn will induce osteoclast formation 
and function. In vivo studies indicate that FGFR1 and FGFR3 contribute to osteoclast 
activity (Ornitz and Marie, 2015). Further, mice with Fgfr1 inactivation in osteoclast and 
osteoclast precursors are normal at birth but have abnormal bone remodeling and 
increased bone mass (Lu et al., 2009). 
In summary, it is clear that the FGF axis is a key player in osteogenesis. 
Furthermore, it is equally clear that its function is multifaceted and highly context-
dependent, with the effects of particular components, as well as interacting proteins, 
varying according to the specific microenvironment and stage of bone development. 
Numerous downstream signaling cascades triggered by the interaction between FGFs 
and FGFRs in association with other pathways regulate the different steps in osteoblast 
maturation (Ornitz and Marie, 2015).  
Overall, the above-mentioned studies emphasize the complexity of bone 
formation dynamics, which require a tight, regulated, fine-tuned coordination of pathways 
and processes, including the fundamental role of the FGF axis and its crosstalk with other 
signaling cascades.  
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Finally, FGF/FGFR is a target in the treatment of bone-associated diseases. 
A feature of particular importance is that FGF activation mediates angiogenesis and 
osteogenesis, two closely related processes of bone formation (Charoenlarp et al., 
2017; Shahi et al., 2017). Hence, the relevance of its therapeutic application in cancers 
involving bone.  
 
FGF axis in PCa  
Besides androgen signaling, epithelial-mesenchymal interactions regulate 
prostate gland homeostasis and development. FGFs partly mediate this interaction; in 
particular FGF2, 7, 9 and 10 are expressed in the stromal, and their receptors in the 
epithelial compartment. 
Alterations in the FGF pathway have been implicated in different types of 
cancer, including breast, bladder, lung and PCa (Wesche et al., 2011). Aberrant FGF 
expression in prostate stroma or epithelium can lead to PIN and is involved in the early 
stages of PCa development; in particular, through a paracrine fashion. Also, increased 
levels of FGF in the epithelial prostate cells also contribute to aberrant growth by 
autocrine signaling. Furthermore, PCa progression and EMT have been shown using 
an inducible FGFR1 prostate mouse model, and its inhibition by conditional inactivation 
of FGFR1 or FRS2a in the TRAMP mouse model (SV40 T antigen-expressing 
transgenic adenocarcinoma of the mouse prostate) (Corn et al., 2013). Finally, several 
FGFs and FGFR1 mainly have been found overexpressed in human prostate tumors, 
in many cases, associated to more aggressive grade and clinical stage (Corn et al., 
2013). 
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FGF family implications in the pathogenesis of PCa bone metastases 
Alterations in the FGF/FGFR axis found in cancer result either from activating 
mutations of receptors or from overexpression of ligand or receptors (see Appendix I: 
“FGF axis implications in bone metastases of other cancers: breast, lung, bladder cancer 
and multiple myeloma”). Not all alterations in the FGF axis in cancer emerge from genomic 
alterations (e.g., PCa).   
FGF axis abnormalities in PCa have been associated with receptor or ligand 
overexpression (Wang et al., 2019), but mutations of FGF axis components have been 
detected in only a small fraction of PCa.   
Previous reports implicate the FGF axis in PCa development and progression 
(Corn et al., 2013; Teishima et al., 2019). Given the role of the FGF axis in bone biology, 
aberrant FGF signaling activation in bone cells would upset the bone homeostasis. 
Studies conducted by our laboratory and others indicate that PCa cells can alter the bone 
microenvironment by triggering the expression of FGFs (in particular FGF9 and FGF8) (Li 
et al., 2008; Valta et al., 2008). Indeed, expression of FGF8 and FGF9 is significantly 
increased in human PCa bone metastases compared with the primary site (Li et al., 2008; 
Valta et al., 2006). Further, ectopic expression of FGF8 and FGF9 in PCa cells promotes, 
while blocking FGF9 reduces, the growth of PCa cells in bone (Huang et al., 2015; Li et 
al., 2008; Valta et al., 2008). These evidences implicate FGF8 and FGF9 in the 
pathogenesis of PCa bone growth.  
Our laboratory also reported that blockade of FGFRs with dovitinib (TKI258, 
Novartis Pharmaceuticals), a receptor tyrosine kinase inhibitor with potent activity against 
FGFR and VEGFR, has clinical activity in a subset of men with CRPC and bone 
metastases (Wan et al., 2014) (Fig. 13). Our findings not only identify the FGF axis as a 
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candidate target for therapy, but also implicate the FGF axis in a positive feedback loop 
between PCa cells and bone cells; and suggest that FGFR1-mediated autocrine and 
paracrine signals in PCa cells enable PCa growth in bone. In support of this, recent reports 
indicate that the FGF axis may underlie CRPC progression (Bluemn et al., 2017) and 
resistance to cabozantinib (c-MET and VEGFR2 inhibitor) treatment (Varkaris et al., 
2016), further underpinning the importance of developing FGFR blockade as therapy or 
secondary prevention for PCa. 
 
 
Furthermore, a previous report from our group showed that FGF2 expression is 
increased in tumor-associated bone cells in an experimental model (Wan et al., 2014). 
Results of a recent study indicate that high FGF2 levels in osteoblasts (secondary to 
Figure 13. FGFR1 is implicated in PCa bone metastases. Illustration of the 
interaction between PCa cells and osteoblasts mediated by the FGF axis, which 
favors the growth of PCa in bone. 
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Tgfβr2 loss) promote PCa bone metastases in mice (Meng et al., 2018). Prostate stromal 
cells express biologically relevant levels of FGF2, and therefore the increase in FGF2 in 
the bone microenvironment may promote PCa cell growth by providing a similar niche 
(Kwabi-Addo et al., 2004; Pecqueux et al., 2018). Together, these studies suggest that 
loss of Tgfβr2 expression in osteoblasts enables FGF2-mediated cross-talk with PCa cells 
and promotes bone metastasis (Meng et al., 2018). In support of these studies, it has 
been shown that loss of Tgfβr2 occurs in the bone marrow of 77% of bone-involved PCa 
cases examined. Further, knockout of Tgfβr2 in mouse stromal fibroblasts results in earlier 
tumor development in intratibially-injected mice (Li et al., 2012).  
Lastly, a study using experimental systems indicates that deletion of FRS2α in 
human or mouse PCa cells results in reduced angiogenesis and impaired tumor growth 
in bone (Liu et al., 2016). These results are in alignment with the known role of the FGF 
axis in angiogenesis attributed to the mitogenic effect on endothelial cells. 
Together, the evidence discussed further suggests that FGF signaling mediates 
autocrine and paracrine signals between PCa cells and bone cells.  
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Hypothesis and Aims  
Bone metastases remain a major therapeutic challenge. 
FGFR1 is implicated in PCa pathogenesis and FGFR blockade has shown 
clinical activity in advanced, metastatic disease. However, the specific mechanism by 
which the FGF axis, FGFR1 in particular, mediates PCa growth in bone remains poorly 
understood. 
In this study, we have found that various FGFR1 isoforms are detected in PCa 
tissue specimens. 
The overall goal of this proposal is to investigate the molecular and clinical 
implications of FGFR1/FGFR1 isoforms expression in the pathogenesis of PCa bone 
metastases.  
We hypothesize that FGFR1 induces PCa progression to bone metastases. We 
further propose that the two best characterized FGFR1 isoforms, alpha and beta, activate 
different genes and pathways in PCa cells, and that this may partly explain PCa 
heterogeneity and pattern of progression. 
We will test these hypotheses in the following Specific Aims:  
 
Aim 1. Assess the role of FGFR1 isoforms in the metastatic potential and growth 
pattern in bone in PCa.  
Given that FGF signaling is a key mediator of bone formation and that FGFR1 
is involved in PCa progression, we propose that FGFR1 isoforms accelerate the bone 
metastatic phenotype of PCa cells. We will  
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(a) evaluate the metastatic dissemination mediated by FGFR1 isoforms after 
intracardiac injection of PCa cells in mice, and  
(b) the induction of PCa growth in bone by direct injection of PCa cells into the 
femur of mice.  
 
Aim 2. Study the signaling cascade induced by FGFR1 isoforms.  
We hypothesize that FGFR1 alpha and beta trigger activation of different 
associated gene signatures that modulate malignancy. We will  
(a) mine the TCGA PCa datasets to examine FGFR1 molecular correlates, and  
(b) determine the activation of downstream targets in PCa cells expressing 
FGFR1 isoforms by Western blot and reverse phase protein array (RPPA). To identify 
candidate genes enriched in FGFR1-mediated metastasis, we will then assess the 
expression of FGFR1-associated proteins/phospho-proteins in human PCa metastases 
specimens by immunohistochemistry (IHC).  
 
Aim 3. Analyze clinical correlates of FGFR1 and its isoforms in human PCa.  
Since we detected various FGFR1 alternative splice variants in PCa samples, 
we will test our postulate that PCa tumors are heterogeneous in FGFR1 levels throughout 
disease progression and that FGFR1 is enriched in PCa metastases.  
We will assess the expression of FGFR1 in clinical samples reflecting the 
progression of the disease by IHC.  
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Dissecting the role of FGFR1 isoforms in PCa bone metastases will significantly 
contribute to the identification of men with FGFR1 activation as candidates for FGFR1 
blockade, to develop new therapies targeting FGF signaling, and to identify predictive 
biomarkers of response to this treatment. 
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Chapter 2: METHODS  
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This chapter is partly based upon “Navone N.M. and E. Labanca, 2017. Modeling Cancer 
Metastasis. In: Patient-Derived Xenograft Models of Human Cancer. Molecular and 
Translational Medicine. Humana Press, Cham. Y. Wang, D. Lin, and P.W. Gout, editors. 
pp. 93-114”, with permission from Springer International Publishing AG 2017, Springer 
Nature. License Number: 4654420161143. 
 
BIOINFORMATICS ANALYSIS 
Data mining from the Prostate Adenocarcinoma Project of The Cancer Genome 
Atlas (PRAD-TCGA) 
 
The human RNA sequencing data from the PRAD-TCGA data portal site 
(http://cancergenome.nih.gov/), which has gene expression data from 476 prostate tumor 
samples and normal adjacent tissue (last access: December 2018) measured by 
massively parallel sequencing (llluminaHiSeq), was used. The dataset was mined for 
expression of FGFR1 isoforms and their molecular correlates. The search was performed 
using the specific sequence of each of the FGFR1 isoforms (a, NM_023110.2; and b, 
NM_023105.2). To perform the analyses, a FGFR1 score was defined as the ratio of 
FGFR1 a to the sum of FGFR1 a and FGFR1 b (Ryan et al., 2012). A high FGFR1 score 
indicates prevalence of FGFR1 a and a low FGFR1 score indicates prevalence of FGFR1 
b. Expression of genes and pathways associated with FGFR1 score was also assessed, 
using Gene Set Enrichment Analysis (GSEA) (Subramanian et al., 2005). BIOCARTA, 
KEGG, NABA, PID, REACTOME, SA, SIG, and ST pathway databases were used. We 
prioritized those pathways that had a P < 0.002 and an absolute value of normalized 
enrichment score (NES) > 1.78.   
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cBioPortal 
The cBio Cancer Genomics Portal (http:/cbioportal.org, open source cancer 
genomics data platform created by Memorial Sloan-Kettering Cancer Center) was used 
to analyze genetic alterations in the LAD1 gene in PCa (Cerami et al., 2012; Gao et al., 
2013). The criteria used in order to include datasets in our analysis were the following: (1) 
type of cancer: prostate (adenocarcinoma); (2) the study must be published; and (3) the 
study must consist of > 300 samples.  
 
Ingenuity Pathway Analysis (IPA) 
Data were analyzed and a network was generated through the use of IPA 
(QIAGEN Inc., https://www.qiagenbioinformatics.com/products/ingenuity- pathway-
analysis) (Kramer et al., 2014). 
 
IN VITRO EXPERIMENTS 
Cell lines 
Two human prostate carcinoma derived cell lines were used in the studies: 
- PC3: PCa cell line which does not express AR and is therefore hormone 
insensitive. It was established from a bone metastasis of a prostatic adenocarcinoma. Its 
pattern of growth in bone is osteolytic.  
- C4-2B: a subline of the human prostate adenocarcinoma LNCaP obtained 
from a bone metastasis in male nude mice, which expresses AR. 
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PC3 and C4-2B cells were purchased from the American Type Culture 
Collection (ATCC) and were maintained in RPMI 1640 (Sigma-Aldrich) supplemented with 
10% fetal bovine serum (FBS) (Sigma-Aldrich) and 1% penicillin and streptomycin 
(Sigma-Aldrich). All cell lines and sublines were grown in a 37°C incubator with a 
humidified 5% CO2 atmosphere and split using Trypsin 0.25%, 
ethylenediaminetetraacetic acid (EDTA) 0.1% (Corning) upon reaching 80% confluency. 
For all experiments, cell line passage number was kept to higher than 2 and smaller than 
20 after thawing. All cell lines and sublines were routinely tested for mycoplasma 
contamination using the Universal Mycoplasma Detection Kit (ATCC). 
Cell lines stocks were prepared in culture medium supplemented with 45% FBS 
and 10% dimethyl sulfoxide (DMSO) (Sigma-Aldrich) and cryopreserved in liquid nitrogen. 
Freezing was done at a controlled slow cooling rate using freezing containers (i.e., 
CoolCell (Corning) or Mr Frosty (Nalgene)) in -80°C freezer, followed by transfer to liquid 
nitrogen storage. Thawing of cryotubes (Nunc) was performed at 37°C directly from liquid 
nitrogen preservation, followed by a wash to eliminate DMSO and placed in the growth 
conditions described above. 
 
Plasmid amplification and purification 
Plasmids amplification was performed by bacterial transformation of DH5a 
competent E. coli (Invitrogen). Briefly, 1-5 µL of DNA were added to 50 µL of bacteria, 
incubated on ice for 30 minutes and heat-shocked at 42°C for exactly 30 seconds. 250 µL 
of Super Optimal broth with Catabolite repression (SOC) media (Invitrogen) were then 
added and cells were incubated on a 37°C shaker for 1 hour. After incubation, 50-200 µL 
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(at least two different volumes) were spread on a prewarmed Luria-Bertani (LB) agar plate 
containing the corresponding antibiotic and incubated at 37°C overnight. 
Colonies were picked the next morning and grown in 2 mL of LB broth (Corning) 
with the corresponding antibiotic for 4 hours on a shaker at 37°C, then transferred to 100 
mL LB broth containing antibiotic for overnight incubation on a shaker at 37°C. One mL 
bacterial stocks were prepared with 25% glycerol (from a 50% glycerol stock prepared in 
H2O) and stored at -80°C. Bacterial cells were harvested by centrifugation at 6,000 x g for 
15 minutes at 4°C and plasmids purified using the EndoFree Plasmid Maxi kit (QIAGEN). 
Plasmid DNA pellet was resuspended in 500 µL water or Tris-EDTA (TE) buffer and 
quantified by pipetting 2 µL in the Take3 Micro-Volume Plate (BioTek) followed by 
absorbance measurement at 260 nm performed in the Synergy HTX multi-mode 
microplate reader (BioTek). Volumes were adjusted accordingly for Midi and Mini preps 
based on manufacturer’s instructions. Ten µL of vectors at a 100 ng/µL concentration 
were sequenced at the Sequencing and Microarray Facility, MD Anderson Cancer Center, 
Houston, TX, using 10 µL of 1 pmol/µL of custom primers or primers provided by the Core.  
 
Transfections and transductions 
FGFR1 a and b sublines were developed from parental cell lines by stably 
transfecting them with pcDNA3.1-FGFR1a-P2A-eGFP (PC3-FGFR1 a  and  C4-2B–
FGFR1 a) or pcDNA3.1-FGFR1b-P2A-eGFP (PC3-FGFR1 b  and  C4-2B–FGFR1 b) 
plasmids (GenScript) (Fig. 14). Control sublines (transfected with empty vectors, PC3-
V  and C4-2B–V) were also generated. Transfections were performed using 
Lipofectamine 3000 Transfection Reagent (Invitrogen) or Fugene HD (Promega). Briefly, 
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2.5 µg (when using Lipofectamine 3000) or 3 µg (when using Fugene HD) of DNA were 
added to 70-90% confluent cells in a 6-well plate, according to the manufacturer’s 
instructions. Transfected cell lines were selected by both, treatment with G418 (500 
µg/mL, Geneticin, Sigma-Aldrich) and subsequent cell sorting for GFP expression by 
fluorescence-activated cell sorting (FACS) at the Flow Cytometry and Cellular Imaging 
Core Facility at MD Anderson Cancer Center, Houston, TX, as described in “Cell sorting” 
section. The optimal antibiotic selection concentration was determined by performing a 
dose response curve for each wild-type cell line. 
 
 
Luciferase(luc)-expressing sublines of C4-2B–FGFR1 a, b, and V were also 
generated, by infecting them with CMV-luciferase (firefly)-2A-RFP lentiviral particles 
(LVP324, ~1 x 10
7 IFU/mL, AMSBIO) (Fig. 15) according to the manufacturer’s 
Figure 14. pcDNA3.1+P2A-eGFP vector map (Genscript). CMV 
promoter = cytomegalovirus promoter (strong promoter for 
constitutive expression); MCS= multiple cloning site; P2A= “self-
cleaving” 2A peptide for bicistronic expression; eGFP= enhanced 
green fluorescent protein; f1 ori= origin of replication for phage 
particles; SV40 promoter= simian vacuolating virus 40 promoter; 
NeoR= neomycin resistance (eukaryotic selection); pUC ori= 
origin of replication for E. coli; AmpR= ampicillin resistance 
(bacterial selection). Reprinted from Genscript. 
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instructions, followed by selection with 1µg/mL puromycin (Thermo Scientific). Briefly, 50 
μL of ready to use pre-made lentivirus were added into each well of a 24-well-plate with 
cells 50%-75% confluent. Fluorescence microscopy, FACS and luciferase in vitro assays 
were used to visualize positive transduction rate.  
 
 
Cell treatment 
PC3 and C4-2B stably expressing FGFR1 isoforms or empty vector controls 
were serum-starved for 3 hours, and 50 ng/mL heparan sulphate proteoglycan (HSPG, 
Sigma-Aldrich) were added during the last hour of starvation. Then, 100 ng/mL of FGF2 
or FGF9 (Peprotech), prepared from a 100 µg/mL stock, were added for 45 minutes to 
activate FGFR pathway. Cells treated with vehicle were used as controls.   
 
Cell sorting 
GFP positive cells were sorted in Beckman Coulter MoFlo Astrios, Becton 
Dickinson FACS Aria II or FACS Aria Fusion Cell Sorter (Flow Cytometry and Cellular 
Figure 15. CMV-Luciferase (firefly)-2A-RFP lentiviral particles (AMSBIO). 
Luciferase and RFP are downstream of the same strong CMV promoter (TetCMV, 
optional inducible), intermediated by a self-cleavage F2A element, thus not 
resulting in expression of a fusion, but as two individual proteins. Puromycin 
antibiotic marker is downstream of Rsv (Rous sarcoma virus) promoter. LTR, Psi 
(Ψ), RRE, cppt and WPRE elements of lentivirus transfer plasmid for integration 
of the insert are also present. Adapted from AMSBIO. 
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Imaging Core Facility, MD Anderson Cancer Center, Houston, TX). Unlabeled parental 
cell lines were used as negative controls, and all samples were filtered through 35 µm cell 
strainer cap tubes (Falcon) prior to running in the sorter to obtain single cell suspensions. 
Cell aggregates were excluded by singlet cell population gating. Fluorescein 
isothiocyanate (FITC) channel (green, 488 nm excitation/ 530 nm emission wavelength) 
was applied. The top percentage (5%-10%) of fluorescent cells was collected. 
 
Western blot analysis 
Cells were harvested at the end of treatment in lysis buffer containing 1% Triton 
X-100, 50 mM HEPES pH 7.4, 150 mM NaCl, 1.5 mM MgCl2, 1 mM  ethylene glycol 
tetraacetic acid (EGTA), 100 mM NaF, 10 mM Na pyrophosphate, 1 mM Na3VO4, 10% 
glycerol, and freshly added protease and phosphatase inhibitor cocktail tablets (Roche). 
Protein concentration was measured using bicinchoninic acid (BCA) Protein Assay Kit 
(Pierce) and read in Synergy HTX multi-mode reader (BioTek). Immunoblot analysis was 
performed using standard procedures as previously described (Wan et al., 2014). Briefly, 
20 to 30 µg of denatured, reduced total cell lysates (using sample buffer containing 200 
mM Tris-Cl pH 6.8, 8% sodium dodecyl sulfate (SDS), 0.4% bromophenol blue, 40% 
glycerol and 400 mM dithiothreitol (DTT), and boiled for 5 minutes) were loaded in equal 
amounts into a 4-20% gradient Tris-Glycine gel (Novex), separated by SDS-
polyacrylamide gel electrophoresis (SDS-PAGE), and then transferred into a 0.2 µm 
nitrocellulose membrane (Thermo Scientific). Blocking was done in either 5% milk or 5% 
bovine serum albumin (BSA) in tris-buffered saline-Tween 20 (TBS-T) (0.1% Tween 20), 
according to the manufacturer’s instructions. The following antibodies were used: for 
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FGFR1 detection, anti-FGFR1 (Cell Signaling Technology, rabbit monoclonal, clone 
D8E4); for p-MAPK detection, Path Scan Multiplex Western Cocktail I against p-p44/42 
MAPK (Erk1/2) (Cell Signaling Technology, rabbit monoclonal); for ladinin 1 detection, 
anti-LAD1 (Sigma-Aldrich, rabbit polyclonal); and for GAPDH, anti-GAPDH (Cell Signaling 
Technology, rabbit monoclonal, clone 14C10). As secondary antibody, goat anti-rabbit 
IgG, horseradish peroxidase (HRP)-conjugated antibody (Cell Signaling Technology) was 
used, followed by chemiluminescence detection using enhanced chemiluminescence 
(ECL) Prime Western Blotting Detection Reagents (Amersham GE Healthcare). Images 
were acquired using either the ChemiDoc MP digital Imaging system (Bio-Rad) or a film 
developer, with Amersham Hyperfilm MP High performance autoradiography film (GE 
Healthcare) or Carestream® Kodak® BioMax® MR film (Kodak). 
  
Reverse phase protein array (RPPA) 
RPPA analysis was performed at the Functional Proteomics RPPA Core Facility 
at MD Anderson Cancer Center, Houston, TX. Briefly, sample preparation consisted of 
harvesting cells using lysis buffer as previously described (see “Western blot analysis” 
section). They were then diluted to a concentration of 1.5 µg/µL and mixed accordingly 
with 4X sample buffer (40% glycerol, 8% SDS, 0.25 M Tris, pH 6.8), to which b-
mercaptoethanol was added (1:10 ratio) before use. 80 µL of each sample (five replicates 
per group) were submitted to the RPPA Core Facility and run using a set of 295 (set 143 
for C4-2B sublines) and 447 (set 160 for PC3 sublines) validated antibodies (Tibes et al., 
2006) to explore expression/activation levels of signaling proteins following a previously 
described protocol (Pin et al., 2014). The list of antibodies used can be found at 
https://www.mdanderson.org/research/research-resources/core-facilities/functional-
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proteomics-rppa-core/antibody-information-and-protocols.html. The criteria for selection 
of candidate proteins was done by prioritizing those exhibiting an adjusted P value (P 
value corrected by the number of antibodies used to eliminate false positives) cutoff at 
0.01 and fold change of 50% or more. 
The heatmap depicting RPPA results using C4-2B was provided by the 
Functional Proteomics RPPA Core. The heatmap depicting results of PC3 sublines was 
generated as previously described (Broom et al., 2017). 
 
Immunocytochemistry 
For immunocytochemistry analysis of FGFR1 expression in PC3 and C4-2B transfected 
cells, cultured cells were trypsinized, collected, fixed in 4% paraformaldehyde and 
pelleted. Liquid low melting point agarose (Sigma-Aldrich) was then mixed with pelleted 
cells and embedded in paraffin. Fixed and paraffin-embedded cell blocks were sectioned 
and sections were stained with anti-FGFR1 antibody (Cell Signaling Technology, rabbit 
monoclonal, clone D8E4) as described in “Immunohistochemistry in tissue specimens 
obtained from human PCa” section.  
 
ANIMAL STUDIES 
 
All practices involving laboratory animals were approved by the Institutional 
Animal Care and Use Committee of MD Anderson, Houston, TX, under the regulation of 
the Animal Welfare Committee (IACUC), and conformed to the National Institutes of 
Health (NIH) Policy on Humane Care and Use of Laboratory Animals. 
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Intrabone injection 
For intrabone assays, 1 x 106 C4-2B–FGFR1 a, b, or empty vector cells, or 0.5 
x 106 PC3-FGFR1 a, b, or empty vector cells were injected into the distal end of femurs 
of 6- to 8-week-old male severe combined immunodeficiency CB17.SCID mice (Charles 
River Laboratories) (n = 6 per group) as previously described (Li et al., 2008).  
Briefly, cells in culture were trypsinized and collected by spinning in a centrifuge 
at 1,000 rpm for 5 minutes at room temperature. After PBS wash, cell concentration was 
adjusted by adding 1X PBS as needed to produce a final suspension containing 0.5 x 106 
or 1 x 106 cells (according to the subline) per 5 μL, and placed on ice in preparation for 
cell implantation into mice. Animals were anesthetized by administering isoflurane 
according to training in the Institution’s Department of Veterinary Medicine and using an 
approved inhalation-induction-vapor recovery apparatus. Isoflurane was administered at 
concentrations of 4–5% for induction and 2–3% for maintenance of anesthesia. With the 
mouse placed in the left lateral decubitus position, hair was shaved over the distal right 
femur, and the surgical field (lateral side of the distal end of the femur) sanitized by 
spraying it with 70% ethanol. After gently finger flipping a few times a tube containing the 
prepared and iced cell suspension to remix, 15 μL were aspirated into a sterile, glass-tight 
25-μl Hamilton syringe with a 28.5-gauge needle. The Hamilton needle has been 
previously cut to a length of 2.5–3.0 cm and sharpened, polished to make a smooth blunt 
end using a Dremel 10.8-V cordless rotary tool and 541 aluminum oxide grinding wheel. 
With sharp 9-cm straight scissors, a 0.5-cm skin incision was made on the lateral side of 
the distal end of the femur. Holding the femur and tibia with eye forceps, bone was 
exposed, and a track through the cortical bone into the bone marrow cavity was manually 
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created by drilling a hole with a sterile 28.5-gauge needle (attached to an insulin syringe) 
into the femur until the marrow cavity was reached and keeping the needle direction 
parallel to longitudinal axis of femur. The needle was gently removed, followed by insertion 
of the 28.5-gauge needle attached to the Hamilton syringe containing the tumor cell 
suspension through the established needle track into the bone marrow cavity, and 5 μL 
of the cell suspension were slowly injected into the cavity. The needle was carefully 
removed and the injection area sprayed with 70% ethanol. The skin wound was closed 
with one or two surgical clips. The mouse was observed for 24 hours after the implantation 
procedure for any apparent physiologic disturbances, such as infection or inability to walk. 
Wound clips were removed in the usual manner at 10–14 days after the implantation 
procedure (Fig. 16). 
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All mice were monitored by X-ray imaging (Faxitron) in the Small Animal 
Imaging Facility (SAIF) at MD Anderson Cancer Center, Houston, TX. Quantification of 
the radiolucent areas of the X-ray analyses was obtained as the ratio of radiolucent area 
to the total tissue area (whole bone) using the BioQuant Osteo software. Magnetic 
resonance imaging (MRI) was performed at the end of the study. Animals were euthanized 
after eight weeks for C4-2B and after four weeks for PC3 tumor-bearing mice. In each 
case, tumor-bearing femurs and contralateral normal femurs were collected and analyzed 
by high resolution microcomputed tomography (µCT) (SCANCO, Baylor College of 
 
Figure 16. Method used for intrafemoral injection of cancer cells in mice. Note: in vivo 
studies performed in this work were done using male SCID mice, following the exact same 
procedure represented in this figure for male athymic nude mice. Adapted with permission 
from Navone N.M. and E. Labanca, 2017. Modeling Cancer Metastasis. In Patient-Derived 
Xenograft Models of Human Cancer. Y. Wang, D. Lin, and P.W. Gout, editors. Humana Press, 
Cham. 93-114. License Number: 4654420161143. 
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Medicine, The Bone Disease Program of Texas, Houston, TX). Femurs were 
subsequently fixed, decalcified in 10% EDTA pH 7.2 solution (changed daily), and 
processed for histologic analysis (Research Histology Core Laboratory (RHCL) at MD 
Anderson Cancer Center, Houston, TX) and bone histomorphometric analysis (Bone 
Histomorphometry Core Laboratory, The Bone Disease Program of Texas) as previously 
described (Li et al., 2008).  
 
Left ventricle intracardiac Injection  
For intracardiac injection, 1 x 106 PC3- or C4-2B–FGFR1 a, b or corresponding 
empty vector cells were injected into the left ventricle of 6- to 8-week-old male CB17.SCID 
mice (Charles River Laboratories) (n = 12 per group) guided by ultrasound imaging (SAIF, 
MD Anderson Cancer Center). This system allows for the monitoring of precise 
intracardiac injection of tumor cells. 
Briefly, cells in culture were trypsinized and collected by spinning in a centrifuge 
at 1,000 rpm for 5 minutes at room temperature. After PBS wash, cell concentration was 
adjusted by adding 1X PBS as needed to produce a final suspension containing 1 x 106 
cells per 100 μL and placed on ice in preparation for cell implantation into mice. Animals 
were anesthetized using isoflurane as described above. All of the hair around the entire 
chest area was removed prior to the injection using hair removal cream. With the mouse 
placed symmetrically in supine position (dorsal side down), limbs were fixed to the imaging 
table with tape; the surgical field (chest) was sanitized by spraying it with 70% ethanol, 
and dried with sterile gauze, followed by application of ultrasound gel in the area. The 
transducer was mounted in the holder and the position adjusted until the left ventricle 
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could be visualized. After gently finger flipping a few times the tube containing the cell 
suspension and making sure it was free of aggregates to prevent embolic obstruction, 200 
μL were aspirated into a syringe with a 26.5-gauge needle and the syringe was secured 
on the syringe mount. The needle was adjusted until the tip came clearly visible in the 
field of view (Fig. 17). Guided by ultrasound imaging, cell mixture was slowly injected. 
Once the injection was completed, the needle was withdrawn, the transducer set aside 
and the tape removed from the mouse. The animal was cleaned, returned to a clean cage 
with a preheated pad and observed for bleeding or other unusual behavior. The mouse 
was monitored until recovered completely from the anesthesia. 
 
 
 
 
 
 
 
 
Metastases development in the bones was monitored by X-ray (Faxitron, SAIF, 
MD Anderson Cancer Center, Houston, TX) since typically osteolytic metastases are 
easily recognized appearing as C-like notches, or in the case of C4-2B–luc, by 
bioluminescence imaging (see “Bioluminescence Imaging” section). The precise location 
of the bioluminescent areas was then identified by MRI. Animals were euthanized after 
Figure 17. Representative image illustrating 
method to monitor the intracardiac injection of 
cancer cells in left ventricle of mice.  
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four weeks for PC3 and after twelve weeks for C4-2B mice. Bone areas suspicious of 
tumor content were collected, fixed, decalcified and processed for histologic examination 
(RHCL, MD Anderson Cancer Center, Houston, TX). Morphological analyses were 
performed in hematoxylin and eosin (HE)-stained tissue paraffin sections.  
In all cases, mice were anesthetized in an induction chamber as previously 
described prior to imaging, and isoflurane delivery via nosecone maintained throughout 
image acquisition when available. 
 
Bone histomorphometric analysis 
Histomorphometric analysis was performed at the Bone Histomorphometry 
Core Laboratory, The Bone Disease Program of Texas as previously described (Li et al., 
2008). Bone (bone mass, osteoblast and osteoclast) parameters were obtained using 
tartrate-resistant acid phosphatase (TRAP) stains and Harris Modified hematoxylin 
counterstains of decalcified bones. Osteoblasts were clearly visible and easily 
differentiated so an additional toluidine blue stain wasn’t needed.  
 
Magnetic resonance imaging (MRI)  
MRI was performed with a 4.7-T Biospec small-animal imaging system (Bruker 
Biospin, SAIF, MD Anderson Cancer Center, Houston, TX). For anatomic tumor imaging, 
sagittal and axial T2-weighted fast spin-echo sequences with and without fat suppression 
were used, and tumors were subsequently measured with Image J software (NIH) (Kundra 
et al., 2007; Yang et al., 2005).  
 52 
Bioluminescence imaging 
Mice were injected (i.p.) with 100 µL of 15 mg/mL D-Luciferin (Goldbio) in PBS, 
prior to macroscopic bioluminescence imaging using a Xenogen In Vivo Imaging System 
(IVIS) 200 (PerkinElmer, SAIF, MD Anderson Cancer Center, Houston, TX) at 3 minutes 
post-injection. Photon flux emitted by luciferase-expressing cells was then recorded using 
the Living Image software (PerkinElmer). 
 
CLINICAL CORRELATES 
Immunohistochemistry (IHC) in tissue specimens obtained from human PCa 
samples   
IHC analysis of FGFR1 and ladinin 1 expression was performed on 60 samples 
obtained from human PCa. Thirty tissue specimens were derived from the peripheral zone 
of non-metastatic, untreated, primary PCa (7, Gleason score 8; 23, Gleason score 9; [10, 
pT2 and 20, pT3]). Another 30 samples were derived from CRPC bone metastases. 
Samples were obtained from the Prostate Tissue Bank, Department of Pathology, MD 
Anderson Cancer Center, Houston, TX, under an Institutional Review Board approved 
protocol. Fresh cut unstained sections as well as HE-stained slides were provided for 
each sample. Bone metastases specimens were decalcified and formalin-fixed, paraffin-
embedded (FFPE) as previously described (Yang et al., 2001).  
Unstained tissue sections were stained with anti-FGFR1 antibody (Abcam, 
rabbit monoclonal, clone EPR806Y) and anti-LAD1 antibody (Sigma-Aldrich, rabbit 
polyclonal) as described elsewhere (Wan et al., 2014). Briefly, slides were dried lying flat 
at 56-60°C overnight prior to staining. After deparaffinization and hydration of sections, 
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heat-induced antigen retrieval was performed using citrate buffer, pH 6.0, in a water bath, 
and then 5% normal goat serum (Sigma-Aldrich) was used for blocking. Slides were 
incubated with diluted primary antibody in a humidity chamber at 4°C overnight. After 
secondary antibody incubation (goat anti-rabbit IgG biotin-conjugated, Invitrogen) at 37°C 
for 45 minutes, slides were incubated in Streptavidin HRP ready-to-use (RTU) solution 
(Vector Laboratories) for 30 minutes at room temperature. NovaRed Peroxidase substrate 
(Vector Laboratories) chromogen was used for visualization of signal (optimal time was 
determined by monitoring the chromogenic reaction in corresponding controls at the pilot 
experiment and kept consistent throughout) and Hematoxylin QS (Vector Laboratories) 
as counterstain, followed by fast dip in lithium carbonate. After hydration and clearing in 
Histoclear (National Diagnostics), slides were mounted using non-aqueous permanent 
Vectamount (Vector Laboratories) and examined under bright-field microscopy. Slides 
were read independently by 2 investigators and classified according to staining intensity 
(-, +/-, +, ++, +++), with - being negative stain and +++ the most intense staining. 
Positive/negative (+/-) expression refers to heterogeneous expression, i.e., some areas 
positive and some areas negative within the same sample, or very slight staining. 
Evaluations were concordant in 90% of the readings; differences were resolved by 
consensus after joint review. 
Corresponding controls including no primary antibody and no secondary 
antibody were processed simultaneously following the exact same procedures. 
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STATISTICS 
GraphPad Prism (GraphPad software) and Microsoft Excel (Microsoft Office 
Package) were used for statistical analysis. Data were expressed as means ± standard 
deviation (SD), unless otherwise indicated. Two experimental groups were compared with 
the two-tailed Student’s t test for unpaired data, unless otherwise specified. 
Nonparametric Mantel-Cox tests were carried out when comparing Kaplan-Meier survival 
curves for mice. Chi-squared test was used to compare the number of bone metastases 
per group. Fisher’s exact test was used to compare immunohistochemical scores in 
human samples. Chi-squared test with Yates correction was used to assess significance 
of gene amplification differences between cBioPortal datasets. P values < 0.05 were 
considered statistically significant. For RPPA analyses, an adjusted P value was 
calculated by correcting it by the number of events (n=295 o 447) to eliminate false 
positives. 
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Chapter 3: RESULTS 
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Previous studies conducted in our laboratory suggested that targeting FGF 
signaling interfered with PCa cells-bone cells interaction (Li et al., 2008), and also 
implicated the FGF axis, mainly FGFR1, in the progression of PCa in bone (Wan et al., 
2014). In this work, we applied in silico, in vitro and in vivo preclinical approaches, 
complemented with correlative studies using human samples to better elucidate the 
significance of FGFR1 activation in PCa bone metastasis. 
 
Different human PCa tissue samples express different FGFR1 isoforms  
Our previous large-scale RNA sequencing study indicated that FGFR1 has the 
highest expression among all FGFRs in human PCa samples (Wan et al., 2014). Here, 
we extended our analysis of this dataset by assessing the expression of FGFR1 isoforms 
and found different FGFR1 isoforms in different PCa (Appendix II). In a further analysis, 
we identified eight different protein-coding transcripts to be the most abundantly 
expressed, three of them with a predicted protein length of 731 to 733 amino acids (aa) 
and lacking the a exon (ENST00000326324; ENST00000356207; ENST00000397103). 
The other five with a predicted protein length of 820 to 853 aa and containing the a exon 
(ENST00000397091; ENST00000397108; ENST00000397113; ENST00000425967; 
ENST00000532791) (Appendix II). Based on the predicted protein lengths of these 
transcripts and the absence or presence of the a exon, we focused this study on the two 
best characterized FGFR1 isoforms, a (containing the a exon; NM_023110.2; 822 aa) 
and b (lacking the a exon; NM_023105.2; 733 aa) (Johnson and Williams, 1993).  
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FGFR1 isoforms are associated with the expression of different genes in human 
PCa  
The findings outlined above suggest that FGFR1 isoforms expression may at 
least partly underlie PCa heterogeneity. We thus mined PRAD-TCGA dataset to identify 
transcripts associated with each FGFR1 isoform, a and b, and subsequently assessed 
the expression of genes correlated with each isoform by differential expression analysis. 
As shown in Fig. 18, we found that each FGFR1 isoform transcript is associated with the 
expression of different genes. In particular, FGFR1 b is associated with a larger number 
of genes than FGFR1 a  (Fig. 18).  
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Figure 18. Heatmap of the 2,000 genes most highly correlated with 
FGFR1 isoforms a and b in PRAD-TCGA dataset. The relative expression 
of each isoform was defined as the proportion of FGFR1 a to the sum of 
FGFR1 a + FGFR1 b (FGFR1 score) in tumor samples (upper bar) (a high 
ratio indicates prevalence of the a isoform, and a low ratio indicates 
prevalence of b isoform). Rows represent specific genes and columns 
represent tumor samples arranged in relative levels of FGFR1 isoforms. As 
the proportion of FGFR1 a increased within the samples, expression of most 
genes decreased. Red: high normalized gene expression; green: low 
normalized gene expression (Broom et al., 2017). 
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Among the top 20 genes correlated with FGFR1 b is CTSK (correlation 
coefficient = 0.539713) (Table 1), coding for cathepsin K, a protease expressed in 
osteoclasts and involved in bone resorption (Drake et al., 2017).  
 
 
  
Table 1. List of the 20 genes most highly correlated with FGFR1 a 
and b isoforms in PRAD-TCGA dataset. Gene: gene symbol; 
correlation: correlation coefficient; coefficient: magnitude of change in 
gene expression from FGFR1 score 0 (prevalence of FGFR1 b) to 1 
(prevalence of FGFR1 a). The arrow indicates CTSK, a gene of particular 
interest, highly correlated to FGFR1 isoform b. 
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Also, GSEA indicated that FGFR1 b isoform is associated with a larger number 
of pathways than FGFR1 a (FGFR1 a n = 17; FGFR1 b n = 500) (Fig. 19, Appendix III 
and IV).  
 
Given the large number of pathways identified, we increased the stringency of 
prioritized pathways by selecting those with a P value < 0.002 and normalized enrichment 
score (NES) > 1.78 for pathways associated with FGFR1 a and < -1.78 for pathways 
associated with FGFR1 b (described in “Methods” section). Using these criteria, we 
identified only one pathway associated with FGFR1 a (“mitochondrial tRNA 
aminoacylation”) (Fig. 20A), while FGFR1 b was found significantly associated with 50 
pathways. Of interest, among those associated with FGFR1 b are “MAPK signaling 
cascade,” “signaling by FGFR in disease,” and “pathways in cancer” (Fig. 20B). 
Figure 19. Proportion of FGFR1 isoforms-
associated pathways. Pie chart representing the 
amount of pathways significantly associated with 
FGFR1 a (light blue) and b (dark blue) resulting from 
GSEA of FGFR1 isoforms in PRAD-TCGA dataset. 
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Figure 20. Most significantly FGFR1 a- and b-associated pathways in 
PRAD-TCGA dataset. Pathways most significantly associated with FGFR1 
a (A) and FGFR1 b (B) identified in GSEA of PRAD-TCGA dataset. The 
selection criteria were the combined P value < 0.002 and NES > or < +/-1.78, 
respectively. Only one pathway significantly associated with FGFR1 a met 
these criteria; while numerous pathways were found significantly associated 
with FGFR1 b under these criteria. The figure depicts particular pathways of 
interest selected for b. 
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Of note, in PRAD-TCGA dataset analyzed, we found that 11 samples expressed 
only FGFR1 a (proportion = 1), and one other sample expressed almost only b (proportion 
= 0.05). The majority of the samples had values between 0.5 and 0.9, indicating a higher 
proportion of FGFR1 a transcripts than FGFR1 b in most PCa. 
To further understand the role of FGFR1 isoforms in PCa, we used two different 
PCa cell lines: PC3, which does not express AR and is therefore hormone insensitive, 
and C4-2B, an AR-expressing subline of LNCaP obtained from a bone metastasis in mice. 
Generated PCa cell lines that stably express FGFR1 isoforms (PC3-FGFR1 a, b; C4-2B–
FGFR1 a, b) or empty vector (V) were treated with FGF (Fig. 21A). Western blot analyses 
showed a greater induction of P-MAPK when cells express FGFR1 b isoform (Fig. 21B), 
which supports our in silico findings that the MAPK cascade is significantly associated 
with the b isoform. RPPA analyses of C4-2B cells that stably express FGFR1 isoforms 
further confirmed our findings that the MAPK cascade is significantly associated with the 
b isoform (Fig. 22). 
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Figure 21. FGFR1 and P-MAPK expression in PCa cells. A. 
Schematic representation of the experimental protocol for cell 
preparation. PC3- or C4-2B–FGFR1 a, b, and control (V) cells were 
cultured in serum-starved conditions for three hours, HSPG (50 ng/mL) 
was added during the last hour. Subsequently, cells were cultured in 
the absence or presence of 100 ng/mL FGF2 or FGF9 for 45 minutes. 
Then, cells were harvested and lysates prepared for Western blot or 
RPPA (A). B. Western blot analyses of FGFR1 and P-MAPK 
(Thr202/Tyr204) expression in C4-2B and PC3 cells expressing 
FGFR1 a, b, or empty vector (V), untreated or treated with FGF2 and 
FGF9 as outlined in A. Similar results were obtained in independent 
experiments. GAPDH was used as loading control. 
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FGFR1 alters the bone phenotype induced by PCa cells in tumor-bearing femurs  
To understand whether the signaling pathways induced by each isoform in 
human PCa result in different biological effects, we evaluated tumor growth and bone 
reaction induced by PC3 cells stably overexpressing FGFR1 isoforms after direct femur 
injection (Fig. 23).  
 
 
 
 
 
Figure 22. Heatmap depicting RPPA results of C4-2B–FGFR1 sublines. The heatmaps 
was generated by antibody unsupervised hierarchical clustering of RPPA analysis of C4-
2B–FGFR1 a, b, and control (V) cells treated or untreated with FGF2. Cell lysates were 
prepared as outlined in Fig. 21. Each column represents a replicate (n = 5 per group). 
“Red” in the heatmaps indicates the values are above the median and “green” indicates 
the values are below the median. 
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X-ray analysis of tumor-bearing bones showed several areas of radiolucency 
that increased overtime, suggesting that these cells induce osteolysis. Quantitative 
analysis (Bioquant Osteo) of lesions in X-ray images at four weeks after cell injection 
revealed an increase in radiolucent areas in bones bearing PC3-FGFR1 isoforms tumors 
compared with PC3-V tumors (P = 0.0094 a vs V; P = 0.0001 b vs V) (Fig. 24).  
 
 
 
 
 
 
Figure 23. PC3-FGFR1 sublines intrabone injection. Schematic 
representation of femur injection of PC3-FGFR1 a, b, or control empty 
vector (V) cells and monitoring during four weeks. Western blot analysis 
and immunocytochemistry results of FGFR1 expression in cells used in 
these studies. GAPDH was used as loading control in the Western blot 
analysis. Injected mice (n = 6 per group) were monitored by X-ray and MRI. 
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Accordingly, tumor volume, as assessed by MRI analysis, was significantly 
increased in PC3-FGFR1 isoforms tumors compared to PC3-V tumors (P = 0.038, Fig. 
25).  
 
 
 
 
 
 
Figure 24. X-ray analysis of mouse femurs injected with PC3-FGFR1 
sublines. Representative radiographs (left panel) and quantification of 
radiolucent areas (right panel) of the X-ray analysis of PC3-FGFR1 a, b, 
and V tumor-bearing femurs at four weeks after injection. Student’s t test; 
error bars indicate SD. 
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Also, bone volume, as assessed by high resolution µCT analysis, was reduced 
in femurs injected with PC3-FGFR1 a or b compared with femurs injected with control 
cells (a P = 0.014; b P = 0.007; Fig. 26).  
 
 
Figure 25. MRI analysis of mouse femurs injected with PC3-FGFR1 
sublines. Representative sagittal MR images of femurs acquired with a 4.7-
T scanner using a T2- weighted fast spin (T2-FS) echo sequence with fat 
suppression (upper panel). Arrows indicate tumor, which appears as areas 
of increased signal on T2-weighted images. Tumor volume of PC3-FGFR1 a, 
b, or V tumor-bearing femurs assessed by MRI analysis (lower panel). 
Student’s t test; error bars indicate SD. 
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Together these results indicate that FGFR1 expression in PCa cells induces 
tumor growth and bone resorption. 
In order to understand the cellular changes behind the observed bone 
phenotype, we performed histomorphometric analyses of tumor-bearing bones. In 
accordance with the µCT results, we found a reduction of bone mass parameters (bone 
volume to tissue volume [BV/TV]) in PC3-FGFR1 isoforms tumor-bearing femurs 
(compared with V controls) (Fig. 27). However, osteoclast parameters (osteoclast surface 
to bone surface [Oc.S/BS]) were increased in PC3-FGFR1 b (but not a) compared with 
PC3-V tumor-bearing femurs (Fig. 27). These results are in accordance with our PRAD-
TCGA mining results, where we found an association between FGFR1 b and CTSK 
transcript (a protein predominantly expressed in osteoclasts) (Table 1), as well as with 
previous reports showing that PCa cells express CTSK (Brubaker et al., 2003; Munari et 
al., 2017). These evidences indicate that PCa cells expressing FGFR1 b are most suited 
Figure 26. µCT analysis of mouse femurs injected with PC3-FGFR1 
sublines. Representative two-dimensional slices of specimens analyzed by 
high-resolution µCT analysis at the end of study (four weeks)  (left panel). Right 
panel indicates bone volume results. Student’s t test; error bars indicate SD. 
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to activate bone remodeling, which may facilitate tumor growth in bone. This is also in 
alignment with the greater increase in tumor volume observed in FGFR1 b tumors by our 
MRI analysis (Fig. 25).  
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Figure 27. Bone histomorphometry analysis of mouse femurs injected with PC3-
FGFR1 sublines. Representative photomicrographs of decalcified tumor-bearing 
femur sections stained with HE (upper left panel) and tartrate-resistant acid 
phosphatase (TRAP) (upper right panel) (20´ magnification, left; 40´ magnification, 
right). Bone histomorphometry analyses indicated a reduced ratio of bone volume to 
tissue volume (BV/TV) in PC3-FGFR1 tumor-bearing mice (lower left panel). Bone 
histomorphometry analyses of TRAP-stained sections indicate an increase in 
osteoclast (Oc) surface to bone surface) in PC3-FGFR1 b tumor-bearing mice (lower 
right panel). Scale bar, 100µ (20´) o 50µ (40´). Student’s t test; error bars indicate SD. 
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In an independent study, we evaluated the effect of FGFR1 isoform expression 
in C4-2B cells (Fig. 28A). Again, we monitored tumor growth and bone response of tumor-
bearing bones by X-ray. Although we followed the same experimental design as outlined 
in Fig. 23, in this case we terminated the study at eight weeks given the slow growth rate 
of this cell line in vivo. In agreement with the mixed osteoblastic/osteolytic bone reaction 
that this cell line typically produces, there were radiolucent and radiopaque areas visible 
at the X-ray analysis that could not be accurately quantified (Fig. 28B).  
 
 
All injected mice developed tumor as demonstrated by MR imaging. However, 
no difference in tumor volume was observed between C4-2B–FGFR1 isoforms and C4-
2B-V groups (Fig. 29). Nonetheless, in µCT analysis, we found a decrease in bone volume 
in the femurs injected with C4-2B–FGFR1 b (but not a) compared with femurs injected 
Figure 28. C4-2B-FGFR1 sublines intrabone injection. A. Western blot 
analysis and immunocytochemistry analysis results of FGFR1 expression in 
C4-2B cells injected into the femurs of mice. Injected mice (n = 6 per group). 
GAPDH was used as loading control in the Western blot analysis. B. 
Representative radiographs of X-ray analysis of femurs injected with C4-2B 
sublines at eight weeks after injection. 
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with C4-2B–V (P = 0.024) (Fig. 30). 
 
  
 
 
 
 
 
 
 
 
 
Figure 29. MRI analysis of mouse femurs injected with C4-
2B-FGFR1 sublines. Representative sagittal MR images of femurs 
acquired as in Fig. 25 (left panels). Arrows indicate tumor. Tumor volume 
assessed by MRI of C4-2B–FGFR1 a, b, or V tumor-bearing femurs (right 
panel). Not significant, Student’s t test; error bars indicate SD. 
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Bone histomorphometry analyses of C4-2B–FGFR1 b (but not a) tumor-bearing 
mouse bones showed an increase in osteoclast parameters (Oc.S/BS) compared with C4-
2B–V mouse bones (Fig. 31). These results support our previous conclusion that PCa 
cells expressing FGFR1 b are most suited to activate osteoclasts.   
Figure 30. µCT analysis of mouse femurs injected with C4-2B-FGFR1 
sublines. Representative two-dimensional slices of specimens analyzed 
by high-resolution µCT analysis at the end of study (upper panel). Lower 
panel indicates bone volume results. One-tailed Student’s t test; error bars 
indicate SD. 
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FGFR1 isoforms significantly increase PCa bone metastases in vivo 
Based on previous reports that FGFR1 is implicated in the pathogenesis of PCa 
bone metastases (Wan et al., 2014), we then sought to investigate whether FGFR1 
isoforms modulate the metastatic potential of PCa cells to bone. In a pilot study we 
Figure 31. Bone histomorphometry analysis of mouse femurs injected with 
C4-2B-FGFR1 sublines. Representative photomicrographs of decalcified tumor-
bearing femur-sections stained with HE (left panels) and TRAP (right panels) (20´ 
magnification, left; 40´ magnification, right). Bone histomorphometry analyses of 
TRAP-stained sections indicate an increase in osteoclast (Oc) surface/bone 
surface) in C4-2B–FGFR1 b tumor-bearing mice (lower panel). Scale bar, 
100µ (20´) o 50µ (40´). One-tailed Student’s t test; error bars indicate SD. 
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analyzed the effect of FGFR1 in PC3 cells stably expressing FGFR1 a after intracardiac 
injection in mice. In animals injected with PC3-FGFR1 a, 3 out of 10 died by four weeks 
post-injection, and 8 out of 10 died by six weeks post-injection (time in which study was 
concluded). In contrast, only 1 out of 10 mice injected with PC3-V died before the study 
was concluded. Statistical analysis indicated that mice injected with PC3-FGFR1 a had 
significantly reduced survival compared with animals injected with PC3-V (P < 0.0001) 
(Fig. 32). 
 
 
In an independent study, we injected mice intracardially with PC3-FGFR1 a, b, 
or V (Fig. 33). Development of bone metastases was monitored by X-ray analysis (Fig. 
34). At four weeks post-injection, the study was concluded and necropsy was performed. 
Figure 32. Kaplan-Meier survival curves of mice 
injected intracardially with PC3-FGFR1 a (red) and PC3 
control cells (V, green) (n = 10 male CB17.SCID mice per 
group) (log-rank (Mantel-Cox test) P < 0.0001). 
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We studied radiolucent lesions detected at X-ray imaging for tumor content by 
morphological analyses of HE-stained tissues (Fig. 35).  
 
 
 
 
 
Figure. 33. PC3 sublines injected into the heart of SCID mice. 
Schematic representation of mice injection intracardially with PC3-
FGFR1 a, b, or control empty vector (V) cells and monitoring by X-
ray analysis (n = 12 per group). Western blot analysis results of 
FGFR1 expression in cells used in these studies. GAPDH was used 
as loading control. 
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Figure 34. Rate of bone metastases of PC3-FGFR1 sublines after 
intracardiac injection into SCID mice. Representative radiographs of injected 
whole mice, illustrating radiolucent areas suspicious of osteolytic bone metastases 
(red arrows) at four weeks post-injection (upper panel). Number of mice with bone 
metastases after four weeks of intracardiac injection (lower panel). P = 0.000045 
FGFR1 a vs V; P = 0.02474 FGFR1 b vs V, chi-squared test. 
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As shown in Fig. 34, significantly more mice injected with PC3-FGFR1 a and 
PC3-FGFR1 b developed bone metastases compared with mice injected with PC3-V (P = 
0.00005 and P = 0.025, respectively). These studies indicate that FGFR1 significantly 
increases bone metastases in PCa.  
To extend our findings, we used C4-2B cells and established FGFR1 isoform 
sublines (Fig. 36). These lines were made to expressed luciferase, because C4-2B do not 
produce clear bone osteolytic lesions, which would allow their identification by direct X-
ray analyses. Therefore, metastases were determined by bioluminescence imaging (Fig. 
Figure 35. Examples of histological validation of PC3-FGFR1 sublines bone 
metastases. Magnification of radiolucent areas indicated by arrows in Fig. 34, upper 
panel). Red arrows: suspicious osteolytic bone metastases. Corresponding 
photomicrographs of decalcified tumor-bearing sections stained with HE (40´ 
magnification, Scale bar 50µ). 
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36). We found mice with suspicious lesions, and the precise location of the bioluminescent 
areas were then identified by MRI (Fig. 37). At necropsy, we harvested suspicious tumors 
and confirmed, by histology, the presence of mandibular metastases in two mice injected 
with C4-2B–FGFR1 a (Fig. 37). We did not find bone metastases in mice injected with 
C4-2B–V or C4-2B–FGFR1 b (Fig. 36). Taken together, these results suggest that FGFR1 
mediates PCa progression to metastasis and that the penetrance of this effect might be 
modulated by FGFR1-specific isoforms and by the cellular genetic background. 
Figure 36. Rate of bone metastases of C4-2B–FGFR1 sublines after 
intracardiac injection into SCID mice. Western blot analysis results of 
FGFR1 expression in C4-2B–FGFR1 a, b, or control empty vector (V) 
luciferase cells used for intracardiac injection (12 mice per group) (upper left 
panel). GAPDH was used as loading control. Representative images signal 
detection monitored by ventral whole-body bioluminescence of mice at 
twelve weeks after injection (upper right panel). Number of mice with bone 
metastases after twelve weeks of intracardiac injection (lower panel). 
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FGFR1 expression is significantly increased in human PCa bone metastases  
To assess the clinical relevance of our findings, we analyzed the expression of 
FGFR1 in human PCa by IHC analysis. We selected thirty untreated, non-metastatic 
primary PCa tissue specimens and thirty bone metastatic tissue specimens with CRPC 
(Fig. 38). Noticeably, we observed a significant enrichment of FGFR1 expression in bone 
metastases (11/26) versus primary PCa (2/29) (P = 0.0007), supporting our postulate that 
FGFR1 induces the metastatic cascade in PCa. In alignment with our previous RNA 
sequencing studies in human samples, levels of FGFR1 are heterogenous across 
samples (Wan et al., 2014).  
Figure 37. Analysis of bioluminescent-positive areas produced by 
intracardiac injection of C4-2B-FGFR1 sublines. MRI images 
corresponds to the mouse injected with C4-2B-FGFR1 a shown in Fig. 36 
acquired as in Fig. 25 (left and middle panels). Arrows indicate tumor at 
mandible. Corresponding photomicrographs of decalcified tumor-bearing 
sections stained with HE (40´ magnification, Scale bar 50µ) (right panel). 
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Figure 38. FGFR1 expression in human PCa. Representative photomicrograph 
images of sections stained with HE and immunostained with FGFR1 (20´ and 40x 
magnification, Scale bar 100µ and 50µ, respectively). Table summarizing FGFR1 
expression findings in human primary PCa and bone metastatic tissue samples assessed 
by immunohistochemical analysis (lower panel). Positive/negative (+/-) expression refers 
to heterogeneous expression, i.e., some areas positive and some areas negative within 
the same sample, or very slight staining. P =  0.0007, Fisher’s exact test. 
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As reference for endogenous levels, we assessed the expression of FGFR1 in 
normal prostate tissue samples (Fig. 39). Additionally, we confirmed our previous report 
that FGFR1 is expressed in tumor-associated osteoblasts (Wan et al., 2014) in 74% 
(14/19) of the samples (Fig. 40). 
 
 
 
Figure 39. FGFR1 expression in human prostate tissue. 
Representative photomicrograph images of sections of the 
peripheral zone of a human normal prostate specimen stained with HE 
and immunostained with FGFR1 (20´ and 40x magnification, Scale 
bar 100µ and 50µ, respectively). 
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FGFR1 isoforms induce the expression of ladinin 1, an anchoring filament protein, 
in PCa PC3 cells. 
To understand the mechanism of FGFR1-induced metastases, we performed 
RPPA analysis of PC3 cells stably expressing FGFR1 isoforms (Fig. 41).  
 
 
 
 
 
 
 
Figure 40. FGFR1 expression in human PCa bone metastasis.  
Representative photomicrograph images of sections of human PCa 
bone metastasis specimen stained with HE and immunostained with 
FGFR1 (20´ and 40x magnification, Scale bar 100µ and 50µ, 
respectively) depicting positive FGFR1 reactivity in tumor-associated 
osteoblasts (arrows). 
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Using Ingenuity Pathway Analysis (IPA) with a fold change of +/- 2, we found 
that FGFR1 expression modulates genes in cell movement-associated networks (Fig. 42).  
 
 
 
 
 
 
 
 
Figure 41. Heatmap depicting RPPA results of PC3-FGFR1 sublines. Left panel: the 
heatmap was generated by antibody unsupervised hierarchical clustering of RPPA 
analysis of PC3-FGFR1 a, b, and control (V) cells treated or untreated with FGF2. Cell 
lysates were prepared as outlined in Fig. 21. Each column represents a replicate (n = 5 
per group). “Blue” indicates the values are above the median and “red” indicates the 
values are below the median. Right panel: detailed view of section outlined in green 
rectangle on left panel. 
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We further prioritized upregulated candidates genes that have been reported to 
be associated with cancer progression and/or PCa (LAD1, CDH1 and GLS) (Putzke et al., 
2011; Roth et al., 2018; Santin et al., 2004; Twum-Ampofo et al., 2016; Wang and Guda, 
2016). We subsequently confirmed ladinin 1 (LAD1) to be upregulated in FGFR1-
overexpressing PC3 cells by Western blot analysis (Fig. 43).  
 
 
 
 
Figure 42. Network identified by IPA using RPPA 
results of PC3-FGFR1 a–induced genes. Similar 
findings were obtained with PC3-FGFR1 b. Red: 
upregulated genes; green: downregulated genes. 
Color intensity is based on fold change. 
 86 
 
Interestingly, in accordance with our results, LAD1 gene was significantly 
amplified in metastatic CRPC (SU2C/PCF Dream Team dataset ((Abida et al., 2019)), 
compared with cases in PRAD-TCGA dataset (Hoadley et al., 2018), which includes only 
primary PCa (7% vs 0.2%; P < 0.0001) (Fig. 44).  
 
 
Immunohistochemical analysis of human CRPC bone metastases revealed a 
significant enrichment of LAD1 expression in bone metastases compared with treatment-
Figure 43. LAD1 expression in PC3-FGFR1 sublines. 
PC3 cells expressing FGFR1 a, b, or control empty 
vector (V) were induced with FGF2. FGFR1 expression 
levels are shown. GAPDH was used as loading control. 
Figure 44. LAD1 genetic alterations in human prostate 
adenocarcinoma. Datasets were selected from cBioPortal Cancer 
Genomics (www.cbioportal.org). TCGA contains primary PCa samples; 
SU2C/PCF Dream Team contains metastatic CRPC samples. 
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naïve, non-metastatic primary tumors (P = 0.0048), supporting the concept that LAD1 
mediates, at least in part, the PCa metastatic phenotype (Fig. 45). 
 
 
  
Figure 45. LAD1 expression in human PCa. Representative 
photomicrograph images of sections immunostained with LAD1 
(20´ and 40x magnification). Table summarizes LAD1 expression 
findings in untreated, non-metastatic PCa and in CRPC bone 
metastases. P = 0.0048, Fisher’s exact test. 
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Chapter 4: DISCUSSION  
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Despite effective treatment, no curative therapy is currently available for 
metastatic PCa. The mechanisms of progression are diverse and include FGF axis 
activation (Bluemn et al., 2017; Corn et al., 2013; Li et al., 2008; Valta et al., 2008; Wan 
et al., 2014). Hence, development of FGFR blockade for advanced PCa is critical.  
Currently, there are FGFR inhibitors available and clinical trials are ongoing in 
other malignancies. However, based on prior experience on clinical trials of inhibitors 
targeting aberrantly activated pathways in CRPC, long-term treatment responses 
occurred in only a subpopulation of patients, and predictors of treatment response have 
yet to be validated (Mateo et al., 2015; Saura et al., 2016; Smith et al., 2013; Wan et al., 
2014; Zafeiriou et al., 2016). Therefore, it might be expected that a monotherapy with an 
FGFR inhibitor may not accomplish the desired significant control of PCa progression, 
and it is essential to identify combination therapies that may optimize efficacy. 
Understanding the molecular heterogeneity of tumors led to the successful 
application of targeted agents in many cancer types (Amirouchene-Angelozzi et al., 2017). 
As previously mentioned, it is increasingly recognized that PCa is a heterogeneous 
disease yet available therapies continue to be applied homogeneously. Indeed, the fact 
that responses to agents with different mechanisms of action were not uniform in PCa 
patients, is one more evidence of the biological heterogeneity of these tumors and 
underscore the urgent need to integrate our knowledge of PCa biology into clinical 
application to address each tumor’s unique behavior.  
Our comprehensive study of the biological role of two FGFR1 isoforms (a and 
b) and the identification of their different associated signaling pathways in PCa, provides 
a better understanding of the complexity of this pathway in a clinical context and underlies 
the importance of defining FGFR1 mediators of PCa progression and markers of FGFR1 
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signaling. This knowledge brings the relevance of FGFR1 isoforms and their associated 
gene signatures to the forefront of PCa research and will help develop effective strategies 
for targeting FGFR1 as PCa therapy. 
 Our studies also indicate that FGFR1 expression in PCa cells enhances their 
metastatic behavior. These data are in alignment with our findings of an increase in 
expression of FGFR1 in CRPC bone metastases compared with primary, untreated PCa. 
Further, it was previously reported that elevated FGF signaling occurs in a subpopulation 
of metastatic CRPC (Armstrong et al., 2011; Bluemn et al., 2017) and that it mediates 
progression under cabozantinib therapy (Varkaris et al., 2016), supporting the concept 
that, under selective pressure, FGFR1 pathway activation occurs later in the progression 
of the disease mediating therapy resistance. Considering that many patients progressing 
under ADT are already metastatic, our observation that FGFR1 further activates the 
metastatic program of a PCa cell line (PC3) that was already metastatic suggests that 
FGFR1 mediates not only progression to therapy but also induces secondary metastases. 
Therefore, the timeframe of initiation of FGFR1 blockade therapy is of upmost relevance 
as a secondary prevention strategy.  
The enhanced metastatic profile of PCa cells expressing FGFR1 was observed 
in the AR-negative PC3 cell line but was less apparent when we used the AR-positive C4-
2B PCa cells, models for AR-negative and AR-positive CRPC, respectively. These results 
are in agreement with a previous report that FGFR axis mediates the castration-resistance 
progression of a subpopulation of AR-negative PCa and that AR experimental 
downregulation results in an increase in FGF signaling (Bluemn et al., 2017). Our results 
expand on this concept and show that the effects mediated by FGFR1 isoforms are 
modulated by the genetic background of PCa cells. Indeed, FGFR1 expression in PC3 
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cells (but not C4-2B) resulted in increased PCa tumor growth in bone. On the other hand, 
expression of FGFR1 b (but not a) in both PC3 and C4-2B induced osteoclast parameters 
in bone after intrafemur injection.  
In summary, our studies point to the significance of FGFR1 isoform diversity in 
PCa and address the need for additional treatment modalities to disrupt the dissemination 
of PCa cells to bone. Dissecting the role of FGFR1 isoforms in PCa bone metastases will 
significantly contribute to the identification of men with FGFR1 activation as candidates 
for FGFR1 blockade. 
Another important contribution of our studies was the identification, for the first 
time, of LAD1 as a downstream target of FGFR1 and its enrichment in CRPC bone 
metastases.  
Constituent of the basement membrane, LAD1 is a relatively uncharacterized 
protein encoded by the LAD1 gene, which may be involved in stabilizing the interaction of 
the epithelium to the mesenchyme (Ishiko et al., 1996). It was recently implicated in actin 
fiber remodeling, proliferation, and motility of mammary cells (Roth et al., 2018). Further, 
increased abundance of LAD1 was reported to predict poor prognosis in high-grade 
breast tumors (Roth et al., 2018), and it was suggested as a new therapy target for triple-
negative breast cancer and ovarian cancer (Santin et al., 2004; Wang and Guda, 2016). 
Further, LAD1 is a downstream target of glucocorticoid receptor (GR) (Chen et al., 2008), 
which is highly implicated as a resistance mechanism mediating CRPC (Narayanan et al., 
2016; Puhr et al., 2018). 
Finally, the evidence presented in this report indicates that LAD1 mediates the 
FGFR1-induced metastases in a subpopulation of cases. The identification of bone 
metastases specimens that do not express FGFR1 but are positive for LAD1 suggest that 
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LAD1 may be downstream of other pathways and have a broader role in PCa metastases 
beyond FGFR1. Hence, the biological implications of LAD1 expression in PCa 
pathogenesis warrant further investigation.  
Overall, here we report for the first time that FGFR1 isoforms are associated 
with a different gene signature in PCa. The clinical relevance of these results relies on the 
identification of PCa patient candidates for FGFR1 blockade therapy and the detection of 
FGFR1 target genes expected to be modulated by FGFR1 targeting. Our findings are also 
the first to showcase that FGFR1 underlies the metastatic dissemination of PCa, and that 
LAD1, a relatively uncharacterized anchoring filament protein, is downstream of FGFR1 
and enriched in human PCa bone metastases. These results, together with reports 
indicating that FGFR1 is a major factor involved in disease progression under treatment 
(Bluemn et al., 2017; Varkaris et al., 2016), suggest that the FGFR1-LAD1 axis mediates 
progression to metastases and provides a framework of new opportunities for 
development of FGFR1-LAD1 targeted therapies and/or the identification of markers of 
progression.  
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Future Directions  
In this dissertation, our study has focused on the two best characterized isoforms 
of FGFR1. It would be of relevant interest to investigate the expression of these isoforms 
in human tissue, by RNA in situ hybridization and study its correlation with PCa clinical 
stage. Nonetheless, it is worth noting that, as previously described, these are not the only 
FGFR1 transcripts. Indeed, Ensembl reports more than forty variants for FGFR1, out of 
Figure 46. A schematic model depicting FGFR1 as a driver of PCa metastatic 
progression. Increased FGFR1 expression in PCa cells occurs under selective pressure of 
ADT and other therapies. PCa cells express various FGFR1 isoforms, e.g., a and b, which 
activate common as well as different pathways. FGFR1 expression in therapy resistant PCa 
mediates growth of PCa cells in bone. Briefly, once PCa cells overexpressing FGFR1 reach 
the bone marrow microvasculature, FGFR1 activated pathways, like LAD1, would mediate 
motility and adhesion enabling the PCa to invade and grow in bone.  
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which twenty are protein coding. Hence, we acknowledge that the detection using this 
technique would include other isoforms as well. 
As an initial approach, not described as it is beyond the scope of this dissertation, 
we have detected expression of some additional variants in PCa and their associated 
clinical parameters by in silico analysis. The clinical relevance as well as the redundancies 
of all these transcripts and our in silico findings remain to be studied in further detail.  
Additionally, the existence of different FGFR isoforms resulting from altered 
splicing can enable stimulation of cancer cells by a broader range of ligands (Brooks et 
al., 2012). The fact that we have detected numerous isoforms in the bioinformatics 
approach could be suggestive of this. In fact, in spite of the differences observed, given 
our findings in which one isoform would support the phenotype/biological effect of the 
other isoform, our postulate is that presence of both isoforms will be associated with a 
poorer prognosis or worst outcome. Future directions of interest would be studying the 
effect of expressing both isoforms simultaneously in the same cell line. 
Next steps in this work for an even more in-depth characterization of the isoforms 
and FGFR1 is immunoprecipitation followed by mass spectrometry. This approach would 
help in two ways: determine the interacting protein partners, which might aid to better 
understand the FGFR1-mediated mechanisms of metastasis, as well as the detection of 
the isoforms at the protein level. 
Notably, we also observed FGFR1 staining in tumor-associated osteoblasts in 
human samples, in line with previous data (Wan et al., 2014); the meaning of this 
observation and its role in PCa-bone interaction open up an avenue to explore.   
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On a clinical perspective, this study served as a basis for further studies using a 
pan-FGFR inhibitor (erdafitinib), of top relevance since it is currently FDA-approved for 
advanced urothelial bladder cancer (Loriot et al., 2019). Pre-clinical studies in our 
laboratory with this drug using patient-derived xenografts (PDX) with high and low FGFR1 
expression have shown its efficacy and would help define responders to treatment and 
resistance. The inhibitor targets the tyrosine kinase domain, thus it would be expected 
that both isoforms will respond the same; however, given their signaling and affinity 
differences, as well as evidence of diverse responses using another drug in other cancers 
(Zhao et al., 2019), the experimental study needs to be carried in PCa models. 
Furthermore, a more clinically relevant approach would be performing studies 
using PDX and organoids. In a preliminary screening, we have analyzed the expression 
of FGFR1 in different PDX by RT-qPCR, Western blot and IHC. We found heterogenous 
expression, in line with the human sample cohort studies. Of particular interest, the bone 
metastasis-derived MDA PCa 118b expresses both isoforms, primarily a. Given this PDX 
expresses high levels of FGFR1, it will be suitable to genetically (with an inducible system) 
and pharmacologically disrupt the receptor in this model in order to further analyze its role 
in the metastatic potential as well as assess modulation of targets that could be driving 
metastatic progression (i.e. LAD1).  
The identification of LAD1 as a novel potential target in PCa progression opens 
ample opportunities for further studies. Future directions include studying the biological 
implications of LAD1 expression in PCa pathogenesis by performing in vitro and in vivo 
preclinical studies, and correlative analysis with human samples. These involve exploring 
the invasion potential in cells overexpressing LAD1 and the impact of silencing LAD1 
 96 
through shRNA or treating with a neutralizing antibody in FGFR1-expressing sublines. 
This and other future exhaustive studies would help determine the biological mechanisms 
of LAD1 which, based on our findings and the knowledge available characterizing this 
protein, could be exerting a dual role, in motility in cancer cells and in adhesion between 
cancer cells and/or to the stroma. Furthermore, intracardiac injection of FGFR1-
expressing cells with LAD1 silencing would help understand the participation of LAD1 in 
activating the metastatic program of PCa. Again, corresponding studies using PDX with 
high LAD1 levels would further complement the approach. Complementary non-invasive 
approaches to monitor patient response to therapy are liquid biopsies, including 
exosomes, which are extracellular vesicles released from cells containing RNA, DNA and 
proteins.  
With a focus on a metastatic CRPC dataset (cBioPortal SU2C/PCF Dream Team 
dataset), we report the detection of LAD1 gene amplification in a number of cases; 
unfortunately, given that the data is recent, expression data is not yet available for the 
dataset of interest. It is possible that there are a number of cases that are not altered at 
the DNA level, yet abnormally increased expression will occur at the protein level. 
Certainly, genetic alterations in PCa are rare, this includes the FGFR1 aberrant 
expression. For instance, when querying FGFR1 in cBioPortal metastatic dataset with 
mRNA expression available, a percentage of cases with high mRNA expression lacks 
genetic alterations. Another important point is to determine what are the relevant levels at 
the clinical scenario.  
Another aspect of relevance for further exploration, based on the evidence 
presented above, is whether or not there is an interaction between FGFR1-LAD1 axis and 
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AR, that may influence the outcome of cells expressing FGFR1 and AR. An initial 
approach would be analyzing the expression of AR by IHC in the human samples used in 
this work and parallel its status to FGFR1 and LAD1 expression.  
Furthermore, as previously mentioned, LAD1 is a downstream target of GR, 
which is upregulated during resistance to ADT as well as other therapies (Narayanan et 
al., 2016; Puhr et al., 2018). Since we have detected LAD1 in a substantial amount of 
human PCa bone metastases cases and propose that the role of this protein might be 
beyond FGFR1, an additional aspect of interest is to investigate if LAD1 would mediate 
GR progression to therapy. 
Our RPPA analysis has provided a very interesting putative candidate target of 
FGFR1. The array analysis has resulted in other targets that could be attractive to PCa 
progression studies. These include the previously mentioned CDH1. Also, a number of 
DNA-damage response proteins were found upregulated, including Wee1 G2 checkpoint 
kinase. Again, bioinformatics tools are helpful in this search, for instance, CDH11 (OB-
cadherin [osteoblast]) co-expresses with FGFR1 in metastatic CRPC (cBioPortal 
SU2C/PCF Dream Team).  
Our models, intracardiac and intrabone, have allowed the study of the late steps 
of metastasis, bypassing the first steps. This does not exclude a role for the FGFR1-LAD1 
axis in the early steps of metastasis, which might shed light to defining markers of 
progression and timing therapy regimen. Unfortunately, growth of PCa cells at the 
orthotopic site does not result in metastatic dissemination to bone, before the health of 
the mouse is compromised by primary tumor burden. However, metastases to local lymph 
node would be of interest to study. The use of transgenic mice, such as the well-known 
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TRAMP model, has proved valuable for the analyses of visceral metastases, since these 
models have been reported to develop not only lymph node metastases, but also distant 
metastases to the lungs; although bone metastases occurring in these models are rare 
(Berish et al., 2018).  
Another limitation of our models is the use of immunocompromised mice, which 
understates the crucial role of the immune system. Specially, in our bioinformatics 
approach mining molecular correlates to FGFR1 isoforms, b was found associated to 
many pathways, in particular, many immune-associated pathways. The use of a mouse 
strain in syngeneic models would compensate this up to certain extent. However, the 
down-side of using a mouse cell line instead of a human cell line has to be considered to 
the overall relevance of this model. Considerable efforts have been directed to 
humanizing mouse models to improve translational outcomes. It is important to highlight 
that the results obtained in human tissues further validate our findings. 
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APPENDIX I 
FGF axis implications in bone metastases of other cancers 
Breast Cancer. Breast cancer is the most common malignancy among women 
worldwide. Breast cancer is classified into different molecular subtypes based on 
expression of hormone receptors (HR): estrogen receptor and/or progesterone receptor 
and human epidermal growth factor receptor 2 (HER2), also known as receptor tyrosine-
protein kinase erbB-2 (Horton et al., 2018). Among the five major subtypes are estrogen 
receptor-positive and triple-negative breast cancer (HR-negative and HER2/neu-negative 
[TNBC]). Breast cancer bone metastases, typically osteolytic, occur in about 70% of cases 
and are the most common site of disease recurrence. Bone metastases secondary to 
breast cancer negatively impact patient survival, mobility, and quality of life (Weilbaecher 
et al., 2011). Breast cancer bone metastases generally produce an osteolytic phenotype 
by secreting factors that activate the normal bone-resorbing cell, the osteoclast. It has 
been suggested that FGFs, among other growth factors (e.g., TGFβ, IGF), are released 
from the bone matrix during bone resorption, which contributes to the vicious cycle 
process, originally defined in the context of breast cancer bone metastasis (D'Oronzo et 
al., 2017; Guise, 2002). FGFR1 gene amplification, which occurs in estrogen receptor-
positive breast cancer, represents the most frequent genomic aberration of the FGF axis, 
whereas amplification of FGFR2-4 genes and FGFR-activating mutations are uncommon 
(Perez-Garcia et al., 2018). However, whether or not an enrichment of these mutations 
occurs in bone metastases has not been studied.  
Experimental studies indicate that the incidence of bone metastases and growth 
of osteolytic breast cancer cells is impaired in osteoclast-specific Tgfbr2 knockout mice, 
and this phenotype is rescued by FGF2. Subsequent correlative analysis of human 
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samples indicate association between the expression of TGFBR2, pSmad-2, and FGFR1 
in breast cancer cells and osteoclasts (Meng et al., 2016). Accordingly, it was shown that 
secreted FGF ligands from breast cancer cells can promote differentiation of osteoclasts, 
that breast cancer cells enhance osteoclast function in an FGFR-dependent manner, and 
that this effect is reduced when FGFR is inhibited (Aukes et al., 2017). It is worth noting 
that the experimental studies outlined below have been done mainly using TNBC cancer 
models. It remains to be seen if this holds true when using models of other breast cancer 
subtypes such as estrogen receptor-positive. 
Lung Cancer. Of the two main types of lung cancer, small cell lung cancer (SCLC) 
and non-small cell lung cancer (NSCLC), which accounts for 85% of lung carcinomas, 
FGFR1 is amplified in 22% of squamous cell lung carcinomas, a subtype of NSCLC 
(Katoh and Nakagama, 2014). Further, preclinical studies have shown FGFR-altered 
NSCLC cell lines respond positively to FGFR inhibitors (Hashemi-Sadraei and Hanna, 
2017). Lung cancer bone metastases, which occur in 30% to 40% of cases, are typically 
osteolytic, and the “vicious cycle” defined for other malignancies has also been implicated 
in this disease (D'Antonio et al., 2014). The release of growth factors from the bone matrix 
in this context includes FGF ligands. 
Bladder Cancer. Urothelial or transitional cell carcinoma is the most common type 
of bladder cancer, and approximately 30% of its metastases are to the bone (Bellmunt et 
al., 2010). Alterations in FGFRs are frequent in bladder cancer. Primarily, FGFR3 
mutations are found in non-invasive, as well as advanced, metastatic bladder cancer (di 
Martino et al., 2016). Recently FDA approved an FGFR inhibitor to treat locally advanced 
or metastatic bladder cancer (Alhalabi et al., 2019). 
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High levels of FGF-2 have been detected in invasive bladder cancers. Only a 
correlative study has aimed to explain the molecular mechanism (EMT induction, 
increased proliferation, and trigger of immune checkpoint) for FGF2-mediated poor 
prognosis (McNiel and Tsichlis, 2017). Once again, it is worth noting that no studies have 
focused yet on the role of FGF specifically in bone metastases in this disease.    
Multiple Myeloma. 70% of patients with multiple myeloma present with bone 
metastases at diagnosis and 90% will progress and develop bone lesions that are typically 
osteolytic (Bataille et al., 1989). 
Fifteen percent of multiple myeloma patients present with a t(4:14) translocation 
that results in overexpression of FGFR3. Therefore, clinical trials targeting the FGF 
pathway have been under study. These included the receptor TKI, dovitinib (TKI258), 
which showed signs of increased progression-free survival and disease stabilization, but 
exhibited severe adverse effects on patients (Ghedini et al., 2018; Porta et al., 2017). 
Other agents that could minimize these off-target effects by being more selective, 
including monoclonal antibodies (i.e., FGFR3-specific antibody MGFR1877S, hampering 
receptor dimerization) and more specific inhibitors (i.e., pan-FGFR inhibitor JNJ-
42756493 [Janssen pharmaceuticals] and NVP-BGJ398 [Novartis]), are currently under 
evaluation (Ghedini et al., 2018; Porta et al., 2017). How these agents have direct 
beneficial effects in bone metastases in particular has not been described in detail, and 
the bone-specific research area in this context remains relatively unexplored. Thus far, 
one laboratory based study has shown that the FGFR1 inhibitor NVP-BGJ398 blocked 
cell growth and blocked the induction of RANKL in co-culture studies of multiple myeloma 
cells with neonatal mouse calvarie (Suvannasankha et al., 2015). 
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APPENDIX II 
 
# PDXs,  human 
prostate, PCa 
and normal cells
Total 
expression on 
RPKM 
(Predicted 
protein length)
ENST0000
0326324- 
(731aa)
ENST0000
0356207 
(733aa)
ENST000
00397091- 
(820aa)
ENST0000
0397103-
(733aa)
ENST0000
0397108-
(820aa)
ENST0000
0397113- 
(820aa)
ENST0000
0425967- 
(853aa)
ENST0000
0532791-
(820aa)
MDA PCa 118b 427.8655514 23.3708 27.7224 48.8548 22.1625 8.54701 55.6413 22.1772
MDA PCa 155-12 117.4654139 6.78437 9.10308 15.615 5.01488
PCa 1 118.1781919 10.9309 9.25578 8.30015 10.1135
PCa 2 113.9026026 9.29076 11.4746 30.2751 7.89804
PCa 3 111.6250986 35.8748 8.01397
PCa 4 138.9190693 16.6888 13.363 8.52724 23.6115 5.93804 10.9061
*prsmc 160.7709822 57.5712 32.7191 12.9844 10.9056
Normal prostate 1 128.4814856 7.53555 12.5837 16.497
Normal prostate 2 107.782019 20.9962 17.6452 14.0647 7.15797 7.02015
MDA PCa 146-12 51.20781506 11.0581
MDA PCa 150-3 65.7305089 15.2953
CWR22 67.34084577 9.21866 12.3439
DU145 79.9512445 10.4639 5.22349 13.3995
LAPC4 83.00887232 9.44943 7.00601
PCa 5 91.47822448 5.54112 5.19175 9.04179 19.898 5.33814
PCa 6 83.53209378 18.5286 5.15877 7.16404 6.20649
PCa 7 78.59047831 11.6889 14.2243 7.72551
PCa 8 73.44139521 8.78434 7.01864 5.73643 10.1642
PCa 9 70.54022119 11.3122 8.57767 5.10366 5.36478
PCa 10 67.10127222 8.19756 6.81305 9.08281 6.35966
PCa 11 67.05405656 9.18127 10.1844
PCa 12 64.59968344 10.9836 5.86476
PCa 13 64.74790703 12.7709 8.5225 6.01785 5.17219
PCa 14 62.4554847 11.8546
PCa 15 62.0401659 5.06302 10.0896 7.10455
PCa 16 61.46145327 5.50829 12.7155 5.85344
PCa 17 61.58574569 15.5619 5.00763
PCa 18 58.9497218 8.9148 5.919 5.57059
PCa 19 57.65514359 6.12587 7.83535 5.63997 10.925
PCa 20 57.2573793 9.42299
PCa 21 56.87449593 6.86283 9.85867
PCa 22 56.00748482 13.2191 8.9097
PCa 23 56.61553416 21.6726 9.17382 6.67297
PCa 24 55.9912692 13.1264 7.9531
PCa 25 55.22165707 8.53278 7.5201 6.33428 5.15267
PCa 26 54.14027146 12.3433
PCa 27 53.52404405 8.64604 10.8808
PCa 28 52.94397734 8.51314 6.61092
PCa 29 51.1457494 9.01973
PCa 30 50.59670269 6.21757 5.79123
PCa 31 50.90175518 11.3804
Normal prostate 3 77.37768737 8.15647 14.3598 8.7716
Normal prostate 4 51.89117413 13.9416 7.89364
Normal prostate 5 68.28438842 11.903
Normal prostate 6 65.5553075 6.90077 7.14267 6.50364 5.4326 7.37166
Normal prostate 7 51.4061802 11.0787 5.34857
Normal prostate 8 72.38834495 10.5589 7.44605 12.5224 6.67624 7.66432
# PDXs: patient derived xenografts; *prsmc: human prostate smooth muscle cells
Most abundant FGFR1 transcript variants expression, grouped by totals levels of expression (reads per kilobase per million (RPKM)). Only RPKM=50 or 
higher were considered. Transcripts ID are based on ensembl reference annotatation.
100-200 
RPKM
50-100 RPKM
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APPENDIX III 
 
ES: enrichment score; Nom. p-val: nominal P value; FWER: family-wise error rate; FDR: false discovery rate. 
 
Gene set numbers and names of pathways in KEGG and REACTOME. Values in each of the parameters associated with the pathways Patways that meet 
selection criteria (P<0.002 
and NES>1.78)
 Gene Set 60 : KEGG_AMINOACYL_TRNA_BIOSYNTHESIS ES = 0.608 NES = 2.01 Nom. p−val= 0.00956 FWER= 0.16 FDR= 0.0817
Gene Set 39 : KEGG_GLYCOSYLPHOSPHATIDYLINOSITOL_GPI_ANCHOR_BIOSYNTHESIS ES = 0.456 NES = 1.67 Nom. p−val= 0.0506 FWER= 0.911 FDR= 0.193
 Gene Set 49 : KEGG_GLYOXYLATE_AND_DICARBOXYLATE_METABOLISM ES = 0.629 NES = 1.65 Nom. p−val= 0.0363 FWER= 0.935 FDR= 0.211
 Gene Set 73 : KEGG_PROTEIN_EXPORT ES = 0.604 NES = 1.82 Nom. p−val= 0.0216 FWER= 0.58 FDR= 0.0998
 Gene Set 58 : KEGG_TERPENOID_BACKBONE_BIOSYNTHESIS ES = 0.696 NES = 1.75 Nom. p−val= 0.0154 FWER= 0.758 FDR= 0.127
REACTOME_ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S ES = 0.574 NES = 1.62 Nom. p−val= 0.0747 FWER= 0.962 FDR= 0.235
 Gene Set 1051 : REACTOME_CHOLESTEROL_BIOSYNTHESIS ES = 0.63 NES = 1.65 Nom. p−val= 0.0455 FWER= 0.93 FDR= 0.21
 REACTOME_FORMATION_OF_TRANSCRIPTION_COUPLED_NER_TC_NER_REPAIR_COMPLEX ES = 0.567 NES = 1.95 Nom. p−val= 0.00797 FWER= 0.257 FDR= 0.0931
 Gene Set 998 : REACTOME_LATE_PHASE_OF_HIV_LIFE_CYCLE ES = 0.4 NES = 1.83 Nom. p−val= 0.0388 FWER= 0.559 FDR= 0.104
 Gene Set 566 : REACTOME_METABOLISM_OF_NON_CODING_RNA ES = 0.53 NES = 1.85 Nom. p−val= 0.0311 FWER= 0.501 FDR= 0.0995
 Gene Set 735 : REACTOME_METABOLISM_OF_POLYAMINES ES = 0.663 NES = 1.79 Nom. p−val= 0.00591 FWER= 0.663 FDR= 0.113
 Gene Set 742 : REACTOME_MITOCHONDRIAL_TRNA_AMINOACYLATION ES = 0.718 NES = 2.1 Nom. p−val= 0 FWER= 0.077 FDR= 0.0622 Y
 Gene Set 774 : REACTOME_MRNA_PROCESSING ES = 0.433 NES = 1.93 Nom. p−val= 0.0244 FWER= 0.3 FDR= 0.0672
Gene Set 989 : REACTOME_NEP_NS2_INTERACTS_WITH_THE_CELLULAR_EXPORT_MACHINERY ES = 0.556 NES = 1.62 Nom. p−val= 0.0348 FWER= 0.961 FDR= 0.248
 Gene Set 797 : REACTOME_NUCLEOTIDE_EXCISION_REPAIR ES = 0.427 NES = 1.61 Nom. p−val= 0.0768 FWER= 0.965 FDR= 0.217
 Gene Set 692 : REACTOME_PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA ES = 0.464 NES = 1.78 Nom. p−val= 0.0318 FWER= 0.707 FDR= 0.118
 Gene Set 1057 : REACTOME_RNA_POL_I_TRANSCRIPTION_INITIATION ES = 0.551 NES = 1.74 Nom. p−val= 0.0133 FWER= 0.805 FDR= 0.134
 Gene Set 771 : REACTOME_TRANSCRIPTION_COUPLED_NER_TC_NER ES = 0.522 NES = 1.86 Nom. p−val= 0.0185 FWER= 0.48 FDR= 0.108
 REACTOME_TRANSPORT_OF_MATURE_MRNA_DERIVED_FROM_AN_INTRONLESS_TRANSCRIPT ES = 0.55 NES = 1.72 Nom. p−val= 0.0114 FWER= 0.844 FDR= 0.149
 Gene Set 706 : REACTOME_TRANSPORT_OF_MATURE_TRANSCRIPT_TO_CYTOPLASM ES = 0.465 NES = 1.59 Nom. p−val= 0.057 FWER= 0.974 FDR= 0.238
 Gene Set 991 : REACTOME_TRANSPORT_OF_RIBONUCLEOPROTEINS_INTO_THE_HOST_NUCLEUS ES = 0.552 NES = 1.61 Nom. p−val= 0.0306 FWER= 0.964 FDR= 0.227
 Gene Set 758 : REACTOME_TRNA_AMINOACYLATION ES = 0.612 NES = 1.94 Nom. p−val= 0.0132 FWER= 0.272 FDR= 0.0752
FGFR1 a associated pathways identified in GSEA of TCGA-PRAD dataset. Total number of pathways=22, Total number of pathways with p<0.002=1 and selected pathways with p<0.002 and NES>1.78=1
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Gene set numbers and names of pathways in BIOCARTA, KEGG, NABA, PID, REACTOME, SA, SIG and ST. Values in each of the parameters associated with the pathways Patways that meet selection criteria 
(P<0.002 and NES<-1.78)
 Gene Set 312 : BIOCARTA_41BB_PATHWAY ES = −0.534 NES = −1.3 Nom. p−val= 0.194 FWER= 1 FDR= 0.21
 Gene Set 294 : BIOCARTA_ACH_PATHWAY ES = −0.566 NES = −1.3 Nom. p−val= 0.186 FWER= 1 FDR= 0.21
 Gene Set 327 : BIOCARTA_ACTINY_PATHWAY ES = −0.476 NES = −1.55 Nom. p−val= 0.0676 FWER= 0.99 FDR= 0.089
 Gene Set 184 : BIOCARTA_AGR_PATHWAY ES = −0.594 NES = −1.55 Nom. p−val= 0.0404 FWER= 0.991 FDR= 0.0894
 Gene Set 185 : BIOCARTA_AKT_PATHWAY ES = −0.534 NES = −1.65 Nom. p−val= 0.0282 FWER= 0.924 FDR= 0.0732
 Gene Set 186 : BIOCARTA_ALK_PATHWAY ES = −0.621 NES = −1.72 Nom. p−val= 0 FWER= 0.785 FDR= 0.0729
 Gene Set 182 : BIOCARTA_AMI_PATHWAY ES = −0.715 NES = −1.47 Nom. p−val= 0.056 FWER= 0.999 FDR= 0.116
 Gene Set 183 : BIOCARTA_ARAP_PATHWAY ES = −0.493 NES = −1.57 Nom. p−val= 0.0446 FWER= 0.985 FDR= 0.0841
 Gene Set 187 : BIOCARTA_AT1R_PATHWAY ES = −0.419 NES = −1.48 Nom. p−val= 0.103 FWER= 0.999 FDR= 0.114
 Gene Set 280 : BIOCARTA_BAD_PATHWAY ES = −0.531 NES = −1.45 Nom. p−val= 0.0669 FWER= 0.999 FDR= 0.121
 Gene Set 192 : BIOCARTA_BCR_PATHWAY ES = −0.589 NES = −1.61 Nom. p−val= 0.0175 FWER= 0.964 FDR= 0.0759
 Gene Set 193 : BIOCARTA_BIOPEPTIDES_PATHWAY ES = −0.433 NES = −1.48 Nom. p−val= 0.0532 FWER= 0.999 FDR= 0.113
 Gene Set 297 : BIOCARTA_BARRESTIN_SRC_PATHWAY ES = −0.529 NES = −1.54 Nom. p−val= 0.054 FWER= 0.993 FDR= 0.0931
 Gene Set 191 : BIOCARTA_BCELLSURVIVAL_PATHWAY ES = −0.476 NES = −1.28 Nom. p−val= 0.181 FWER= 1 FDR= 0.218
 Gene Set 214 : BIOCARTA_CALCINEURIN_PATHWAY ES = −0.551 NES = −1.51 Nom. p−val= 0.0447 FWER= 0.996 FDR= 0.101
 Gene Set 288 : BIOCARTA_CARDIACEGF_PATHWAY ES = −0.564 NES = −1.36 Nom. p−val= 0.115 FWER= 1 FDR= 0.171
 Gene Set 195 : BIOCARTA_CARM_ER_PATHWAY ES = −0.449 NES = −1.52 Nom. p−val= 0.0403 FWER= 0.995 FDR= 0.0978
 Gene Set 196 : BIOCARTA_CASPASE_PATHWAY ES = −0.611 NES = −1.65 Nom. p−val= 0.0301 FWER= 0.927 FDR= 0.0731
 Gene Set 197 : BIOCARTA_CCR3_PATHWAY ES = −0.639 NES = −1.68 Nom. p−val= 0.00399 FWER= 0.892 FDR= 0.0726
 Gene Set 269 : BIOCARTA_CCR5_PATHWAY ES = −0.736 NES = −1.57 Nom. p−val= 0.00984 FWER= 0.987 FDR= 0.086
 Gene Set 198 : BIOCARTA_CD40_PATHWAY ES = −0.599 NES = −1.45 Nom. p−val= 0.0559 FWER= 0.999 FDR= 0.123
 Gene Set 295 : BIOCARTA_CDC42RAC_PATHWAY ES = −0.535 NES = −1.58 Nom. p−val= 0.0062 FWER= 0.983 FDR= 0.0812
 Gene Set 194 : BIOCARTA_CDMAC_PATHWAY ES = −0.569 NES = −1.46 Nom. p−val= 0.0651 FWER= 0.999 FDR= 0.119
 Gene Set 209 : BIOCARTA_CELLCYCLE_PATHWAY ES = −0.504 NES = −1.29 Nom. p−val= 0.208 FWER= 1 FDR= 0.213
 Gene Set 188 : BIOCARTA_CHEMICAL_PATHWAY ES = −0.452 NES = −1.63 Nom. p−val= 0.0252 FWER= 0.943 FDR= 0.0763
 Gene Set 279 : BIOCARTA_CHREBP2_PATHWAY ES = −0.334 NES = −1.31 Nom. p−val= 0.171 FWER= 1 FDR= 0.205
 Gene Set 281 : BIOCARTA_CK1_PATHWAY ES = −0.473 NES = −1.24 Nom. p−val= 0.169 FWER= 1 FDR= 0.248
 Gene Set 204 : BIOCARTA_COMP_PATHWAY ES = −0.762 NES = −1.61 Nom. p−val= 0.00195 FWER= 0.963 FDR= 0.0763
 Gene Set 321 : BIOCARTA_CREB_PATHWAY ES = −0.401 NES = −1.24 Nom. p−val= 0.225 FWER= 1 FDR= 0.247
 Gene Set 181 : BIOCARTA_CSK_PATHWAY ES = −0.698 NES = −1.5 Nom. p−val= 0.048 FWER= 0.997 FDR= 0.107
 Gene Set 207 : BIOCARTA_CTCF_PATHWAY ES = −0.629 NES = −1.61 Nom. p−val= 0.0139 FWER= 0.964 FDR= 0.0761
 Gene Set 313 : BIOCARTA_CTLA4_PATHWAY ES = −0.795 NES = −1.39 Nom. p−val= 0.0542 FWER= 1 FDR= 0.153
 Gene Set 208 : BIOCARTA_CXCR4_PATHWAY ES = −0.5 NES = −1.51 Nom. p−val= 0.0585 FWER= 0.996 FDR= 0.101
 Gene Set 210 : BIOCARTA_CYTOKINE_PATHWAY ES = −0.672 NES = −1.32 Nom. p−val= 0.129 FWER= 1 FDR= 0.197
 Gene Set 212 : BIOCARTA_DC_PATHWAY ES = −0.765 NES = −1.47 Nom. p−val= 0.0266 FWER= 0.999 FDR= 0.115
 Gene Set 243 : BIOCARTA_DEATH_PATHWAY ES = −0.486 NES = −1.73 Nom. p−val= 0.0114 FWER= 0.768 FDR= 0.0725
 Gene Set 218 : BIOCARTA_ECM_PATHWAY ES = −0.573 NES = −1.72 Nom. p−val= 0.00393 FWER= 0.794 FDR= 0.0731
 Gene Set 271 : BIOCARTA_EDG1_PATHWAY ES = −0.581 NES = −1.57 Nom. p−val= 0.0298 FWER= 0.987 FDR= 0.0857
 Gene Set 215 : BIOCARTA_EGF_PATHWAY ES = −0.489 NES = −1.51 Nom. p−val= 0.0617 FWER= 0.996 FDR= 0.101
 Gene Set 217 : BIOCARTA_EPO_PATHWAY ES = −0.448 NES = −1.46 Nom. p−val= 0.0793 FWER= 0.999 FDR= 0.118
 Gene Set 219 : BIOCARTA_ERK_PATHWAY ES = −0.487 NES = −1.61 Nom. p−val= 0.0308 FWER= 0.965 FDR= 0.0758
 Gene Set 290 : BIOCARTA_ERK5_PATHWAY ES = −0.624 NES = −1.72 Nom. p−val= 0.00604 FWER= 0.796 FDR= 0.0736
 Gene Set 220 : BIOCARTA_ERYTH_PATHWAY ES = −0.716 NES = −1.49 Nom. p−val= 0.0229 FWER= 0.998 FDR= 0.111
 Gene Set 254 : BIOCARTA_ETS_PATHWAY ES = −0.576 NES = −1.55 Nom. p−val= 0.0199 FWER= 0.99 FDR= 0.0891
 Gene Set 222 : BIOCARTA_FAS_PATHWAY ES = −0.435 NES = −1.42 Nom. p−val= 0.15 FWER= 1 FDR= 0.137
 Gene Set 223 : BIOCARTA_FCER1_PATHWAY ES = −0.623 NES = −1.68 Nom. p−val= 0.00402 FWER= 0.891 FDR= 0.0732
 Gene Set 224 : BIOCARTA_FMLP_PATHWAY ES = −0.494 NES = −1.58 Nom. p−val= 0.0406 FWER= 0.983 FDR= 0.0809
 Gene Set 199 : BIOCARTA_G1_PATHWAY ES = −0.476 NES = −1.39 Nom. p−val= 0.12 FWER= 1 FDR= 0.153
 Gene Set 225 : BIOCARTA_GATA3_PATHWAY ES = −0.521 NES = −1.26 Nom. p−val= 0.185 FWER= 1 FDR= 0.239
 Gene Set 206 : BIOCARTA_GCR_PATHWAY ES = −0.551 NES = −1.51 Nom. p−val= 0.0481 FWER= 0.996 FDR= 0.101
 Gene Set 226 : BIOCARTA_GH_PATHWAY ES = −0.543 NES = −1.57 Nom. p−val= 0.0305 FWER= 0.986 FDR= 0.0861
FGFR1 b associated pathways identified in GSEA of TCGA-PRAD dataset. Total number of pathways=749, Total number of pathways with p<0.002=105 and selected pathways with p<0.002 and NES<-1.78=50
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 Gene Set 245 : BIOCARTA_GLEEVEC_PATHWAY ES = −0.456 NES = −1.43 Nom. p−val= 0.109 FWER= 1 FDR= 0.133
 Gene Set 301 : BIOCARTA_GPCR_PATHWAY ES = −0.373 NES = −1.24 Nom. p−val= 0.224 FWER= 1 FDR= 0.247
 Gene Set 242 : BIOCARTA_GSK3_PATHWAY ES = −0.599 NES = −1.74 Nom. p−val= 0.002 FWER= 0.757 FDR= 0.0734
 Gene Set 205 : BIOCARTA_HDAC_PATHWAY ES = −0.467 NES = −1.35 Nom. p−val= 0.146 FWER= 1 FDR= 0.177
 Gene Set 289 : BIOCARTA_HER2_PATHWAY ES = −0.534 NES = −1.28 Nom. p−val= 0.227 FWER= 1 FDR= 0.221
 Gene Set 227 : BIOCARTA_HIVNEF_PATHWAY ES = −0.421 NES = −1.62 Nom. p−val= 0.046 FWER= 0.946 FDR= 0.0756
 Gene Set 306 : BIOCARTA_HSP27_PATHWAY ES = −0.702 NES = −1.54 Nom. p−val= 0.0153 FWER= 0.993 FDR= 0.0927
 Gene Set 232 : BIOCARTA_IGF1_PATHWAY ES = −0.445 NES = −1.26 Nom. p−val= 0.244 FWER= 1 FDR= 0.233
 Gene Set 299 : BIOCARTA_IL1R_PATHWAY ES = −0.537 NES = −1.43 Nom. p−val= 0.0757 FWER= 0.999 FDR= 0.129
 Gene Set 234 : BIOCARTA_IL2_PATHWAY ES = −0.644 NES = −1.51 Nom. p−val= 0.0615 FWER= 0.996 FDR= 0.103
 Gene Set 239 : BIOCARTA_IL2RB_PATHWAY ES = −0.626 NES = −1.62 Nom. p−val= 0.0229 FWER= 0.958 FDR= 0.0762
 Gene Set 236 : BIOCARTA_IL6_PATHWAY ES = −0.569 NES = −1.52 Nom. p−val= 0.0444 FWER= 0.995 FDR= 0.0998
 Gene Set 241 : BIOCARTA_IL7_PATHWAY ES = −0.712 NES = −1.48 Nom. p−val= 0.0331 FWER= 0.999 FDR= 0.113
 Gene Set 237 : BIOCARTA_IL10_PATHWAY ES = −0.67 NES = −1.43 Nom. p−val= 0.0824 FWER= 1 FDR= 0.133
 Gene Set 238 : BIOCARTA_IL12_PATHWAY ES = −0.82 NES = −1.48 Nom. p−val= 0.0115 FWER= 0.998 FDR= 0.112
 Gene Set 233 : BIOCARTA_IL17_PATHWAY ES = −0.76 NES = −1.33 Nom. p−val= 0.0937 FWER= 1 FDR= 0.188
 Gene Set 240 : BIOCARTA_IL22BP_PATHWAY ES = −0.637 NES = −1.37 Nom. p−val= 0.107 FWER= 1 FDR= 0.163
 Gene Set 211 : BIOCARTA_INFLAM_PATHWAY ES = −0.704 NES = −1.45 Nom. p−val= 0.0247 FWER= 0.999 FDR= 0.122
 Gene Set 246 : BIOCARTA_INSULIN_PATHWAY ES = −0.485 NES = −1.41 Nom. p−val= 0.0988 FWER= 1 FDR= 0.141
 Gene Set 247 : BIOCARTA_INTEGRIN_PATHWAY ES = −0.564 NES = −1.78 Nom. p−val= 0.00394 FWER= 0.655 FDR= 0.0758
 Gene Set 248 : BIOCARTA_INTRINSIC_PATHWAY ES = −0.672 NES = −1.45 Nom. p−val= 0.0514 FWER= 0.999 FDR= 0.122
 Gene Set 249 : BIOCARTA_KERATINOCYTE_PATHWAY ES = −0.511 NES = −1.58 Nom. p−val= 0.045 FWER= 0.983 FDR= 0.0811
 Gene Set 201 : BIOCARTA_LAIR_PATHWAY ES = −0.741 NES = −1.4 Nom. p−val= 0.0502 FWER= 1 FDR= 0.148
 Gene Set 314 : BIOCARTA_LONGEVITY_PATHWAY ES = −0.476 NES = −1.25 Nom. p−val= 0.2 FWER= 1 FDR= 0.245
 Gene Set 291 : BIOCARTA_MAL_PATHWAY ES = −0.522 NES = −1.64 Nom. p−val= 0.0269 FWER= 0.934 FDR= 0.0736
 Gene Set 251 : BIOCARTA_MAPK_PATHWAY ES = −0.351 NES = −1.52 Nom. p−val= 0.0661 FWER= 0.995 FDR= 0.0991
 Gene Set 252 : BIOCARTA_MCALPAIN_PATHWAY ES = −0.542 NES = −1.53 Nom. p−val= 0.0294 FWER= 0.993 FDR= 0.0953
 Gene Set 292 : BIOCARTA_MEF2D_PATHWAY ES = −0.484 NES = −1.39 Nom. p−val= 0.119 FWER= 1 FDR= 0.153
 Gene Set 300 : BIOCARTA_MET_PATHWAY ES = −0.549 NES = −1.67 Nom. p−val= 0.00992 FWER= 0.901 FDR= 0.0725
 Gene Set 213 : BIOCARTA_MTA3_PATHWAY ES = −0.647 NES = −1.6 Nom. p−val= 0.00954 FWER= 0.97 FDR= 0.0767
 Gene Set 272 : BIOCARTA_MYOSIN_PATHWAY ES = −0.567 NES = −1.7 Nom. p−val= 0.00784 FWER= 0.828 FDR= 0.0758
 Gene Set 216 : BIOCARTA_NDKDYNAMIN_PATHWAY ES = −0.53 NES = −1.79 Nom. p−val= 0.0118 FWER= 0.628 FDR= 0.0782
 Gene Set 260 : BIOCARTA_NFAT_PATHWAY ES = −0.587 NES = −1.7 Nom. p−val= 0 FWER= 0.834 FDR= 0.0759
 Gene Set 262 : BIOCARTA_NFKB_PATHWAY ES = −0.562 NES = −1.58 Nom. p−val= 0.0273 FWER= 0.985 FDR= 0.0834
 Gene Set 258 : BIOCARTA_NGF_PATHWAY ES = −0.577 NES = −1.51 Nom. p−val= 0.0562 FWER= 0.996 FDR= 0.103
 Gene Set 278 : BIOCARTA_NKCELLS_PATHWAY ES = −0.642 NES = −1.41 Nom. p−val= 0.0884 FWER= 1 FDR= 0.144
 Gene Set 298 : BIOCARTA_NKT_PATHWAY ES = −0.781 NES = −1.48 Nom. p−val= 0.025 FWER= 0.999 FDR= 0.113
 Gene Set 180 : BIOCARTA_NO1_PATHWAY ES = −0.617 NES = −1.48 Nom. p−val= 0.0546 FWER= 0.998 FDR= 0.112
 Gene Set 264 : BIOCARTA_NO2IL12_PATHWAY ES = −0.821 NES = −1.36 Nom. p−val= 0.0813 FWER= 1 FDR= 0.168
 Gene Set 261 : BIOCARTA_NTHI_PATHWAY ES = −0.539 NES = −1.45 Nom. p−val= 0.0868 FWER= 0.999 FDR= 0.122
 Gene Set 266 : BIOCARTA_P38MAPK_PATHWAY ES = −0.46 NES = −1.69 Nom. p−val= 0.0119 FWER= 0.866 FDR= 0.0763
 Gene Set 267 : BIOCARTA_P53_PATHWAY ES = −0.496 NES = −1.43 Nom. p−val= 0.12 FWER= 1 FDR= 0.134
 Gene Set 230 : BIOCARTA_P53HYPOXIA_PATHWAY ES = −0.664 NES = −2.03 Nom. p−val= 0 FWER= 0.126 FDR= 0.0881 Y
 Gene Set 315 : BIOCARTA_PAR1_PATHWAY ES = −0.491 NES = −1.5 Nom. p−val= 0.0592 FWER= 0.996 FDR= 0.106
 Gene Set 268 : BIOCARTA_PDGF_PATHWAY ES = −0.562 NES = −1.66 Nom. p−val= 0.00198 FWER= 0.919 FDR= 0.0734
 Gene Set 284 : BIOCARTA_PGC1A_PATHWAY ES = −0.594 NES = −1.49 Nom. p−val= 0.0741 FWER= 0.998 FDR= 0.109
 Gene Set 257 : BIOCARTA_PITX2_PATHWAY ES = −0.627 NES = −1.61 Nom. p−val= 0.0349 FWER= 0.96 FDR= 0.076
 Gene Set 285 : BIOCARTA_PML_PATHWAY ES = −0.695 NES = −1.71 Nom. p−val= 0.00758 FWER= 0.826 FDR= 0.0767
 Gene Set 253 : BIOCARTA_PPARA_PATHWAY ES = −0.493 NES = −1.59 Nom. p−val= 0.0115 FWER= 0.978 FDR= 0.0794
 Gene Set 270 : BIOCARTA_PTDINS_PATHWAY ES = −0.371 NES = −1.37 Nom. p−val= 0.108 FWER= 1 FDR= 0.162
 Gene Set 275 : BIOCARTA_PTEN_PATHWAY ES = −0.459 NES = −1.47 Nom. p−val= 0.0905 FWER= 0.999 FDR= 0.114
 Gene Set 250 : BIOCARTA_PYK2_PATHWAY ES = −0.425 NES = −1.65 Nom. p−val= 0.0198 FWER= 0.925 FDR= 0.0728
 Gene Set 276 : BIOCARTA_RAC1_PATHWAY ES = −0.673 NES = −1.68 Nom. p−val= 0.00197 FWER= 0.878 FDR= 0.0751
 Gene Set 244 : BIOCARTA_RACCYCD_PATHWAY ES = −0.374 NES = −1.36 Nom. p−val= 0.154 FWER= 1 FDR= 0.167
 Gene Set 277 : BIOCARTA_RAS_PATHWAY ES = −0.493 NES = −1.74 Nom. p−val= 0.00794 FWER= 0.755 FDR= 0.0736
 Gene Set 179 : BIOCARTA_RELA_PATHWAY ES = −0.52 NES = −1.55 Nom. p−val= 0.045 FWER= 0.99 FDR= 0.0897
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 Gene Set 286 : BIOCARTA_RHO_PATHWAY ES = −0.51 NES = −1.83 Nom. p−val= 0.00591 FWER= 0.542 FDR= 0.0817
 Gene Set 303 : BIOCARTA_SHH_PATHWAY ES = −0.567 NES = −1.4 Nom. p−val= 0.109 FWER= 1 FDR= 0.149
 Gene Set 189 : BIOCARTA_SPPA_PATHWAY ES = −0.583 NES = −1.56 Nom. p−val= 0.0464 FWER= 0.989 FDR= 0.0881
 Gene Set 304 : BIOCARTA_SPRY_PATHWAY ES = −0.472 NES = −1.29 Nom. p−val= 0.168 FWER= 1 FDR= 0.214
 Gene Set 305 : BIOCARTA_STATHMIN_PATHWAY ES = −0.785 NES = −1.77 Nom. p−val= 0 FWER= 0.694 FDR= 0.0716
 Gene Set 283 : BIOCARTA_STEM_PATHWAY ES = −0.677 NES = −1.37 Nom. p−val= 0.0869 FWER= 1 FDR= 0.166
 Gene Set 308 : BIOCARTA_TALL1_PATHWAY ES = −0.684 NES = −1.49 Nom. p−val= 0.0276 FWER= 0.998 FDR= 0.111
 Gene Set 307 : BIOCARTA_TCR_PATHWAY ES = −0.692 NES = −1.68 Nom. p−val= 0.00775 FWER= 0.895 FDR= 0.0724
 Gene Set 322 : BIOCARTA_TFF_PATHWAY ES = −0.434 NES = −1.38 Nom. p−val= 0.11 FWER= 1 FDR= 0.157
 Gene Set 310 : BIOCARTA_TGFB_PATHWAY ES = −0.599 NES = −1.73 Nom. p−val= 0 FWER= 0.771 FDR= 0.0724
 Gene Set 311 : BIOCARTA_TH1TH2_PATHWAY ES = −0.794 NES = −1.48 Nom. p−val= 0.019 FWER= 0.999 FDR= 0.114
 Gene Set 203 : BIOCARTA_TID_PATHWAY ES = −0.54 NES = −1.46 Nom. p−val= 0.0692 FWER= 0.999 FDR= 0.118
 Gene Set 318 : BIOCARTA_TNFR2_PATHWAY ES = −0.582 NES = −1.5 Nom. p−val= 0.0453 FWER= 0.997 FDR= 0.107
 Gene Set 296 : BIOCARTA_TOB1_PATHWAY ES = −0.766 NES = −1.51 Nom. p−val= 0.00582 FWER= 0.996 FDR= 0.102
 Gene Set 319 : BIOCARTA_TOLL_PATHWAY ES = −0.6 NES = −1.61 Nom. p−val= 0.0196 FWER= 0.96 FDR= 0.0756
 Gene Set 320 : BIOCARTA_TPO_PATHWAY ES = −0.572 NES = −1.59 Nom. p−val= 0.0245 FWER= 0.976 FDR= 0.0793
 Gene Set 324 : BIOCARTA_UCALPAIN_PATHWAY ES = −0.623 NES = −1.47 Nom. p−val= 0.0511 FWER= 0.999 FDR= 0.115
 Gene Set 325 : BIOCARTA_VEGF_PATHWAY ES = −0.56 NES = −1.72 Nom. p−val= 0.02 FWER= 0.784 FDR= 0.0737
 Gene Set 259 : BIOCARTA_VIP_PATHWAY ES = −0.511 NES = −1.44 Nom. p−val= 0.0946 FWER= 0.999 FDR= 0.127
 Gene Set 326 : BIOCARTA_WNT_PATHWAY ES = −0.459 NES = −1.62 Nom. p−val= 0.0351 FWER= 0.945 FDR= 0.0757
 Gene Set 65 : KEGG_ABC_TRANSPORTERS ES = −0.507 NES = −1.38 Nom. p−val= 0.0777 FWER= 1 FDR= 0.157
 Gene Set 166 : KEGG_ACUTE_MYELOID_LEUKEMIA ES = −0.587 NES = −1.99 Nom. p−val= 0.00197 FWER= 0.186 FDR= 0.102
 Gene Set 109 : KEGG_ADHERENS_JUNCTION ES = −0.539 NES = −1.9 Nom. p−val= 0 FWER= 0.371 FDR= 0.0821 Y
 Gene Set 138 : KEGG_ADIPOCYTOKINE_SIGNALING_PATHWAY ES = −0.504 NES = −1.61 Nom. p−val= 0.00803 FWER= 0.96 FDR= 0.0758
 Gene Set 15 : KEGG_ALANINE_ASPARTATE_AND_GLUTAMATE_METABOLISM ES = −0.478 NES = −1.43 Nom. p−val= 0.075 FWER= 1 FDR= 0.133
 Gene Set 142 : KEGG_ALDOSTERONE_REGULATED_SODIUM_REABSORPTION ES = −0.59 NES = −1.54 Nom. p−val= 0.0116 FWER= 0.992 FDR= 0.0911
 Gene Set 172 : KEGG_ALLOGRAFT_REJECTION ES = −0.751 NES = −1.52 Nom. p−val= 0.0223 FWER= 0.995 FDR= 0.0997
 Gene Set 145 : KEGG_ALZHEIMERS_DISEASE ES = −0.31 NES = −1.38 Nom. p−val= 0.0759 FWER= 1 FDR= 0.155
 Gene Set 32 : KEGG_AMINO_SUGAR_AND_NUCLEOTIDE_SUGAR_METABOLISM ES = −0.443 NES = −1.52 Nom. p−val= 0.0679 FWER= 0.995 FDR= 0.0989
 Gene Set 147 : KEGG_AMYOTROPHIC_LATERAL_SCLEROSIS_ALS ES = −0.499 NES = −1.52 Nom. p−val= 0.0392 FWER= 0.995 FDR= 0.0998
 Gene Set 113 : KEGG_ANTIGEN_PROCESSING_AND_PRESENTATION ES = −0.586 NES = −1.7 Nom. p−val= 0.0113 FWER= 0.833 FDR= 0.0759
 Gene Set 96 : KEGG_APOPTOSIS ES = −0.534 NES = −1.84 Nom. p−val= 0 FWER= 0.516 FDR= 0.0875 Y
 Gene Set 42 : KEGG_ARACHIDONIC_ACID_METABOLISM ES = −0.496 NES = −1.29 Nom. p−val= 0.109 FWER= 1 FDR= 0.215
Gene Set 176 : KEGG_ARRHYTHMOGENIC_RIGHT_VENTRICULAR_CARDIOMYOPATHY_ARVC ES = −0.648 NES = −1.61 Nom. p−val= 0.00582 FWER= 0.965 FDR= 0.0757
 Gene Set 169 : KEGG_ASTHMA ES = −0.76 NES = −1.62 Nom. p−val= 0.0075 FWER= 0.958 FDR= 0.0765
 Gene Set 170 : KEGG_AUTOIMMUNE_THYROID_DISEASE ES = −0.674 NES = −1.63 Nom. p−val= 0.00575 FWER= 0.941 FDR= 0.0749
 Gene Set 104 : KEGG_AXON_GUIDANCE ES = −0.562 NES = −1.71 Nom. p−val= 0 FWER= 0.823 FDR= 0.0763
 Gene Set 123 : KEGG_B_CELL_RECEPTOR_SIGNALING_PATHWAY ES = −0.69 NES = −1.84 Nom. p−val= 0.00381 FWER= 0.501 FDR= 0.0866
 Gene Set 162 : KEGG_BASAL_CELL_CARCINOMA ES = −0.608 NES = −1.55 Nom. p−val= 0.00787 FWER= 0.99 FDR= 0.0896
 Gene Set 164 : KEGG_BLADDER_CANCER ES = −0.411 NES = −1.34 Nom. p−val= 0.126 FWER= 1 FDR= 0.183
 Gene Set 81 : KEGG_CALCIUM_SIGNALING_PATHWAY ES = −0.619 NES = −1.65 Nom. p−val= 0 FWER= 0.931 FDR= 0.0739
 Gene Set 97 : KEGG_CARDIAC_MUSCLE_CONTRACTION ES = −0.625 NES = −1.62 Nom. p−val= 0.0133 FWER= 0.948 FDR= 0.0755
 Gene Set 108 : KEGG_CELL_ADHESION_MOLECULES_CAMS ES = −0.696 NES = −1.65 Nom. p−val= 0.00192 FWER= 0.924 FDR= 0.0727
 Gene Set 83 : KEGG_CHEMOKINE_SIGNALING_PATHWAY ES = −0.649 NES = −1.66 Nom. p−val= 0.00388 FWER= 0.921 FDR= 0.0736
 Gene Set 165 : KEGG_CHRONIC_MYELOID_LEUKEMIA ES = −0.467 NES = −1.83 Nom. p−val= 0 FWER= 0.525 FDR= 0.0873 Y
 Gene Set 155 : KEGG_COLORECTAL_CANCER ES = −0.498 NES = −1.84 Nom. p−val= 0.00203 FWER= 0.507 FDR= 0.0871
 Gene Set 112 : KEGG_COMPLEMENT_AND_COAGULATION_CASCADES ES = −0.69 NES = −1.61 Nom. p−val= 0 FWER= 0.963 FDR= 0.0756
 Gene Set 82 : KEGG_CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION ES = −0.691 NES = −1.63 Nom. p−val= 0 FWER= 0.942 FDR= 0.0764
 Gene Set 118 : KEGG_CYTOSOLIC_DNA_SENSING_PATHWAY ES = −0.621 NES = −1.78 Nom. p−val= 0.00381 FWER= 0.668 FDR= 0.0771
 Gene Set 177 : KEGG_DILATED_CARDIOMYOPATHY ES = −0.651 NES = −1.6 Nom. p−val= 0.0019 FWER= 0.973 FDR= 0.0783
 Gene Set 100 : KEGG_DORSO_VENTRAL_AXIS_FORMATION ES = −0.644 NES = −1.64 Nom. p−val= 0.00794 FWER= 0.939 FDR= 0.0746
 Gene Set 62 : KEGG_DRUG_METABOLISM_CYTOCHROME_P450 ES = −0.566 NES = −1.41 Nom. p−val= 0.0395 FWER= 1 FDR= 0.139
 Gene Set 63 : KEGG_DRUG_METABOLISM_OTHER_ENZYMES ES = −0.529 NES = −1.34 Nom. p−val= 0.106 FWER= 1 FDR= 0.184
 Gene Set 107 : KEGG_ECM_RECEPTOR_INTERACTION ES = −0.668 NES = −1.7 Nom. p−val= 0 FWER= 0.833 FDR= 0.0763
 Gene Set 93 : KEGG_ENDOCYTOSIS ES = −0.463 NES = −1.97 Nom. p−val= 0 FWER= 0.218 FDR= 0.102 Y
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 Gene Set 158 : KEGG_ENDOMETRIAL_CANCER ES = −0.456 NES = −1.63 Nom. p−val= 0.0331 FWER= 0.945 FDR= 0.0768
 Gene Set 151 : KEGG_EPITHELIAL_CELL_SIGNALING_IN_HELICOBACTER_PYLORI_INFECTION ES = −0.484 NES = −1.66 Nom. p−val= 0.0195 FWER= 0.922 FDR= 0.073
 Gene Set 80 : KEGG_ERBB_SIGNALING_PATHWAY ES = −0.449 NES = −1.53 Nom. p−val= 0.026 FWER= 0.993 FDR= 0.0958
 Gene Set 41 : KEGG_ETHER_LIPID_METABOLISM ES = −0.5 NES = −1.39 Nom. p−val= 0.0712 FWER= 1 FDR= 0.15
 Gene Set 8 : KEGG_FATTY_ACID_METABOLISM ES = −0.478 NES = −1.4 Nom. p−val= 0.103 FWER= 1 FDR= 0.146
 Gene Set 124 : KEGG_FC_EPSILON_RI_SIGNALING_PATHWAY ES = −0.568 NES = −1.68 Nom. p−val= 0.00383 FWER= 0.885 FDR= 0.0754
 Gene Set 125 : KEGG_FC_GAMMA_R_MEDIATED_PHAGOCYTOSIS ES = −0.662 NES = −1.93 Nom. p−val= 0 FWER= 0.285 FDR= 0.0951 Y
 Gene Set 106 : KEGG_FOCAL_ADHESION ES = −0.638 NES = −1.86 Nom. p−val= 0 FWER= 0.462 FDR= 0.0907 Y
 Gene Set 6 : KEGG_GALACTOSE_METABOLISM ES = −0.467 NES = −1.49 Nom. p−val= 0.0542 FWER= 0.998 FDR= 0.108
 Gene Set 111 : KEGG_GAP_JUNCTION ES = −0.532 NES = −1.66 Nom. p−val= 0.00393 FWER= 0.922 FDR= 0.0735
 Gene Set 159 : KEGG_GLIOMA ES = −0.49 NES = −1.65 Nom. p−val= 0.00199 FWER= 0.927 FDR= 0.0728
 Gene Set 27 : KEGG_GLUTATHIONE_METABOLISM ES = −0.442 NES = −1.24 Nom. p−val= 0.221 FWER= 1 FDR= 0.249
 Gene Set 37 : KEGG_GLYCEROLIPID_METABOLISM ES = −0.492 NES = −1.49 Nom. p−val= 0.0209 FWER= 0.998 FDR= 0.108
 Gene Set 40 : KEGG_GLYCEROPHOSPHOLIPID_METABOLISM ES = −0.524 NES = −1.8 Nom. p−val= 0 FWER= 0.619 FDR= 0.0806 Y
 Gene Set 1 : KEGG_GLYCOLYSIS_GLUCONEOGENESIS ES = −0.478 NES = −1.49 Nom. p−val= 0.0363 FWER= 0.998 FDR= 0.111
Gene Set 34 : KEGG_GLYCOSAMINOGLYCAN_BIOSYNTHESIS_CHONDROITIN_SULFATE ES = −0.511 NES = −1.42 Nom. p−val= 0.101 FWER= 1 FDR= 0.136
 Gene Set 36 : KEGG_GLYCOSAMINOGLYCAN_BIOSYNTHESIS_HEPARAN_SULFATE ES = −0.482 NES = −1.27 Nom. p−val= 0.163 FWER= 1 FDR= 0.229
 Gene Set 35 : KEGG_GLYCOSAMINOGLYCAN_BIOSYNTHESIS_KERATAN_SULFATE ES = −0.638 NES = −1.48 Nom. p−val= 0.039 FWER= 0.999 FDR= 0.114
 Gene Set 33 : KEGG_GLYCOSAMINOGLYCAN_DEGRADATION ES = −0.627 NES = −1.63 Nom. p−val= 0.0117 FWER= 0.945 FDR= 0.0766
 Gene Set 47 : KEGG_GLYCOSPHINGOLIPID_BIOSYNTHESIS_GANGLIO_SERIES ES = −0.668 NES = −1.5 Nom. p−val= 0.0403 FWER= 0.997 FDR= 0.107
 Gense Set 46 : KEGG_GLYCOSPHINGOLIPID_BIOSYNTHESIS_LACTO_AND_NEOLACTO_SERIES ES = −0.574 NES = −1.39 Nom. p−val= 0.0973 FWER= 1 FDR= 0.153
 Gene Set 135 : KEGG_GNRH_SIGNALING_PATHWAY ES = −0.431 NES = −1.54 Nom. p−val= 0.0174 FWER= 0.993 FDR= 0.0929
 Gene Set 173 : KEGG_GRAFT_VERSUS_HOST_DISEASE ES = −0.742 NES = −1.5 Nom. p−val= 0.0208 FWER= 0.996 FDR= 0.104
 Gene Set 102 : KEGG_HEDGEHOG_SIGNALING_PATHWAY ES = −0.582 NES = −1.49 Nom. p−val= 0.016 FWER= 0.998 FDR= 0.108
 Gene Set 120 : KEGG_HEMATOPOIETIC_CELL_LINEAGE ES = −0.719 NES = −1.56 Nom. p−val= 0.00952 FWER= 0.989 FDR= 0.0885
 Gene Set 21 : KEGG_HISTIDINE_METABOLISM ES = −0.499 NES = −1.34 Nom. p−val= 0.104 FWER= 1 FDR= 0.182
 Gene Set 148 : KEGG_HUNTINGTONS_DISEASE ES = −0.306 NES = −1.38 Nom. p−val= 0.105 FWER= 1 FDR= 0.158
 Gene Set 175 : KEGG_HYPERTROPHIC_CARDIOMYOPATHY_HCM ES = −0.674 NES = −1.63 Nom. p−val= 0 FWER= 0.941 FDR= 0.0761
 Gene Set 38 : KEGG_INOSITOL_PHOSPHATE_METABOLISM ES = −0.456 NES = −1.55 Nom. p−val= 0.023 FWER= 0.99 FDR= 0.0894
 Gene Set 134 : KEGG_INSULIN_SIGNALING_PATHWAY ES = −0.453 NES = −1.76 Nom. p−val= 0.002 FWER= 0.719 FDR= 0.0731
 Gene Set 127 : KEGG_INTESTINAL_IMMUNE_NETWORK_FOR_IGA_PRODUCTION ES = −0.784 NES = −1.6 Nom. p−val= 0.00388 FWER= 0.968 FDR= 0.0765
 Gene Set 119 : KEGG_JAK_STAT_SIGNALING_PATHWAY ES = −0.606 NES = −1.68 Nom. p−val= 0 FWER= 0.889 FDR= 0.0734
 Gene Set 153 : KEGG_LEISHMANIA_INFECTION ES = −0.702 NES = −1.62 Nom. p−val= 0.00586 FWER= 0.95 FDR= 0.0759
 Gene Set 126 : KEGG_LEUKOCYTE_TRANSENDOTHELIAL_MIGRATION ES = −0.614 NES = −1.75 Nom. p−val= 0 FWER= 0.727 FDR= 0.0746
 Gene Set 130 : KEGG_LONG_TERM_DEPRESSION ES = −0.523 NES = −1.56 Nom. p−val= 0.0192 FWER= 0.989 FDR= 0.0872
 Gene Set 128 : KEGG_LONG_TERM_POTENTIATION ES = −0.451 NES = −1.49 Nom. p−val= 0.0398 FWER= 0.998 FDR= 0.108
 Gene Set 19 : KEGG_LYSINE_DEGRADATION ES = −0.342 NES = −1.46 Nom. p−val= 0.0615 FWER= 0.999 FDR= 0.118
 Gene Set 92 : KEGG_LYSOSOME ES = −0.355 NES = −1.47 Nom. p−val= 0.109 FWER= 0.999 FDR= 0.116
 Gene Set 79 : KEGG_MAPK_SIGNALING_PATHWAY ES = −0.527 NES = −1.79 Nom. p−val= 0 FWER= 0.633 FDR= 0.0766 Y
 Gene Set 137 : KEGG_MELANOGENESIS ES = −0.551 NES = −1.63 Nom. p−val= 0.00189 FWER= 0.943 FDR= 0.0763
 Gene Set 163 : KEGG_MELANOMA ES = −0.601 NES = −1.74 Nom. p−val= 0 FWER= 0.741 FDR= 0.0737
 Gene Set 61 : KEGG_METABOLISM_OF_XENOBIOTICS_BY_CYTOCHROME_P450 ES = −0.543 NES = −1.35 Nom. p−val= 0.0707 FWER= 1 FDR= 0.178
 Gene Set 95 : KEGG_MTOR_SIGNALING_PATHWAY ES = −0.366 NES = −1.41 Nom. p−val= 0.0713 FWER= 1 FDR= 0.14
 Gene Set 121 : KEGG_NATURAL_KILLER_CELL_MEDIATED_CYTOTOXICITY ES = −0.62 NES = −1.68 Nom. p−val= 0.0038 FWER= 0.889 FDR= 0.0739
 Gene Set 85 : KEGG_NEUROACTIVE_LIGAND_RECEPTOR_INTERACTION ES = −0.603 NES = −1.61 Nom. p−val= 0 FWER= 0.964 FDR= 0.0762
 Gene Set 129 : KEGG_NEUROTROPHIN_SIGNALING_PATHWAY ES = −0.466 NES = −1.83 Nom. p−val= 0 FWER= 0.545 FDR= 0.0778 Y
 Gene Set 54 : KEGG_NICOTINATE_AND_NICOTINAMIDE_METABOLISM ES = −0.628 NES = −1.65 Nom. p−val= 0.00587 FWER= 0.927 FDR= 0.0733
 Gene Set 116 : KEGG_NOD_LIKE_RECEPTOR_SIGNALING_PATHWAY ES = −0.67 NES = −1.62 Nom. p−val= 0.00196 FWER= 0.945 FDR= 0.0759
 Gene Set 168 : KEGG_NON_SMALL_CELL_LUNG_CANCER ES = −0.515 NES = −1.76 Nom. p−val= 0.00195 FWER= 0.708 FDR= 0.0729
 Gene Set 88 : KEGG_P53_SIGNALING_PATHWAY ES = −0.447 NES = −1.49 Nom. p−val= 0.0532 FWER= 0.998 FDR= 0.11
 Gene Set 157 : KEGG_PANCREATIC_CANCER ES = −0.491 NES = −1.75 Nom. p−val= 0.00393 FWER= 0.735 FDR= 0.0728
 Gene Set 55 : KEGG_PANTOTHENATE_AND_COA_BIOSYNTHESIS ES = −0.641 NES = −1.51 Nom. p−val= 0.0366 FWER= 0.996 FDR= 0.102
 Gene Set 146 : KEGG_PARKINSONS_DISEASE ES = −0.394 NES = −1.38 Nom. p−val= 0.173 FWER= 1 FDR= 0.158
 Gene Set 152 : KEGG_PATHOGENIC_ESCHERICHIA_COLI_INFECTION ES = −0.456 NES = −1.51 Nom. p−val= 0.0489 FWER= 0.996 FDR= 0.101
 Gene Set 154 : KEGG_PATHWAYS_IN_CANCER ES = −0.56 NES = −1.9 Nom. p−val= 0 FWER= 0.37 FDR= 0.0846 Y
 Gene Set 94 : KEGG_PEROXISOME ES = −0.326 NES = −1.27 Nom. p−val= 0.169 FWER= 1 FDR= 0.229
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 Gene Set 23 : KEGG_PHENYLALANINE_METABOLISM ES = −0.534 NES = −1.31 Nom. p−val= 0.129 FWER= 1 FDR= 0.204
 Gene Set 84 : KEGG_PHOSPHATIDYLINOSITOL_SIGNALING_SYSTEM ES = −0.512 NES = −1.66 Nom. p−val= 0.00389 FWER= 0.922 FDR= 0.073
 Gene Set 74 : KEGG_PPAR_SIGNALING_PATHWAY ES = −0.566 NES = −1.58 Nom. p−val= 0.0157 FWER= 0.983 FDR= 0.0807
 Gene Set 10 : KEGG_PRIMARY_BILE_ACID_BIOSYNTHESIS ES = −0.556 NES = −1.31 Nom. p−val= 0.115 FWER= 1 FDR= 0.2
 Gene Set 174 : KEGG_PRIMARY_IMMUNODEFICIENCY ES = −0.792 NES = −1.54 Nom. p−val= 0.0241 FWER= 0.991 FDR= 0.0905
 Gene Set 149 : KEGG_PRION_DISEASES ES = −0.646 NES = −1.68 Nom. p−val= 0.00774 FWER= 0.885 FDR= 0.0748
 Gene Set 136 : KEGG_PROGESTERONE_MEDIATED_OOCYTE_MATURATION ES = −0.39 NES = −1.3 Nom. p−val= 0.166 FWER= 1 FDR= 0.212
 Gene Set 160 : KEGG_PROSTATE_CANCER ES = −0.482 NES = −1.77 Nom. p−val= 0.00588 FWER= 0.684 FDR= 0.0733
Gene Set 144 : KEGG_PROXIMAL_TUBULE_BICARBONATE_RECLAMATION ES = −0.637 NES = −1.56 Nom. p−val= 0.00787 FWER= 0.989 FDR= 0.0866
 Gene Set 13 : KEGG_PURINE_METABOLISM ES = −0.387 NES = −1.64 Nom. p−val= 0.00406 FWER= 0.938 FDR= 0.0744
 Gene Set 14 : KEGG_PYRIMIDINE_METABOLISM ES = −0.29 NES = −1.29 Nom. p−val= 0.153 FWER= 1 FDR= 0.216
 Gene Set 133 : KEGG_REGULATION_OF_ACTIN_CYTOSKELETON ES = −0.584 NES = −1.91 Nom. p−val= 0 FWER= 0.342 FDR= 0.0992 Y
 Gene Set 156 : KEGG_RENAL_CELL_CARCINOMA ES = −0.527 NES = −1.83 Nom. p−val= 0.00199 FWER= 0.529 FDR= 0.0846
 Gene Set 114 : KEGG_RENIN_ANGIOTENSIN_SYSTEM ES = −0.575 NES = −1.29 Nom. p−val= 0.122 FWER= 1 FDR= 0.215
 Gene Set 56 : KEGG_RETINOL_METABOLISM ES = −0.538 NES = −1.34 Nom. p−val= 0.0723 FWER= 1 FDR= 0.184
 Gene Set 117 : KEGG_RIG_I_LIKE_RECEPTOR_SIGNALING_PATHWAY ES = −0.42 NES = −1.52 Nom. p−val= 0.0455 FWER= 0.995 FDR= 0.0995
 Gene Set 167 : KEGG_SMALL_CELL_LUNG_CANCER ES = −0.532 NES = −1.75 Nom. p−val= 0.00594 FWER= 0.724 FDR= 0.0735
 Gene Set 90 : KEGG_SNARE_INTERACTIONS_IN_VESICULAR_TRANSPORT ES = −0.521 NES = −1.96 Nom. p−val= 0 FWER= 0.224 FDR= 0.0967 Y
 Gene Set 28 : KEGG_STARCH_AND_SUCROSE_METABOLISM ES = −0.485 NES = −1.26 Nom. p−val= 0.148 FWER= 1 FDR= 0.235
 Gene Set 11 : KEGG_STEROID_HORMONE_BIOSYNTHESIS ES = −0.545 NES = −1.36 Nom. p−val= 0.0745 FWER= 1 FDR= 0.171
 Gene Set 171 : KEGG_SYSTEMIC_LUPUS_ERYTHEMATOSUS ES = −0.52 NES = −1.29 Nom. p−val= 0.158 FWER= 1 FDR= 0.215
 Gene Set 122 : KEGG_T_CELL_RECEPTOR_SIGNALING_PATHWAY ES = −0.657 NES = −1.67 Nom. p−val= 0.00589 FWER= 0.896 FDR= 0.0722
 Gene Set 103 : KEGG_TGF_BETA_SIGNALING_PATHWAY ES = −0.616 NES = −1.83 Nom. p−val= 0 FWER= 0.546 FDR= 0.0767 Y
 Gene Set 161 : KEGG_THYROID_CANCER ES = −0.575 NES = −1.8 Nom. p−val= 0.00986 FWER= 0.621 FDR= 0.0793
 Gene Set 110 : KEGG_TIGHT_JUNCTION ES = −0.516 NES = −1.77 Nom. p−val= 0 FWER= 0.689 FDR= 0.072
 Gene Set 115 : KEGG_TOLL_LIKE_RECEPTOR_SIGNALING_PATHWAY ES = −0.622 NES = −1.75 Nom. p−val= 0.00195 FWER= 0.735 FDR= 0.074
 Gene Set 24 : KEGG_TRYPTOPHAN_METABOLISM ES = −0.445 NES = −1.25 Nom. p−val= 0.135 FWER= 1 FDR= 0.24
 Gene Set 140 : KEGG_TYPE_I_DIABETES_MELLITUS ES = −0.713 NES = −1.52 Nom. p−val= 0.0207 FWER= 0.995 FDR= 0.0978
 Gene Set 139 : KEGG_TYPE_II_DIABETES_MELLITUS ES = −0.488 NES = −1.39 Nom. p−val= 0.0772 FWER= 1 FDR= 0.154
 Gene Set 22 : KEGG_TYROSINE_METABOLISM ES = −0.463 NES = −1.27 Nom. p−val= 0.144 FWER= 1 FDR= 0.23
 Gene Set 89 : KEGG_UBIQUITIN_MEDIATED_PROTEOLYSIS ES = −0.212 NES = −1.24 Nom. p−val= 0.209 FWER= 1 FDR= 0.248
 Gene Set 98 : KEGG_VASCULAR_SMOOTH_MUSCLE_CONTRACTION ES = −0.597 NES = −1.76 Nom. p−val= 0 FWER= 0.716 FDR= 0.0736
 Gene Set 143 : KEGG_VASOPRESSIN_REGULATED_WATER_REABSORPTION ES = −0.446 NES = −1.65 Nom. p−val= 0.023 FWER= 0.927 FDR= 0.0733
 Gene Set 105 : KEGG_VEGF_SIGNALING_PATHWAY ES = −0.51 NES = −1.75 Nom. p−val= 0.00191 FWER= 0.735 FDR= 0.0734
 Gene Set 150 : KEGG_VIBRIO_CHOLERAE_INFECTION ES = −0.398 NES = −1.46 Nom. p−val= 0.0716 FWER= 0.999 FDR= 0.118
 Gene Set 178 : KEGG_VIRAL_MYOCARDITIS ES = −0.73 NES = −1.78 Nom. p−val= 0 FWER= 0.667 FDR= 0.0777
 Gene Set 99 : KEGG_WNT_SIGNALING_PATHWAY ES = −0.525 NES = −1.77 Nom. p−val= 0 FWER= 0.681 FDR= 0.0739
 Gene Set 1070 : NABA_BASEMENT_MEMBRANES ES = −0.684 NES = −1.65 Nom. p−val= 0 FWER= 0.927 FDR= 0.0728
 Gene Set 1063 : NABA_COLLAGENS ES = −0.702 NES = −1.58 Nom. p−val= 0.00781 FWER= 0.983 FDR= 0.0816
 Gene Set 1069 : NABA_CORE_MATRISOME ES = −0.684 NES = −1.78 Nom. p−val= 0 FWER= 0.658 FDR= 0.0755
 Gene Set 1066 : NABA_ECM_AFFILIATED ES = −0.612 NES = −1.64 Nom. p−val= 0 FWER= 0.94 FDR= 0.0744
 Gene Set 1064 : NABA_ECM_GLYCOPROTEINS ES = −0.674 NES = −1.79 Nom. p−val= 0 FWER= 0.629 FDR= 0.0773 Y
 Gene Set 1065 : NABA_ECM_REGULATORS ES = −0.632 NES = −1.69 Nom. p−val= 0 FWER= 0.869 FDR= 0.0754
 Gene Set 1067 : NABA_PROTEOGLYCANS ES = −0.728 NES = −1.61 Nom. p−val= 0.00385 FWER= 0.963 FDR= 0.0766
 Gene Set 1068 : NABA_SECRETED_FACTORS ES = −0.649 NES = −1.66 Nom. p−val= 0 FWER= 0.922 FDR= 0.0732
 Gene Set 516 : PID_A6B1_A6B4_INTEGRIN_PATHWAY ES = −0.507 NES = −1.5 Nom. p−val= 0.0435 FWER= 0.997 FDR= 0.107
 Gene Set 455 : PID_AJDISS_2PATHWAY ES = −0.593 NES = −1.79 Nom. p−val= 0.00607 FWER= 0.652 FDR= 0.0762
 Gene Set 482 : PID_ALK1_PATHWAY ES = −0.616 NES = −1.77 Nom. p−val= 0.00404 FWER= 0.678 FDR= 0.0743
 Gene Set 541 : PID_ALPHA_SYNUCLEIN_PATHWAY ES = −0.71 NES = −1.9 Nom. p−val= 0 FWER= 0.368 FDR= 0.0873 Y
 Gene Set 463 : PID_AMB2_NEUTROPHILS_PATHWAY ES = −0.716 NES = −1.65 Nom. p−val= 0.00193 FWER= 0.927 FDR= 0.0729
 Gene Set 427 : PID_ANGIOPOIETIN_RECEPTOR_PATHWAY ES = −0.545 NES = −1.66 Nom. p−val= 0.0098 FWER= 0.916 FDR= 0.0739
 Gene Set 533 : PID_ANTHRAX_PATHWAY ES = −0.708 NES = −1.5 Nom. p−val= 0.0273 FWER= 0.996 FDR= 0.105
 Gene Set 471 : PID_AP1_PATHWAY ES = −0.612 NES = −1.66 Nom. p−val= 0.00578 FWER= 0.921 FDR= 0.0734
 Gene Set 499 : PID_AR_NONGENOMIC_PATHWAY ES = −0.516 NES = −1.7 Nom. p−val= 0.0131 FWER= 0.852 FDR= 0.074
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 Gene Set 520 : PID_ARF_3PATHWAY ES = −0.384 NES = −1.49 Nom. p−val= 0.0442 FWER= 0.998 FDR= 0.108
 Gene Set 443 : PID_ARF6_DOWNSTREAM_PATHWAY ES = −0.54 NES = −1.63 Nom. p−val= 0.0433 FWER= 0.944 FDR= 0.0764
 Gene Set 422 : PID_ARF6_PATHWAY ES = −0.534 NES = −1.6 Nom. p−val= 0.016 FWER= 0.971 FDR= 0.0778
 Gene Set 409 : PID_ARF6_TRAFFICKING_PATHWAY ES = −0.639 NES = −1.91 Nom. p−val= 0 FWER= 0.336 FDR= 0.103 Y
 Gene Set 470 : PID_ATF2_PATHWAY ES = −0.6 NES = −1.63 Nom. p−val= 0.018 FWER= 0.944 FDR= 0.0766
 Gene Set 464 : PID_AVB3_INTEGRIN_PATHWAY ES = −0.638 NES = −1.73 Nom. p−val= 0 FWER= 0.778 FDR= 0.0728
 Gene Set 406 : PID_AVB3_OPN_PATHWAY ES = −0.604 NES = −1.64 Nom. p−val= 0.00967 FWER= 0.939 FDR= 0.0746
 Gene Set 368 : PID_BCR_5PATHWAY ES = −0.623 NES = −1.66 Nom. p−val= 0.0154 FWER= 0.917 FDR= 0.0738
 Gene Set 504 : PID_BETA_CATENIN_NUC_PATHWAY ES = −0.562 NES = −1.73 Nom. p−val= 0 FWER= 0.765 FDR= 0.0731
 Gene Set 478 : PID_BMP_PATHWAY ES = −0.571 NES = −1.62 Nom. p−val= 0.0101 FWER= 0.945 FDR= 0.0755
 Gene Set 502 : PID_CASPASE_PATHWAY ES = −0.516 NES = −1.88 Nom. p−val= 0 FWER= 0.412 FDR= 0.087 Y
 Gene Set 538 : PID_CD8_TCR_DOWNSTREAM_PATHWAY ES = −0.675 NES = −1.62 Nom. p−val= 0.0116 FWER= 0.958 FDR= 0.0762
 Gene Set 424 : PID_CD8_TCR_PATHWAY ES = −0.744 NES = −1.59 Nom. p−val= 0.00965 FWER= 0.978 FDR= 0.0798
 Gene Set 394 : PID_CD40_PATHWAY ES = −0.603 NES = −1.65 Nom. p−val= 0.0136 FWER= 0.931 FDR= 0.0741
 Gene Set 418 : PID_CDC42_PATHWAY ES = −0.347 NES = −1.46 Nom. p−val= 0.0948 FWER= 0.999 FDR= 0.117
 Gene Set 420 : PID_CDC42_REG_PATHWAY ES = −0.509 NES = −1.58 Nom. p−val= 0.0324 FWER= 0.983 FDR= 0.081
 Gene Set 486 : PID_CMYB_PATHWAY ES = −0.57 NES = −1.82 Nom. p−val= 0.0019 FWER= 0.56 FDR= 0.0746
 Gene Set 503 : PID_CXCR3_PATHWAY ES = −0.593 NES = −1.66 Nom. p−val= 0.0154 FWER= 0.922 FDR= 0.0733
 Gene Set 446 : PID_CXCR4_PATHWAY ES = −0.643 NES = −1.76 Nom. p−val= 0 FWER= 0.711 FDR= 0.0732
 Gene Set 513 : PID_DELTA_NP63_PATHWAY ES = −0.602 NES = −1.62 Nom. p−val= 0.00806 FWER= 0.959 FDR= 0.0757
 Gene Set 392 : PID_DNA_PK_PATHWAY ES = −0.518 NES = −1.57 Nom. p−val= 0.0545 FWER= 0.985 FDR= 0.0844
 Gene Set 481 : PID_ECADHERIN_KERATINOCYTE_PATHWAY ES = −0.422 NES = −1.24 Nom. p−val= 0.256 FWER= 1 FDR= 0.247
 Gene Set 462 : PID_ECADHERIN_NASCENT_AJ_PATHWAY ES = −0.302 NES = −1.26 Nom. p−val= 0.19 FWER= 1 FDR= 0.237
 Gene Set 509 : PID_ECADHERIN_STABILIZATION_PATHWAY ES = −0.503 NES = −1.63 Nom. p−val= 0.0202 FWER= 0.943 FDR= 0.0765
 Gene Set 367 : PID_ENDOTHELIN_PATHWAY ES = −0.608 NES = −1.66 Nom. p−val= 0 FWER= 0.913 FDR= 0.0732
 Gene Set 476 : PID_EPHA_FWDPATHWAY ES = −0.667 NES = −1.72 Nom. p−val= 0 FWER= 0.794 FDR= 0.0731
 Gene Set 539 : PID_EPHA2_FWD_PATHWAY ES = −0.482 NES = −1.39 Nom. p−val= 0.139 FWER= 1 FDR= 0.15
 Gene Set 405 : PID_EPHB_FWD_PATHWAY ES = −0.52 NES = −1.7 Nom. p−val= 0.0134 FWER= 0.849 FDR= 0.0747
 Gene Set 528 : PID_EPHRINB_REV_PATHWAY ES = −0.654 NES = −1.62 Nom. p−val= 0.00945 FWER= 0.958 FDR= 0.076
 Gene Set 510 : PID_EPO_PATHWAY ES = −0.553 NES = −1.67 Nom. p−val= 0.00956 FWER= 0.91 FDR= 0.0739
 Gene Set 391 : PID_ER_NONGENOMIC_PATHWAY ES = −0.594 NES = −1.69 Nom. p−val= 0.002 FWER= 0.865 FDR= 0.076
 Gene Set 491 : PID_ERA_GENOMIC_PATHWAY ES = −0.434 NES = −1.68 Nom. p−val= 0.0115 FWER= 0.877 FDR= 0.0753
 Gene Set 442 : PID_ERB_GENOMIC_PATHWAY ES = −0.628 NES = −1.55 Nom. p−val= 0.0498 FWER= 0.99 FDR= 0.0896
 Gene Set 468 : PID_ERBB1_DOWNSTREAM_PATHWAY ES = −0.39 NES = −1.72 Nom. p−val= 0.0201 FWER= 0.783 FDR= 0.0738
 Gene Set 500 : PID_ERBB1_INTERNALIZATION_PATHWAY ES = −0.446 NES = −1.6 Nom. p−val= 0.0452 FWER= 0.967 FDR= 0.0764
 Gene Set 448 : PID_ERBB1_RECEPTOR_PROXIMAL_PATHWAY ES = −0.36 NES = −1.3 Nom. p−val= 0.211 FWER= 1 FDR= 0.21
 Gene Set 474 : PID_ERBB2_ERBB3_PATHWAY ES = −0.432 NES = −1.59 Nom. p−val= 0.0278 FWER= 0.981 FDR= 0.0807
 Gene Set 371 : PID_ERBB4_PATHWAY ES = −0.51 NES = −1.45 Nom. p−val= 0.081 FWER= 0.999 FDR= 0.121
 Gene Set 546 : PID_FAK_PATHWAY ES = −0.51 NES = −1.79 Nom. p−val= 0.008 FWER= 0.647 FDR= 0.0785
 Gene Set 428 : PID_FAS_PATHWAY ES = −0.54 NES = −1.74 Nom. p−val= 0.00385 FWER= 0.743 FDR= 0.0735
 Gene Set 366 : PID_FCER1_PATHWAY ES = −0.666 NES = −1.77 Nom. p−val= 0.00196 FWER= 0.698 FDR= 0.0718
 Gene Set 542 : PID_FGF_PATHWAY ES = −0.586 NES = −1.67 Nom. p−val= 0.00372 FWER= 0.911 FDR= 0.0735
 Gene Set 407 : PID_FRA_PATHWAY ES = −0.683 NES = −1.61 Nom. p−val= 0.008 FWER= 0.964 FDR= 0.0763
 Gene Set 386 : PID_GLYPICAN_1PATHWAY ES = −0.702 NES = −1.71 Nom. p−val= 0.00406 FWER= 0.827 FDR= 0.0763
 Gene Set 379 : PID_GMCSF_PATHWAY ES = −0.582 NES = −1.59 Nom. p−val= 0.0293 FWER= 0.981 FDR= 0.0806
 Gene Set 383 : PID_HDAC_CLASSII_PATHWAY ES = −0.537 NES = −1.89 Nom. p−val= 0.00769 FWER= 0.38 FDR= 0.0816
 Gene Set 497 : PID_HEDGEHOG_2PATHWAY ES = −0.633 NES = −1.48 Nom. p−val= 0.0599 FWER= 0.999 FDR= 0.113
 Gene Set 501 : PID_HEDGEHOG_GLI_PATHWAY ES = −0.417 NES = −1.48 Nom. p−val= 0.0875 FWER= 0.998 FDR= 0.112
 Gene Set 549 : PID_HES_HEY_PATHWAY ES = −0.409 NES = −1.41 Nom. p−val= 0.0378 FWER= 1 FDR= 0.142
 Gene Set 526 : PID_HIF1_TFPATHWAY ES = −0.553 NES = −1.77 Nom. p−val= 0.00784 FWER= 0.687 FDR= 0.0732
 Gene Set 477 : PID_HIF1A_PATHWAY ES = −0.486 NES = −1.55 Nom. p−val= 0.0629 FWER= 0.99 FDR= 0.0896
 Gene Set 393 : PID_HIF2PATHWAY ES = −0.584 NES = −1.91 Nom. p−val= 0 FWER= 0.342 FDR= 0.0946 Y
 Gene Set 488 : PID_HIV_NEF_PATHWAY ES = −0.542 NES = −1.7 Nom. p−val= 0.00984 FWER= 0.841 FDR= 0.0755
 Gene Set 465 : PID_IFNG_PATHWAY ES = −0.503 NES = −1.65 Nom. p−val= 0.0174 FWER= 0.924 FDR= 0.0729
 Gene Set 437 : PID_IL1_PATHWAY ES = −0.513 NES = −1.5 Nom. p−val= 0.0635 FWER= 0.997 FDR= 0.107
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 Gene Set 445 : PID_IL2_1PATHWAY ES = −0.602 NES = −1.65 Nom. p−val= 0.00787 FWER= 0.931 FDR= 0.0738
 Gene Set 456 : PID_IL2_PI3K_PATHWAY ES = −0.499 NES = −1.45 Nom. p−val= 0.0967 FWER= 0.999 FDR= 0.123
 Gene Set 511 : PID_IL2_STAT5_PATHWAY ES = −0.661 NES = −1.48 Nom. p−val= 0.0578 FWER= 0.999 FDR= 0.114
 Gene Set 479 : PID_IL3_PATHWAY ES = −0.577 NES = −1.6 Nom. p−val= 0.02 FWER= 0.967 FDR= 0.0765
 Gene Set 382 : PID_IL4_2PATHWAY ES = −0.64 NES = −1.64 Nom. p−val= 0.0038 FWER= 0.934 FDR= 0.0738
 Gene Set 480 : PID_IL6_7_PATHWAY ES = −0.571 NES = −1.55 Nom. p−val= 0.0358 FWER= 0.99 FDR= 0.0895
 Gene Set 524 : PID_IL8_CXCR1_PATHWAY ES = −0.665 NES = −1.55 Nom. p−val= 0.0115 FWER= 0.99 FDR= 0.0898
 Gene Set 496 : PID_IL8_CXCR2_PATHWAY ES = −0.674 NES = −1.59 Nom. p−val= 0.0115 FWER= 0.976 FDR= 0.0788
 Gene Set 400 : PID_IL12_2PATHWAY ES = −0.689 NES = −1.47 Nom. p−val= 0.0564 FWER= 0.999 FDR= 0.116
 Gene Set 550 : PID_IL12_STAT4_PATHWAY ES = −0.763 NES = −1.51 Nom. p−val= 0.0242 FWER= 0.996 FDR= 0.103
 Gene Set 487 : PID_IL23_PATHWAY ES = −0.694 NES = −1.41 Nom. p−val= 0.0658 FWER= 1 FDR= 0.144
 Gene Set 388 : PID_IL27_PATHWAY ES = −0.749 NES = −1.48 Nom. p−val= 0.0189 FWER= 0.999 FDR= 0.113
 Gene Set 413 : PID_ILK_PATHWAY ES = −0.545 NES = −1.98 Nom. p−val= 0.00192 FWER= 0.196 FDR= 0.097
 Gene Set 521 : PID_INSULIN_GLUCOSE_PATHWAY ES = −0.423 NES = −1.34 Nom. p−val= 0.159 FWER= 1 FDR= 0.182
 Gene Set 374 : PID_INSULIN_PATHWAY ES = −0.438 NES = −1.7 Nom. p−val= 0.0156 FWER= 0.85 FDR= 0.0743
 Gene Set 543 : PID_INTEGRIN_A4B1_PATHWAY ES = −0.667 NES = −1.89 Nom. p−val= 0 FWER= 0.392 FDR= 0.0833 Y
 Gene Set 441 : PID_INTEGRIN_A9B1_PATHWAY ES = −0.661 NES = −1.55 Nom. p−val= 0.012 FWER= 0.99 FDR= 0.089
 Gene Set 396 : PID_INTEGRIN_CS_PATHWAY ES = −0.753 NES = −1.56 Nom. p−val= 0 FWER= 0.989 FDR= 0.0872
 Gene Set 376 : PID_INTEGRIN1_PATHWAY ES = −0.694 NES = −1.69 Nom. p−val= 0 FWER= 0.877 FDR= 0.0759
 Gene Set 472 : PID_INTEGRIN2_PATHWAY ES = −0.756 NES = −1.58 Nom. p−val= 0.0148 FWER= 0.984 FDR= 0.0832
 Gene Set 399 : PID_INTEGRIN3_PATHWAY ES = −0.701 NES = −1.69 Nom. p−val= 0 FWER= 0.87 FDR= 0.075
 Gene Set 498 : PID_INTEGRIN5_PATHWAY ES = −0.72 NES = −1.49 Nom. p−val= 0.0233 FWER= 0.998 FDR= 0.111
 Gene Set 508 : PID_KIT_PATHWAY ES = −0.541 NES = −1.61 Nom. p−val= 0.0193 FWER= 0.96 FDR= 0.0754
 Gene Set 402 : PID_LPA4_PATHWAY ES = −0.663 NES = −1.45 Nom. p−val= 0.0461 FWER= 0.999 FDR= 0.123
 Gene Set 540 : PID_LYMPH_ANGIOGENESIS_PATHWAY ES = −0.64 NES = −1.74 Nom. p−val= 0.00192 FWER= 0.755 FDR= 0.0746
 Gene Set 373 : PID_LYSOPHOSPHOLIPID_PATHWAY ES = −0.513 NES = −1.63 Nom. p−val= 0.0254 FWER= 0.944 FDR= 0.0767
 Gene Set 397 : PID_MET_PATHWAY ES = −0.382 NES = −1.74 Nom. p−val= 0.012 FWER= 0.755 FDR= 0.074
 Gene Set 408 : PID_MYC_ACTIV_PATHWAY ES = −0.396 NES = −1.54 Nom. p−val= 0.0631 FWER= 0.991 FDR= 0.09
 Gene Set 525 : PID_MYC_REPRESS_PATHWAY ES = −0.521 NES = −1.82 Nom. p−val= 0 FWER= 0.553 FDR= 0.0757 Y
 Gene Set 532 : PID_NCADHERIN_PATHWAY ES = −0.582 NES = −1.67 Nom. p−val= 0.00604 FWER= 0.909 FDR= 0.0739
 Gene Set 414 : PID_NECTIN_PATHWAY ES = −0.408 NES = −1.38 Nom. p−val= 0.171 FWER= 1 FDR= 0.156
 Gene Set 485 : PID_NEPHRIN_NEPH1_PATHWAY ES = −0.548 NES = −1.74 Nom. p−val= 0.00391 FWER= 0.745 FDR= 0.073
 Gene Set 436 : PID_NETRIN_PATHWAY ES = −0.637 NES = −1.84 Nom. p−val= 0 FWER= 0.494 FDR= 0.0875 Y
 Gene Set 438 : PID_NFAT_3PATHWAY ES = −0.526 NES = −1.87 Nom. p−val= 0 FWER= 0.423 FDR= 0.0852 Y
 Gene Set 404 : PID_NFAT_TFPATHWAY ES = −0.66 NES = −1.46 Nom. p−val= 0.043 FWER= 0.999 FDR= 0.117
 Gene Set 375 : PID_NOTCH_PATHWAY ES = −0.427 NES = −1.4 Nom. p−val= 0.0778 FWER= 1 FDR= 0.145
 Gene Set 507 : PID_P38_ALPHA_BETA_DOWNSTREAM_PATHWAY ES = −0.496 NES = −1.7 Nom. p−val= 0.0202 FWER= 0.845 FDR= 0.0744
 Gene Set 415 : PID_P38_ALPHA_BETA_PATHWAY ES = −0.623 NES = −1.75 Nom. p−val= 0.00394 FWER= 0.729 FDR= 0.0743
 Gene Set 490 : PID_P38_MK2_PATHWAY ES = −0.507 NES = −1.52 Nom. p−val= 0.0596 FWER= 0.995 FDR= 0.0976
 Gene Set 458 : PID_P53_DOWNSTREAM_PATHWAY ES = −0.556 NES = −1.8 Nom. p−val= 0.00192 FWER= 0.614 FDR= 0.0799
 Gene Set 377 : PID_P73PATHWAY ES = −0.388 NES = −1.34 Nom. p−val= 0.133 FWER= 1 FDR= 0.184
 Gene Set 460 : PID_P75_NTR_PATHWAY ES = −0.408 NES = −1.56 Nom. p−val= 0.0399 FWER= 0.99 FDR= 0.0888
 Gene Set 494 : PID_PDGFRA_PATHWAY ES = −0.58 NES = −1.55 Nom. p−val= 0.0501 FWER= 0.99 FDR= 0.0894
 Gene Set 483 : PID_PDGFRB_PATHWAY ES = −0.504 NES = −1.9 Nom. p−val= 0 FWER= 0.343 FDR= 0.0915 Y
 Gene Set 537 : PID_PI3K_PLC_TRK_PATHWAY ES = −0.628 NES = −2 Nom. p−val= 0 FWER= 0.167 FDR= 0.103 Y
 Gene Set 454 : PID_PI3KCI_PATHWAY ES = −0.683 NES = −1.72 Nom. p−val= 0.00759 FWER= 0.79 FDR= 0.0727
 Gene Set 369 : PID_PRL_SIGNALING_EVENTS_PATHWAY ES = −0.414 NES = −1.35 Nom. p−val= 0.136 FWER= 1 FDR= 0.173
 Gene Set 412 : PID_PS1_PATHWAY ES = −0.368 NES = −1.31 Nom. p−val= 0.146 FWER= 1 FDR= 0.2
 Gene Set 398 : PID_PTP1B_PATHWAY ES = −0.656 NES = −1.79 Nom. p−val= 0 FWER= 0.648 FDR= 0.0766 Y
 Gene Set 544 : PID_RAC1_PATHWAY ES = −0.432 NES = −1.58 Nom. p−val= 0.0441 FWER= 0.984 FDR= 0.0825
 Gene Set 518 : PID_RAC1_REG_PATHWAY ES = −0.635 NES = −1.63 Nom. p−val= 0.00591 FWER= 0.945 FDR= 0.0761
 Gene Set 535 : PID_RAS_PATHWAY ES = −0.654 NES = −1.62 Nom. p−val= 0.00377 FWER= 0.953 FDR= 0.0766
 Gene Set 545 : PID_RB_1PATHWAY ES = −0.52 NES = −1.83 Nom. p−val= 0.00384 FWER= 0.543 FDR= 0.0789
 Gene Set 439 : PID_REG_GR_PATHWAY ES = −0.446 NES = −1.41 Nom. p−val= 0.084 FWER= 1 FDR= 0.14
 Gene Set 419 : PID_RET_PATHWAY ES = −0.533 NES = −1.72 Nom. p−val= 0.004 FWER= 0.785 FDR= 0.0734
 Gene Set 495 : PID_RETINOIC_ACID_PATHWAY ES = −0.494 NES = −1.63 Nom. p−val= 0.016 FWER= 0.943 FDR= 0.0762
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 Gene Set 370 : PID_RHOA_PATHWAY ES = −0.431 NES = −1.51 Nom. p−val= 0.0574 FWER= 0.996 FDR= 0.101
 Gene Set 410 : PID_RHOA_REG_PATHWAY ES = −0.525 NES = −1.67 Nom. p−val= 0.00765 FWER= 0.91 FDR= 0.0737
 Gene Set 466 : PID_RXR_VDR_PATHWAY ES = −0.641 NES = −1.8 Nom. p−val= 0 FWER= 0.61 FDR= 0.0792 Y
 Gene Set 461 : PID_S1P_META_PATHWAY ES = −0.627 NES = −1.58 Nom. p−val= 0.0098 FWER= 0.983 FDR= 0.081
 Gene Set 433 : PID_S1P_S1P1_PATHWAY ES = −0.611 NES = −1.48 Nom. p−val= 0.0425 FWER= 0.999 FDR= 0.114
 Gene Set 534 : PID_S1P_S1P2_PATHWAY ES = −0.498 NES = −1.43 Nom. p−val= 0.102 FWER= 1 FDR= 0.131
 Gene Set 401 : PID_S1P_S1P3_PATHWAY ES = −0.624 NES = −1.64 Nom. p−val= 0.00407 FWER= 0.934 FDR= 0.0735
 Gene Set 431 : PID_SHP2_PATHWAY ES = −0.622 NES = −1.62 Nom. p−val= 0.00398 FWER= 0.958 FDR= 0.0762
 Gene Set 365 : PID_SMAD2_3NUCLEAR_PATHWAY ES = −0.453 NES = −1.6 Nom. p−val= 0.0176 FWER= 0.971 FDR= 0.0783
 Gene Set 489 : PID_SYNDECAN_1_PATHWAY ES = −0.704 NES = −1.67 Nom. p−val= 0.00392 FWER= 0.911 FDR= 0.0735
 Gene Set 517 : PID_SYNDECAN_2_PATHWAY ES = −0.558 NES = −1.73 Nom. p−val= 0 FWER= 0.778 FDR= 0.073
 Gene Set 523 : PID_SYNDECAN_3_PATHWAY ES = −0.605 NES = −1.55 Nom. p−val= 0.0376 FWER= 0.99 FDR= 0.0897
 Gene Set 469 : PID_SYNDECAN_4_PATHWAY ES = −0.663 NES = −1.69 Nom. p−val= 0 FWER= 0.866 FDR= 0.0761
 Gene Set 527 : PID_TAP63_PATHWAY ES = −0.566 NES = −1.66 Nom. p−val= 0.0103 FWER= 0.922 FDR= 0.0731
 Gene Set 426 : PID_TCPTP_PATHWAY ES = −0.53 NES = −1.55 Nom. p−val= 0.0336 FWER= 0.991 FDR= 0.0897
 Gene Set 512 : PID_TCR_CALCIUM_PATHWAY ES = −0.625 NES = −1.43 Nom. p−val= 0.0727 FWER= 1 FDR= 0.133
 Gene Set 387 : PID_TCR_PATHWAY ES = −0.75 NES = −1.64 Nom. p−val= 0.00771 FWER= 0.939 FDR= 0.0743
 Gene Set 548 : PID_TGFBR_PATHWAY ES = −0.444 NES = −1.7 Nom. p−val= 0.0167 FWER= 0.844 FDR= 0.0749
 Gene Set 515 : PID_THROMBIN_PAR1_PATHWAY ES = −0.585 NES = −1.73 Nom. p−val= 0.00189 FWER= 0.765 FDR= 0.0736
 Gene Set 452 : PID_THROMBIN_PAR4_PATHWAY ES = −0.646 NES = −1.54 Nom. p−val= 0.0263 FWER= 0.991 FDR= 0.0905
 Gene Set 449 : PID_TNF_PATHWAY ES = −0.454 NES = −1.63 Nom. p−val= 0.0163 FWER= 0.945 FDR= 0.0762
 Gene Set 531 : PID_TOLL_ENDOGENOUS_PATHWAY ES = −0.711 NES = −1.58 Nom. p−val= 0.0174 FWER= 0.983 FDR= 0.0808
 Gene Set 417 : PID_TRAIL_PATHWAY ES = −0.473 NES = −1.46 Nom. p−val= 0.0743 FWER= 0.999 FDR= 0.117
 Gene Set 484 : PID_TRKR_PATHWAY ES = −0.495 NES = −1.7 Nom. p−val= 0.0176 FWER= 0.834 FDR= 0.0755
 Gene Set 430 : PID_TXA2PATHWAY ES = −0.635 NES = −1.62 Nom. p−val= 0.00579 FWER= 0.955 FDR= 0.076
 Gene Set 473 : PID_UPA_UPAR_PATHWAY ES = −0.686 NES = −1.61 Nom. p−val= 0.00192 FWER= 0.964 FDR= 0.0758
 Gene Set 514 : PID_VEGFR1_2_PATHWAY ES = −0.444 NES = −1.68 Nom. p−val= 0.0277 FWER= 0.887 FDR= 0.074
 Gene Set 505 : PID_VEGFR1_PATHWAY ES = −0.535 NES = −1.5 Nom. p−val= 0.0536 FWER= 0.996 FDR= 0.105
 Gene Set 425 : PID_WNT_CANONICAL_PATHWAY ES = −0.599 NES = −1.78 Nom. p−val= 0.00379 FWER= 0.668 FDR= 0.0756
 Gene Set 380 : PID_WNT_NONCANONICAL_PATHWAY ES = −0.625 NES = −1.85 Nom. p−val= 0 FWER= 0.485 FDR= 0.0853 Y
 Gene Set 416 : PID_WNT_SIGNALING_PATHWAY ES = −0.631 NES = −1.52 Nom. p−val= 0.00962 FWER= 0.995 FDR= 0.0986
 REACTOME_A_TETRASACCHARIDE_LINKER_SEQUENCE_IS_REQUIRED_FOR_GAG_SYNTHESIS ES = −0.599 NES = −1.56 Nom. p−val= 0.0158 FWER= 0.988 FDR= 0.0866
 Gene Set 757 : REACTOME_ABC_FAMILY_PROTEINS_MEDIATED_TRANSPORT ES = −0.521 NES = −1.34 Nom. p−val= 0.0837 FWER= 1 FDR= 0.18
 Gene Set 583 : REACTOME_ABCA_TRANSPORTERS_IN_LIPID_HOMEOSTASIS ES = −0.644 NES = −1.53 Nom. p−val= 0.0238 FWER= 0.993 FDR= 0.0959
Gene Set 756 : REACTOME_ACETYLCHOLINE_BINDING_AND_DOWNSTREAM_EVENTS ES = −0.643 NES = −1.3 Nom. p−val= 0.136 FWER= 1 FDR= 0.21
Gene Set 624 : REACTOME_ACTIVATED_NOTCH1_TRANSMITS_SIGNAL_TO_THE_NUCLEUS ES = −0.466 NES = −1.39 Nom. p−val= 0.0825 FWER= 1 FDR= 0.151
 Gene Set 658 : REACTOME_ACTIVATED_POINT_MUTANTS_OF_FGFR2 ES = −0.682 NES = −1.35 Nom. p−val= 0.0867 FWER= 1 FDR= 0.177
 Gene Set 1018 : REACTOME_ACTIVATED_TLR4_SIGNALLING ES = −0.497 NES = −1.76 Nom. p−val= 0.00587 FWER= 0.719 FDR= 0.0734
 Gene Set 889 : REACTOME_ACTIVATION_OF_KAINATE_RECEPTORS_UPON_GLUTAMATE_BINDING ES = −0.642 NES = −1.68 Nom. p−val= 0.0019 FWER= 0.892 FDR= 0.0728
 Gene Set 626 : REACTOME_ACTIVATION_OF_NF_KAPPAB_IN_B_CELLS ES = −0.398 NES = −1.62 Nom. p−val= 0.0576 FWER= 0.948 FDR= 0.0758
 REACTOME_ACTIVATION_OF_NMDA_RECEPTOR_UPON_GLUTAMATE_BINDING_AND_POSTSYNAPTIC_EVENTS ES = −0.576 NES = −1.53 Nom. p−val= 0.0212 FWER= 0.993 FDR= 0.093
 Gene Set 655 : REACTOME_ACYL_CHAIN_REMODELLING_OF_PC ES = −0.54 NES = −1.37 Nom. p−val= 0.0985 FWER= 1 FDR= 0.162
 Gene Set 679 : REACTOME_ACYL_CHAIN_REMODELLING_OF_PE ES = −0.547 NES = −1.36 Nom. p−val= 0.123 FWER= 1 FDR= 0.172
 Gene Set 678 : REACTOME_ACYL_CHAIN_REMODELLING_OF_PG ES = −0.569 NES = −1.34 Nom. p−val= 0.115 FWER= 1 FDR= 0.184
 Gene Set 646 : REACTOME_ACYL_CHAIN_REMODELLING_OF_PI ES = −0.645 NES = −1.46 Nom. p−val= 0.0538 FWER= 0.999 FDR= 0.119
 Gene Set 680 : REACTOME_ACYL_CHAIN_REMODELLING_OF_PS ES = −0.627 NES = −1.42 Nom. p−val= 0.0609 FWER= 1 FDR= 0.138
 Gene Set 828 : REACTOME_ADHERENS_JUNCTIONS_INTERACTIONS ES = −0.514 NES = −1.36 Nom. p−val= 0.0789 FWER= 1 FDR= 0.172
 Gene Set 824 : REACTOME_ADP_SIGNALLING_THROUGH_P2RY1 ES = −0.593 NES = −1.62 Nom. p−val= 0.0171 FWER= 0.958 FDR= 0.0759
 Gene Set 873 : REACTOME_ADP_SIGNALLING_THROUGH_P2RY12 ES = −0.608 NES = −1.47 Nom. p−val= 0.0395 FWER= 0.999 FDR= 0.114
 Gene Set 875 : REACTOME_AMINE_COMPOUND_SLC_TRANSPORTERS ES = −0.53 NES = −1.3 Nom. p−val= 0.1 FWER= 1 FDR= 0.209
 Gene Set 785 : REACTOME_AMINE_LIGAND_BINDING_RECEPTORS ES = −0.667 NES = −1.56 Nom. p−val= 0.00196 FWER= 0.988 FDR= 0.0865
Gene Set 851 : REACTOME_AMINO_ACID_AND_OLIGOPEPTIDE_SLC_TRANSPORTERS ES = −0.54 NES = −1.47 Nom. p−val= 0.0247 FWER= 0.999 FDR= 0.116
Gene Set 727 : REACTOME_AMINO_ACID_TRANSPORT_ACROSS_THE_PLASMA_MEMBRANE ES = −0.558 NES = −1.51 Nom. p−val= 0.0209 FWER= 0.996 FDR= 0.101
 REACTOME_ANTIGEN_ACTIVATES_B_CELL_RECEPTOR_LEADING_TO_GENERATION_OF_SECOND_MESSENGERS ES = −0.697 NES = −1.6 Nom. p−val= 0.0176 FWER= 0.973 FDR= 0.0786
 REACTOME_ANTIGEN_PRESENTATION_FOLDING_ASSEMBLY_AND_PEPTIDE_LOADING_OF_CLASS_I_MHC ES = −0.476 NES = −1.29 Nom. p−val= 0.232 FWER= 1 FDR= 0.215
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 Gene Set 579 : REACTOME_ANTIGEN_PROCESSING_CROSS_PRESENTATION ES = −0.583 NES = −1.9 Nom. p−val= 0.00184 FWER= 0.353 FDR= 0.0868
 : REACTOME_ANTIGEN_PROCESSING_UBIQUITINATION_PROTEASOME_DEGRADATION ES = −0.347 NES = −2.13 Nom. p−val= 0 FWER= 0.051 FDR= 0.0441 Y
 Gene Set 984 : REACTOME_APOPTOSIS ES = −0.341 NES = −1.68 Nom. p−val= 0.0175 FWER= 0.886 FDR= 0.0743
 Gene Set 930 : REACTOME_AQUAPORIN_MEDIATED_TRANSPORT ES = −0.594 NES = −1.64 Nom. p−val= 0.0019 FWER= 0.935 FDR= 0.0738
 Gene Set 639 : REACTOME_ARMS_MEDIATED_ACTIVATION ES = −0.612 NES = −1.75 Nom. p−val= 0.0141 FWER= 0.72 FDR= 0.0728
 REACTOME_ASSOCIATION_OF_TRIC_CCT_WITH_TARGET_PROTEINS_DURING_BIOSYNTHESIS ES = −0.304 NES = −1.3 Nom. p−val= 0.142 FWER= 1 FDR= 0.209
 Gene Set 798 : REACTOME_AXON_GUIDANCE ES = −0.607 NES = −1.94 Nom. p−val= 0 FWER= 0.282 FDR= 0.106 Y
Gene Set 695 : REACTOME_BASIGIN_INTERACTIONS ES = −0.575 NES = −1.49 Nom. p−val= 0.031 FWER= 0.998 FDR= 0.111
 Gene Set 611 : REACTOME_BETA_DEFENSINS ES = −0.591 NES = −1.55 Nom. p−val= 0.0136 FWER= 0.991 FDR= 0.09
 Gene Set 710 : REACTOME_BIOLOGICAL_OXIDATIONS ES = −0.538 NES = −1.5 Nom. p−val= 0.0115 FWER= 0.996 FDR= 0.104
Gene Set 578 : REACTOME_BMAL1_CLOCK_NPAS2_ACTIVATES_CIRCADIAN_EXPRESSION ES = −0.539 NES = −1.55 Nom. p−val= 0.0419 FWER= 0.99 FDR= 0.0897
 Gene Set 593 : REACTOME_BOTULINUM_NEUROTOXICITY ES = −0.611 NES = −1.44 Nom. p−val= 0.0524 FWER= 0.999 FDR= 0.128
 Gene Set 744 : REACTOME_CA_DEPENDENT_EVENTS ES = −0.616 NES = −1.63 Nom. p−val= 0.0152 FWER= 0.945 FDR= 0.0764
 Gene Set 826 : REACTOME_CD28_CO_STIMULATION ES = −0.622 NES = −1.61 Nom. p−val= 0.0294 FWER= 0.963 FDR= 0.0766
 Gene Set 844 : REACTOME_CD28_DEPENDENT_PI3K_AKT_SIGNALING ES = −0.615 NES = −1.51 Nom. p−val= 0.0549 FWER= 0.996 FDR= 0.101
 Gene Set 582 : REACTOME_CELL_CELL_COMMUNICATION ES = −0.52 NES = −1.68 Nom. p−val= 0.00199 FWER= 0.885 FDR= 0.0752
 Gene Set 840 : REACTOME_CELL_CELL_JUNCTION_ORGANIZATION ES = −0.489 NES = −1.46 Nom. p−val= 0.0176 FWER= 0.999 FDR= 0.117
Gene Set 724 : REACTOME_CELL_DEATH_SIGNALLING_VIA_NRAGE_NRIF_AND_NADE ES = −0.578 NES = −1.82 Nom. p−val= 0.00193 FWER= 0.559 FDR= 0.0754
 Gene Set 874 : REACTOME_CELL_JUNCTION_ORGANIZATION ES = −0.516 NES = −1.58 Nom. p−val= 0.00604 FWER= 0.984 FDR= 0.0833
Gene Set 643 : REACTOME_CELL_SURFACE_INTERACTIONS_AT_THE_VASCULAR_WALL ES = −0.702 NES = −1.86 Nom. p−val= 0 FWER= 0.437 FDR= 0.0876 Y
 Gene Set 922 : REACTOME_CGMP_EFFECTS ES = −0.606 NES = −1.38 Nom. p−val= 0.111 FWER= 1 FDR= 0.157
 Gene Set 746 : REACTOME_CHEMOKINE_RECEPTORS_BIND_CHEMOKINES ES = −0.753 NES = −1.46 Nom. p−val= 0.0269 FWER= 0.999 FDR= 0.119
 Gene Set 663 : REACTOME_CHONDROITIN_SULFATE_BIOSYNTHESIS ES = −0.69 NES = −1.56 Nom. p−val= 0.0078 FWER= 0.989 FDR= 0.0871
Gene Set 671 : REACTOME_CHONDROITIN_SULFATE_DERMATAN_SULFATE_METABOLISM ES = −0.587 NES = −1.68 Nom. p−val= 0.00594 FWER= 0.885 FDR= 0.0757
 Gene Set 1015 : REACTOME_CHYLOMICRON_MEDIATED_LIPID_TRANSPORT ES = −0.654 NES = −1.35 Nom. p−val= 0.143 FWER= 1 FDR= 0.173
 Gene Set 941 : REACTOME_CIRCADIAN_CLOCK ES = −0.507 NES = −1.62 Nom. p−val= 0.0239 FWER= 0.955 FDR= 0.0762
 Gene Set 634 : REACTOME_CIRCADIAN_REPRESSION_OF_EXPRESSION_BY_REV_ERBA ES = −0.541 NES = −1.48 Nom. p−val= 0.0787 FWER= 0.999 FDR= 0.114
 Gene Set 736 : REACTOME_CLASS_A1_RHODOPSIN_LIKE_RECEPTORS ES = −0.646 NES = −1.65 Nom. p−val= 0 FWER= 0.927 FDR= 0.0725
 Gene Set 813 : REACTOME_CLASS_B_2_SECRETIN_FAMILY_RECEPTORS ES = −0.603 NES = −1.66 Nom. p−val= 0 FWER= 0.916 FDR= 0.0738
Gene Set 1032 : REACTOME_CLASS_I_MHC_MEDIATED_ANTIGEN_PROCESSING_PRESENTATION ES = −0.443 NES = −2.38 Nom. p−val= 0 FWER= 0.004 FDR= 0.0136 Y
 Gene Set 648 : REACTOME_COLLAGEN_FORMATION ES = −0.698 NES = −1.65 Nom. p−val= 0.00194 FWER= 0.927 FDR= 0.0726
 Gene Set 1021 : REACTOME_COMPLEMENT_CASCADE ES = −0.735 NES = −1.57 Nom. p−val= 0.00604 FWER= 0.987 FDR= 0.0858
 Gene Set 842 : REACTOME_COSTIMULATION_BY_THE_CD28_FAMILY ES = −0.713 NES = −1.69 Nom. p−val= 0.00967 FWER= 0.877 FDR= 0.0759
Gene Set 866 : REACTOME_CREB_PHOSPHORYLATION_THROUGH_THE_ACTIVATION_OF_RAS ES = −0.542 NES = −1.5 Nom. p−val= 0.034 FWER= 0.996 FDR= 0.105
 REACTOME_CROSS_PRESENTATION_OF_SOLUBLE_EXOGENOUS_ANTIGENS_ENDOSOMES ES = −0.608 NES = −1.93 Nom. p−val= 0.00373 FWER= 0.284 FDR= 0.101
 Gene Set 849 : REACTOME_CTLA4_INHIBITORY_SIGNALING ES = −0.638 NES = −1.68 Nom. p−val= 0.0212 FWER= 0.883 FDR= 0.0757
 Gene Set 715 : REACTOME_CYTOCHROME_P450_ARRANGED_BY_SUBSTRATE_TYPE ES = −0.515 NES = −1.26 Nom. p−val= 0.125 FWER= 1 FDR= 0.237
 Gene Set 1029 : REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM ES = −0.574 NES = −1.83 Nom. p−val= 0 FWER= 0.527 FDR= 0.0858 Y
 Gene Set 576 : REACTOME_DAG_AND_IP3_SIGNALING ES = −0.577 NES = −1.6 Nom. p−val= 0.0152 FWER= 0.973 FDR= 0.0784
 Gene Set 745 : REACTOME_DARPP_32_EVENTS ES = −0.359 NES = −1.27 Nom. p−val= 0.186 FWER= 1 FDR= 0.228
 Gene Set 607 : REACTOME_DEFENSINS ES = −0.609 NES = −1.6 Nom. p−val= 0.00189 FWER= 0.971 FDR= 0.0783
 Gene Set 621 : REACTOME_DEGRADATION_OF_THE_EXTRACELLULAR_MATRIX ES = −0.641 NES = −1.46 Nom. p−val= 0.0442 FWER= 0.999 FDR= 0.117
 Gene Set 573 : REACTOME_DEVELOPMENTAL_BIOLOGY ES = −0.564 NES = −1.95 Nom. p−val= 0 FWER= 0.254 FDR= 0.104 Y
 Gene Set 750 : REACTOME_DIABETES_PATHWAYS ES = −0.382 NES = −1.68 Nom. p−val= 0.00992 FWER= 0.885 FDR= 0.0744
 Gene Set 647 : REACTOME_DOWNREGULATION_OF_TGF_BETA_RECEPTOR_SIGNALING ES = −0.467 NES = −1.8 Nom. p−val= 0.00208 FWER= 0.606 FDR= 0.0788
 Gene Set 787 : REACTOME_DOWNSTREAM_SIGNAL_TRANSDUCTION ES = −0.406 NES = −1.7 Nom. p−val= 0.0102 FWER= 0.845 FDR= 0.0749
 Gene Set 625 : REACTOME_DOWNSTREAM_SIGNALING_EVENTS_OF_B_CELL_RECEPTOR_BCR ES = −0.344 NES = −1.71 Nom. p−val= 0.0362 FWER= 0.819 FDR= 0.0759
 Gene Set 882 : REACTOME_DOWNSTREAM_SIGNALING_OF_ACTIVATED_FGFR ES = −0.493 NES = −1.72 Nom. p−val= 0.00572 FWER= 0.794 FDR= 0.073
 Gene Set 694 : REACTOME_DOWNSTREAM_TCR_SIGNALING ES = −0.728 NES = −1.65 Nom. p−val= 0.00786 FWER= 0.927 FDR= 0.0726
 Gene Set 901 : REACTOME_EFFECTS_OF_PIP2_HYDROLYSIS ES = −0.68 NES = −1.59 Nom. p−val= 0.008 FWER= 0.981 FDR= 0.0805
 Gene Set 810 : REACTOME_EICOSANOID_LIGAND_BINDING_RECEPTORS ES = −0.771 NES = −1.47 Nom. p−val= 0.00954 FWER= 0.999 FDR= 0.116
 Gene Set 728 : REACTOME_ENDOGENOUS_STEROLS ES = −0.646 NES = −1.42 Nom. p−val= 0.0413 FWER= 1 FDR= 0.138
 Gene Set 686 : REACTOME_ENOS_ACTIVATION_AND_REGULATION ES = −0.556 NES = −1.77 Nom. p−val= 0.00818 FWER= 0.694 FDR= 0.0723
 Gene Set 701 : REACTOME_ERK_MAPK_TARGETS ES = −0.459 NES = −1.45 Nom. p−val= 0.117 FWER= 0.999 FDR= 0.121
 Gene Set 632 : REACTOME_EXTRACELLULAR_MATRIX_ORGANIZATION ES = −0.678 NES = −1.69 Nom. p−val= 0.00191 FWER= 0.872 FDR= 0.075
 REACTOME_FACTORS_INVOLVED_IN_MEGAKARYOCYTE_DEVELOPMENT_AND_PLATELET_PRODUCTION ES = −0.382 NES = −1.29 Nom. p−val= 0.139 FWER= 1 FDR= 0.215
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 Gene Set 912 : REACTOME_FATTY_ACID_TRIACYLGLYCEROL_AND_KETONE_BODY_METABOLISM ES = −0.394 NES = −1.7 Nom. p−val= 0.00196 FWER= 0.828 FDR= 0.0757
 Gene Set 1050 : REACTOME_FGFR_LIGAND_BINDING_AND_ACTIVATION ES = −0.647 NES = −1.42 Nom. p−val= 0.0271 FWER= 1 FDR= 0.139
 Gene Set 856 : REACTOME_FORMATION_OF_FIBRIN_CLOT_CLOTTING_CASCADE ES = −0.645 NES = −1.47 Nom. p−val= 0.043 FWER= 0.999 FDR= 0.116
 Gene Set 878 : REACTOME_FRS2_MEDIATED_CASCADE ES = −0.577 NES = −1.49 Nom. p−val= 0.0236 FWER= 0.998 FDR= 0.108
 Gene Set 830 : REACTOME_G_ALPHA_I_SIGNALLING_EVENTS ES = −0.641 NES = −1.66 Nom. p−val= 0 FWER= 0.918 FDR= 0.0736
 Gene Set 802 : REACTOME_G_ALPHA_Q_SIGNALLING_EVENTS ES = −0.606 NES = −1.68 Nom. p−val= 0 FWER= 0.885 FDR= 0.0747
 Gene Set 839 : REACTOME_G_ALPHA_S_SIGNALLING_EVENTS ES = −0.608 NES = −1.7 Nom. p−val= 0 FWER= 0.841 FDR= 0.075
 Gene Set 841 : REACTOME_G_ALPHA_Z_SIGNALLING_EVENTS ES = −0.591 NES = −1.61 Nom. p−val= 0.00372 FWER= 0.963 FDR= 0.0764
 Gene Set 815 : REACTOME_G_ALPHA1213_SIGNALLING_EVENTS ES = −0.614 NES = −1.81 Nom. p−val= 0 FWER= 0.586 FDR= 0.0767 Y
 Gense Set 835 : REACTOME_G_BETA_GAMMA_SIGNALLING_THROUGH_PI3KGAMMA ES = −0.69 NES = −1.7 Nom. p−val= 0.00387 FWER= 0.828 FDR= 0.0763
 Gene Set 825 : REACTOME_G_BETA_GAMMA_SIGNALLING_THROUGH_PLC_BETA ES = −0.664 NES = −1.6 Nom. p−val= 0.0116 FWER= 0.971 FDR= 0.0781
 Gene Set 755 : REACTOME_G_PROTEIN_ACTIVATION ES = −0.578 NES = −1.45 Nom. p−val= 0.0316 FWER= 0.999 FDR= 0.124
 Gene Set 846 : REACTOME_G_PROTEIN_BETA_GAMMA_SIGNALLING ES = −0.696 NES = −1.78 Nom. p−val= 0.0019 FWER= 0.668 FDR= 0.0763
 Gene Set 947 : REACTOME_GABA_B_RECEPTOR_ACTIVATION ES = −0.589 NES = −1.54 Nom. p−val= 0.0148 FWER= 0.992 FDR= 0.0912
 Gene Set 955 : REACTOME_GABA_RECEPTOR_ACTIVATION ES = −0.54 NES = −1.43 Nom. p−val= 0.0286 FWER= 0.999 FDR= 0.13
 Gene Set 1055 : REACTOME_GAP_JUNCTION_ASSEMBLY ES = −0.576 NES = −1.28 Nom. p−val= 0.132 FWER= 1 FDR= 0.22
 Gene Set 1052 : REACTOME_GAP_JUNCTION_TRAFFICKING ES = −0.549 NES = −1.36 Nom. p−val= 0.075 FWER= 1 FDR= 0.169
 Gene Set 662 : REACTOME_GASTRIN_CREB_SIGNALLING_PATHWAY_VIA_PKC_AND_MAPK ES = −0.595 NES = −1.7 Nom. p−val= 0 FWER= 0.838 FDR= 0.0757
 Gene Set 703 : REACTOME_GENERATION_OF_SECOND_MESSENGER_MOLECULES ES = −0.816 NES = −1.54 Nom. p−val= 0.0132 FWER= 0.993 FDR= 0.0932
 Gene Set 773 : REACTOME_GLUCAGON_SIGNALING_IN_METABOLIC_REGULATION ES = −0.587 NES = −1.66 Nom. p−val= 0.00562 FWER= 0.915 FDR= 0.0735
 Gene Set 814 : REACTOME_GLUCAGON_TYPE_LIGAND_RECEPTORS ES = −0.556 NES = −1.41 Nom. p−val= 0.047 FWER= 1 FDR= 0.14
 Gene Set 1025 : REACTOME_GLUCOSE_METABOLISM ES = −0.339 NES = −1.27 Nom. p−val= 0.211 FWER= 1 FDR= 0.228
 Gene Set 877 : REACTOME_GLUCOSE_TRANSPORT ES = −0.389 NES = −1.38 Nom. p−val= 0.0818 FWER= 1 FDR= 0.155
 Gene Set 700 : REACTOME_GLUTAMATE_NEUROTRANSMITTER_RELEASE_CYCLE ES = −0.606 NES = −1.39 Nom. p−val= 0.0966 FWER= 1 FDR= 0.153
 Gene Set 683 : REACTOME_GLYCEROPHOSPHOLIPID_BIOSYNTHESIS ES = −0.504 NES = −1.8 Nom. p−val= 0.00382 FWER= 0.619 FDR= 0.0795
 Gene Set 551 : REACTOME_GLYCOGEN_BREAKDOWN_GLYCOGENOLYSIS ES = −0.601 NES = −1.66 Nom. p−val= 0.0253 FWER= 0.922 FDR= 0.0731
 Gene Set 677 : REACTOME_GLYCOSAMINOGLYCAN_METABOLISM ES = −0.589 NES = −1.77 Nom. p−val= 0 FWER= 0.678 FDR= 0.0755
 Gene Set 892 : REACTOME_GPCR_LIGAND_BINDING ES = −0.631 NES = −1.67 Nom. p−val= 0 FWER= 0.901 FDR= 0.0727
 Gene Set 778 : REACTOME_GPVI_MEDIATED_ACTIVATION_CASCADE ES = −0.72 NES = −1.64 Nom. p−val= 0.00192 FWER= 0.935 FDR= 0.0741
 REACTOME_GRB2_SOS_PROVIDES_LINKAGE_TO_MAPK_SIGNALING_FOR_INTERGRINS_ ES = −0.654 NES = −1.42 Nom. p−val= 0.102 FWER= 1 FDR= 0.138
 Gene Set 580 : REACTOME_GROWTH_HORMONE_RECEPTOR_SIGNALING ES = −0.539 NES = −1.55 Nom. p−val= 0.026 FWER= 0.99 FDR= 0.0894
 Gene Set 716 : REACTOME_HDL_MEDIATED_LIPID_TRANSPORT ES = −0.637 NES = −1.31 Nom. p−val= 0.15 FWER= 1 FDR= 0.204
 Gene Set 986 : REACTOME_HEMOSTASIS ES = −0.568 NES = −1.88 Nom. p−val= 0 FWER= 0.406 FDR= 0.0874 Y
 Gene Set 676 : REACTOME_HEPARAN_SULFATE_HEPARIN_HS_GAG_METABOLISM ES = −0.521 NES = −1.53 Nom. p−val= 0.0259 FWER= 0.993 FDR= 0.0928
 Gene Set 990 : REACTOME_HIV_INFECTION ES = −0.403 NES = −2.24 Nom. p−val= 0.00577 FWER= 0.014 FDR= 0.0156
 Gene Set 994 : REACTOME_HOST_INTERACTIONS_OF_HIV_FACTORS ES = −0.477 NES = −2.26 Nom. p−val= 0.00192 FWER= 0.011 FDR= 0.021
 Gene Set 674 : REACTOME_HS_GAG_BIOSYNTHESIS ES = −0.532 NES = −1.42 Nom. p−val= 0.0527 FWER= 1 FDR= 0.138
 Gene Set 651 : REACTOME_HS_GAG_DEGRADATION ES = −0.57 NES = −1.56 Nom. p−val= 0.0207 FWER= 0.99 FDR= 0.0888
 Gene Set 971 : REACTOME_IL_2_SIGNALING ES = −0.64 NES = −1.68 Nom. p−val= 0.00789 FWER= 0.877 FDR= 0.0756
 Gene Set 926 : REACTOME_IL_3_5_AND_GM_CSF_SIGNALING ES = −0.624 NES = −1.56 Nom. p−val= 0.0299 FWER= 0.989 FDR= 0.0886
 Gene Set 931 : REACTOME_IL_RECEPTOR_SHC_SIGNALING ES = −0.689 NES = −1.57 Nom. p−val= 0.0159 FWER= 0.987 FDR= 0.0859
 Gene Set 920 : REACTOME_IL1_SIGNALING ES = −0.475 NES = −1.47 Nom. p−val= 0.0866 FWER= 0.999 FDR= 0.114
 REACTOME_IMMUNOREGULATORY_INTERACTIONS_BETWEEN_A_LYMPHOID_AND_A_NON_LYMPHOID_CELL ES = −0.756 NES = −1.54 Nom. p−val= 0.0132 FWER= 0.991 FDR= 0.0909
 Gene Set 1036 : REACTOME_INFLAMMASOMES ES = −0.807 NES = −1.6 Nom. p−val= 0 FWER= 0.967 FDR= 0.0763
 REACTOME_INHIBITION_OF_INSULIN_SECRETION_BY_ADRENALINE_NORADRENALINE ES = −0.587 NES = −1.49 Nom. p−val= 0.0329 FWER= 0.998 FDR= 0.108
 REACTOME_INHIBITION_OF_VOLTAGE_GATED_CA2_CHANNELS_VIA_GBETA_GAMMA_SUBUNITS ES = −0.592 NES = −1.44 Nom. p−val= 0.0418 FWER= 0.999 FDR= 0.128
 Gene Set 1007 : REACTOME_INNATE_IMMUNE_SYSTEM ES = −0.587 NES = −1.91 Nom. p−val= 0 FWER= 0.334 FDR= 0.106 Y
 Gene Set 638 : REACTOME_INSULIN_RECEPTOR_SIGNALLING_CASCADE ES = −0.406 NES = −1.47 Nom. p−val= 0.0478 FWER= 0.999 FDR= 0.116
 Gene Set 737 : REACTOME_INTEGRATION_OF_ENERGY_METABOLISM ES = −0.416 NES = −1.48 Nom. p−val= 0.0136 FWER= 0.998 FDR= 0.112
 Gene Set 764 : REACTOME_INTEGRIN_ALPHAIIB_BETA3_SIGNALING ES = −0.607 NES = −1.56 Nom. p−val= 0.028 FWER= 0.989 FDR= 0.0872
 Gene Set 713 : REACTOME_INTEGRIN_CELL_SURFACE_INTERACTIONS ES = −0.676 NES = −1.74 Nom. p−val= 0 FWER= 0.755 FDR= 0.0734
 Gene Set 910 : REACTOME_INTERACTION_BETWEEN_L1_AND_ANKYRINS ES = −0.646 NES = −1.44 Nom. p−val= 0.0373 FWER= 0.999 FDR= 0.127
 Gene Set 954 : REACTOME_INTERFERON_ALPHA_BETA_SIGNALING ES = −0.621 NES = −1.61 Nom. p−val= 0.022 FWER= 0.964 FDR= 0.0757
 Gene Set 952 : REACTOME_INTERFERON_GAMMA_SIGNALING ES = −0.681 NES = −1.62 Nom. p−val= 0.00766 FWER= 0.954 FDR= 0.0766
 Gene Set 959 : REACTOME_INTERFERON_SIGNALING ES = −0.577 NES = −1.82 Nom. p−val= 0.002 FWER= 0.55 FDR= 0.0765
 Gene Set 1059 : REACTOME_INTRINSIC_PATHWAY_FOR_APOPTOSIS ES = −0.386 NES = −1.39 Nom. p−val= 0.132 FWER= 1 FDR= 0.153
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 Gene Set 975 : REACTOME_INTRINSIC_PATHWAY ES = −0.618 NES = −1.39 Nom. p−val= 0.0838 FWER= 1 FDR= 0.151
 Gene Set 1039 : REACTOME_INWARDLY_RECTIFYING_K_CHANNELS ES = −0.591 NES = −1.47 Nom. p−val= 0.0251 FWER= 0.999 FDR= 0.114
 Gene Set 953 : REACTOME_ION_TRANSPORT_BY_P_TYPE_ATPASES ES = −0.483 NES = −1.33 Nom. p−val= 0.0884 FWER= 1 FDR= 0.19
 Gene Set 950 : REACTOME_IRON_UPTAKE_AND_TRANSPORT ES = −0.535 NES = −1.56 Nom. p−val= 0.0314 FWER= 0.989 FDR= 0.0865
REACTOME_ JNK_C_JUN_KINASES_PHOSPHORYLATION_AND_ACTIVATION_MEDIATED_BY_ACTIVATED_HUMAN_TAK1 ES = −0.451 NES = −1.29 Nom. p−val= 0.203 FWER= 1 FDR= 0.212
 Gene Set 668 : REACTOME_KERATAN_SULFATE_BIOSYNTHESIS ES = −0.673 NES = −1.64 Nom. p−val= 0.00379 FWER= 0.941 FDR= 0.0748
 Gene Set 675 : REACTOME_KERATAN_SULFATE_KERATIN_METABOLISM ES = −0.659 NES = −1.69 Nom. p−val= 0.00376 FWER= 0.862 FDR= 0.0746
 Gene Set 906 : REACTOME_L1CAM_INTERACTIONS ES = −0.609 NES = −1.83 Nom. p−val= 0 FWER= 0.542 FDR= 0.0803 Y
 REACTOME_LATENT_INFECTION_OF_HOMO_SAPIENS_WITH_MYCOBACTERIUM_TUBERCULOSIS ES = −0.611 NES = −1.51 Nom. p−val= 0.0422 FWER= 0.996 FDR= 0.103
 Gene Set 985 : REACTOME_LIPID_DIGESTION_MOBILIZATION_AND_TRANSPORT ES = −0.591 NES = −1.49 Nom. p−val= 0.03 FWER= 0.998 FDR= 0.109
 Gene Set 1012 : REACTOME_LIPOPROTEIN_METABOLISM ES = −0.624 NES = −1.42 Nom. p−val= 0.0649 FWER= 1 FDR= 0.136
 Gene Set 890 : REACTOME_MAPK_TARGETS_NUCLEAR_EVENTS_MEDIATED_BY_MAP_KINASES ES = −0.433 NES = −1.43 Nom. p−val= 0.119 FWER= 1 FDR= 0.133
 Gene Set 589 : REACTOME_MEMBRANE_TRAFFICKING ES = −0.258 NES = −1.32 Nom. p−val= 0.145 FWER= 1 FDR= 0.196
 Gene Set 707 : REACTOME_METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES ES = −0.351 NES = −1.35 Nom. p−val= 0.0543 FWER= 1 FDR= 0.178
 Gene Set 980 : REACTOME_METABOLISM_OF_CARBOHYDRATES ES = −0.49 NES = −1.87 Nom. p−val= 0 FWER= 0.412 FDR= 0.0843 Y
 Gene Set 909 : REACTOME_METABOLISM_OF_LIPIDS_AND_LIPOPROTEINS ES = −0.411 NES = −1.73 Nom. p−val= 0 FWER= 0.759 FDR= 0.0735
 Gene Set 784 : REACTOME_METABOLISM_OF_NUCLEOTIDES ES = −0.41 NES = −1.62 Nom. p−val= 0.00768 FWER= 0.958 FDR= 0.0763
 Gene Set 786 : REACTOME_METABOLISM_OF_PROTEINS ES = −0.257 NES = −1.3 Nom. p−val= 0.17 FWER= 1 FDR= 0.212
 Gene Set 568 : REACTOME_METABOLISM_OF_STEROID_HORMONES_AND_VITAMINS_A_AND_D ES = −0.523 NES = −1.31 Nom. p−val= 0.0961 FWER= 1 FDR= 0.204
 Gene Set 862 : REACTOME_METAL_ION_SLC_TRANSPORTERS ES = −0.455 NES = −1.24 Nom. p−val= 0.186 FWER= 1 FDR= 0.247
 Gene Set 682 : REACTOME_MHC_CLASS_II_ANTIGEN_PRESENTATION ES = −0.538 NES = −1.77 Nom. p−val= 0.0119 FWER= 0.678 FDR= 0.076
 Gene Set 788 : REACTOME_MUSCLE_CONTRACTION ES = −0.726 NES = −1.45 Nom. p−val= 0.071 FWER= 0.999 FDR= 0.121
Gene Set 1006 : REACTOME_MYD88_MAL_CASCADE_INITIATED_ON_PLASMA_MEMBRANE ES = −0.466 NES = −1.66 Nom. p−val= 0.0137 FWER= 0.913 FDR= 0.0735
 Gene Set 886 : REACTOME_MYOGENESIS ES = −0.583 NES = −1.45 Nom. p−val= 0.0981 FWER= 0.999 FDR= 0.124
Gene Set 855 : REACTOME_NA_CL_DEPENDENT_NEUROTRANSMITTER_TRANSPORTERS ES = −0.595 NES = −1.34 Nom. p−val= 0.0848 FWER= 1 FDR= 0.184
 Gene Set 806 : REACTOME_NCAM_SIGNALING_FOR_NEURITE_OUT_GROWTH ES = −0.631 NES = −1.77 Nom. p−val= 0 FWER= 0.69 FDR= 0.0718
 Gene Set 804 : REACTOME_NCAM1_INTERACTIONS ES = −0.686 NES = −1.62 Nom. p−val= 0.00195 FWER= 0.954 FDR= 0.0764
NEF_MEDIATES_DOWN_MODULATION_OF_CELL_SURFACE_RECEPTORS_BY_RECRUITING_THEM_TO_CLATHRIN_ADAPTERS ES = −0.603 NES = −1.68 Nom. p−val= 0.0187 FWER= 0.883 FDR= 0.0754
 Gene Set 586 : REACTOME_NEGATIVE_REGULATION_OF_FGFR_SIGNALING ES = −0.605 NES = −1.55 Nom. p−val= 0.0155 FWER= 0.99 FDR= 0.0896
 Gene Set 960 : REACTOME_NEGATIVE_REGULATORS_OF_RIG_I_MDA5_SIGNALING ES = −0.466 NES = −1.52 Nom. p−val= 0.095 FWER= 0.996 FDR= 0.101
 Gene Set 925 : REACTOME_NEPHRIN_INTERACTIONS ES = −0.555 NES = −1.44 Nom. p−val= 0.0867 FWER= 0.999 FDR= 0.127
 Gene Set 908 : REACTOME_NETRIN1_SIGNALING ES = −0.697 NES = −1.77 Nom. p−val= 0 FWER= 0.688 FDR= 0.0726
 Gene Set 720 : REACTOME_NEURONAL_SYSTEM ES = −0.542 NES = −1.57 Nom. p−val= 0.00373 FWER= 0.986 FDR= 0.086
 NEUROTRANSMITTER_RECEPTOR_BINDING_AND_DOWNSTREAM_TRANSMISSION_IN_THE_POSTSYNAPTIC_CELL ES = −0.555 NES = −1.58 Nom. p−val= 0.0038 FWER= 0.983 FDR= 0.0809
 Gene Set 725 : REACTOME_NEUROTRANSMITTER_RELEASE_CYCLE ES = −0.519 NES = −1.31 Nom. p−val= 0.11 FWER= 1 FDR= 0.2
 REACTOME_NFKB_AND_MAP_KINASES_ACTIVATION_MEDIATED_BY_TLR4_SIGNALING_REPERTOIRE ES = −0.45 NES = −1.68 Nom. p−val= 0.0117 FWER= 0.889 FDR= 0.074
 Gene Set 644 : REACTOME_NGF_SIGNALLING_VIA_TRKA_FROM_THE_PLASMA_MEMBRANE ES = −0.425 NES = −1.83 Nom. p−val= 0 FWER= 0.531 FDR= 0.0827 Y
 Gene Set 927 : REACTOME_NITRIC_OXIDE_STIMULATES_GUANYLATE_CYCLASE ES = −0.566 NES = −1.32 Nom. p−val= 0.117 FWER= 1 FDR= 0.198
 Gene Set 1028 : REACTOME_NOD1_2_SIGNALING_PATHWAY ES = −0.45 NES = −1.33 Nom. p−val= 0.167 FWER= 1 FDR= 0.191
Gene Set 633 : REACTOME_NOTCH1_INTRACELLULAR_DOMAIN_REGULATES_TRANSCRIPTION ES = −0.416 NES = −1.68 Nom. p−val= 0.0204 FWER= 0.895 FDR= 0.0718
 Gene Set 717 : REACTOME_NRAGE_SIGNALS_DEATH_THROUGH_JNK ES = −0.637 NES = −1.72 Nom. p−val= 0.00382 FWER= 0.789 FDR= 0.0731
 REACTOME_NUCLEAR_EVENTS_KINASE_AND_TRANSCRIPTION_FACTOR_ACTIVATION ES = −0.457 NES = −1.54 Nom. p−val= 0.0786 FWER= 0.993 FDR= 0.0929
 Gene Set 765 : REACTOME_NUCLEAR_RECEPTOR_TRANSCRIPTION_PATHWAY ES = −0.577 NES = −1.59 Nom. p−val= 0.00978 FWER= 0.976 FDR= 0.0791
 Gene Set 616 : REACTOME_NUCLEAR_SIGNALING_BY_ERBB4 ES = −0.545 NES = −1.48 Nom. p−val= 0.0366 FWER= 0.999 FDR= 0.113
 NUCLEOTIDE_BINDING_DOMAIN_LEUCINE_RICH_REPEAT_CONTAINING_RECEPTOR_NLR_SIGNALING_PATHWAYS ES = −0.61 NES = −1.64 Nom. p−val= 0.00783 FWER= 0.94 FDR= 0.0745
 Gene Set 808 : REACTOME_NUCLEOTIDE_LIKE_PURINERGIC_RECEPTORS ES = −0.814 NES = −1.59 Nom. p−val= 0 FWER= 0.976 FDR= 0.0791
 Gene Set 601 : REACTOME_O_LINKED_GLYCOSYLATION_OF_MUCINS ES = −0.509 NES = −1.31 Nom. p−val= 0.141 FWER= 1 FDR= 0.206
 Gene Set 740 : REACTOME_OPIOID_SIGNALLING ES = −0.558 NES = −1.77 Nom. p−val= 0 FWER= 0.678 FDR= 0.0748
 Gene Set 829 : REACTOME_OTHER_SEMAPHORIN_INTERACTIONS ES = −0.736 NES = −1.62 Nom. p−val= 0.00194 FWER= 0.957 FDR= 0.0765
 REACTOME_OXYGEN_DEPENDENT_PROLINE_HYDROXYLATION_OF_HYPOXIA_INDUCIBLE_FACTOR_ALPHA ES = −0.578 NES = −1.83 Nom. p−val= 0.00947 FWER= 0.529 FDR= 0.0839
 Gene Set 726 : REACTOME_P75_NTR_RECEPTOR_MEDIATED_SIGNALLING ES = −0.517 NES = −1.82 Nom. p−val= 0.00194 FWER= 0.56 FDR= 0.0736
 Gene Set 751 : REACTOME_P130CAS_LINKAGE_TO_MAPK_SIGNALING_FOR_INTEGRINS ES = −0.643 NES = −1.41 Nom. p−val= 0.101 FWER= 1 FDR= 0.144
 Gene Set 838 : REACTOME_PD1_SIGNALING ES = −0.843 NES = −1.47 Nom. p−val= 0.0152 FWER= 0.999 FDR= 0.116
 Gene Set 734 : REACTOME_PEPTIDE_LIGAND_BINDING_RECEPTORS ES = −0.626 NES = −1.59 Nom. p−val= 0 FWER= 0.976 FDR= 0.0787
 Gene Set 781 : REACTOME_PEROXISOMAL_LIPID_METABOLISM ES = −0.482 NES = −1.5 Nom. p−val= 0.0786 FWER= 0.996 FDR= 0.106
 Gene Set 1022 : REACTOME_PHASE_II_CONJUGATION ES = −0.504 NES = −1.42 Nom. p−val= 0.0564 FWER= 1 FDR= 0.139
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 Gene Set 722 : REACTOME_PHASE1_FUNCTIONALIZATION_OF_COMPOUNDS ES = −0.564 NES = −1.42 Nom. p−val= 0.0466 FWER= 1 FDR= 0.134
 Gene Set 888 : REACTOME_PHOSPHOLIPASE_C_MEDIATED_CASCADE ES = −0.602 NES = −1.6 Nom. p−val= 0.00951 FWER= 0.971 FDR= 0.0781
 Gene Set 659 : REACTOME_PHOSPHOLIPID_METABOLISM ES = −0.401 NES = −1.65 Nom. p−val= 0.00194 FWER= 0.927 FDR= 0.0734
Gene Set 699 : REACTOME_PHOSPHORYLATION_OF_CD3_AND_TCR_ZETA_CHAINS ES = −0.826 NES = −1.45 Nom. p−val= 0.0265 FWER= 0.999 FDR= 0.124
 Gene Set 881 : REACTOME_PI_3K_CASCADE ES = −0.505 NES = −1.55 Nom. p−val= 0.0215 FWER= 0.99 FDR= 0.0895
 Gene Set 670 : REACTOME_PI_METABOLISM ES = −0.431 NES = −1.45 Nom. p−val= 0.0824 FWER= 0.999 FDR= 0.121
 Gene Set 689 : REACTOME_PI3K_AKT_ACTIVATION ES = −0.345 NES = −1.36 Nom. p−val= 0.157 FWER= 1 FDR= 0.167
 Gene Set 1060 : REACTOME_PI3K_CASCADE ES = −0.438 NES = −1.45 Nom. p−val= 0.0494 FWER= 0.999 FDR= 0.124
 Gene Set 761 : REACTOME_PKA_MEDIATED_PHOSPHORYLATION_OF_CREB ES = −0.595 NES = −1.47 Nom. p−val= 0.0574 FWER= 0.999 FDR= 0.115
 Gene Set 1043 : REACTOME_PLATELET_ACTIVATION_SIGNALING_AND_AGGREGATION ES = −0.598 NES = −1.83 Nom. p−val= 0 FWER= 0.537 FDR= 0.0825 Y
 Gene Set 972 : REACTOME_PLATELET_AGGREGATION_PLUG_FORMATION ES = −0.591 NES = −1.54 Nom. p−val= 0.0208 FWER= 0.991 FDR= 0.0907
 Gene Set 933 : REACTOME_PLATELET_CALCIUM_HOMEOSTASIS ES = −0.637 NES = −1.39 Nom. p−val= 0.0806 FWER= 1 FDR= 0.152
 Gene Set 928 : REACTOME_PLATELET_HOMEOSTASIS ES = −0.584 NES = −1.67 Nom. p−val= 0 FWER= 0.909 FDR= 0.0737
 Gene Set 929 : REACTOME_PLATELET_SENSITIZATION_BY_LDL ES = −0.636 NES = −1.78 Nom. p−val= 0.00197 FWER= 0.67 FDR= 0.0746
 Gene Set 752 : REACTOME_PLC_BETA_MEDIATED_EVENTS ES = −0.588 NES = −1.65 Nom. p−val= 0.00965 FWER= 0.924 FDR= 0.0724
 Gene Set 867 : REACTOME_POST_NMDA_RECEPTOR_ACTIVATION_EVENTS ES = −0.516 NES = −1.46 Nom. p−val= 0.0322 FWER= 0.999 FDR= 0.119
 REACTOME_POST_TRANSLATIONAL_MODIFICATION_SYNTHESIS_OF_GPI_ANCHORED_PROTEINS ES = −0.336 NES = −1.34 Nom. p−val= 0.123 FWER= 1 FDR= 0.18
 Gene Set 903 : REACTOME_POST_TRANSLATIONAL_PROTEIN_MODIFICATION ES = −0.371 NES = −1.38 Nom. p−val= 0.0812 FWER= 1 FDR= 0.157
 Gene Set 1037 : REACTOME_POTASSIUM_CHANNELS ES = −0.573 NES = −1.5 Nom. p−val= 0.00763 FWER= 0.996 FDR= 0.105
 Gene Set 618 : REACTOME_PPARA_ACTIVATES_GENE_EXPRESSION ES = −0.446 NES = −1.68 Nom. p−val= 0.00395 FWER= 0.892 FDR= 0.0726
 Gene Set 630 : REACTOME_PRE_NOTCH_EXPRESSION_AND_PROCESSING ES = −0.346 NES = −1.3 Nom. p−val= 0.156 FWER= 1 FDR= 0.209
 Gene Set 620 : REACTOME_PRE_NOTCH_TRANSCRIPTION_AND_TRANSLATION ES = −0.404 NES = −1.27 Nom. p−val= 0.241 FWER= 1 FDR= 0.232
 Gene Set 640 : REACTOME_PROLONGED_ERK_ACTIVATION_EVENTS ES = −0.599 NES = −1.79 Nom. p−val= 0.00811 FWER= 0.648 FDR= 0.0776
Gene Set 934 : REACTOME_PROSTACYCLIN_SIGNALLING_THROUGH_PROSTACYCLIN_RECEPTOR ES = −0.687 NES = −1.57 Nom. p−val= 0.0135 FWER= 0.988 FDR= 0.0861
Gene Set 596 : REACTOME_PROTEOLYTIC_CLEAVAGE_OF_SNARE_COMPLEX_PROTEINS ES = −0.686 NES = −1.68 Nom. p−val= 0.00577 FWER= 0.892 FDR= 0.0723
 REACTOME_PTM_GAMMA_CARBOXYLATION_HYPUSINE_FORMATION_AND_ARYLSULFATASE_ACTIVATION ES = −0.493 NES = −1.3 Nom. p−val= 0.125 FWER= 1 FDR= 0.208
 Gene Set 982 : REACTOME_PURINE_METABOLISM ES = −0.474 NES = −1.67 Nom. p−val= 0.0184 FWER= 0.906 FDR= 0.073
 Gene Set 1058 : REACTOME_PYRIMIDINE_METABOLISM ES = −0.62 NES = −1.61 Nom. p−val= 0.00759 FWER= 0.963 FDR= 0.0756
 Gene Set 932 : REACTOME_RAP1_SIGNALLING ES = −0.514 NES = −1.27 Nom. p−val= 0.2 FWER= 1 FDR= 0.226
Gene Set 861 : REACTOME_RAS_ACTIVATION_UOPN_CA2_INFUX_THROUGH_NMDA_RECEPTOR ES = −0.66 NES = −1.5 Nom. p−val= 0.0398 FWER= 0.996 FDR= 0.106
 Gene Set 915 : REACTOME_RECYCLING_PATHWAY_OF_L1 ES = −0.544 NES = −1.68 Nom. p−val= 0.00615 FWER= 0.889 FDR= 0.0737
 Gene Set 718 : REACTOME_REGULATION_OF_APOPTOSIS ES = −0.334 NES = −1.34 Nom. p−val= 0.182 FWER= 1 FDR= 0.184
 REACTOME_REGULATION_OF_GLUCOKINASE_BY_GLUCOKINASE_REGULATORY_PROTEIN ES = −0.361 NES = −1.28 Nom. p−val= 0.191 FWER= 1 FDR= 0.225
 Gene Set 654 : REACTOME_REGULATION_OF_HYPOXIA_INDUCIBLE_FACTOR_HIF_BY_OXYGEN ES = −0.45 NES = −1.52 Nom. p−val= 0.0558 FWER= 0.994 FDR= 0.0976
REACTOME_REGULATION_ OF_INSULIN_LIKE_GROWTH_FACTOR_IGF_ACTIVITY_BY_INSULIN_LIKE_GROWTH_FACTOR_BINDING_PROTEINS_IGFBPS ES = −0.684 NES = −1.53 Nom. p−val= 0.0153 FWER= 0.993 FDR= 0.0952
 : REACTOME_REGULATION_OF_INSULIN_SECRETION_BY_GLUCAGON_LIKE_PEPTIDE1 ES = −0.509 NES = −1.52 Nom. p−val= 0.0101 FWER= 0.995 FDR= 0.0999
 Gene Set 805 : REACTOME_REGULATION_OF_INSULIN_SECRETION ES = −0.44 NES = −1.45 Nom. p−val= 0.014 FWER= 0.999 FDR= 0.122
 Gene Set 588 : REACTOME_REGULATION_OF_KIT_SIGNALING ES = −0.667 NES = −1.59 Nom. p−val= 0.0134 FWER= 0.976 FDR= 0.0792
 Gene Set 923 : REACTOME_REGULATION_OF_SIGNALING_BY_CBL ES = −0.588 NES = −1.39 Nom. p−val= 0.107 FWER= 1 FDR= 0.151
 Gene Set 938 : REACTOME_REGULATION_OF_WATER_BALANCE_BY_RENAL_AQUAPORINS ES = −0.598 NES = −1.7 Nom. p−val= 0.00188 FWER= 0.841 FDR= 0.0746
 Gene Set 705 : REACTOME_RESPONSE_TO_ELEVATED_PLATELET_CYTOSOLIC_CA2_ ES = −0.623 NES = −1.75 Nom. p−val= 0 FWER= 0.721 FDR= 0.0726
 : REACTOME_RIG_I_MDA5_MEDIATED_INDUCTION_OF_IFN_ALPHA_BETA_PATHWAYS ES = −0.423 NES = −1.62 Nom. p−val= 0.0296 FWER= 0.955 FDR= 0.0765
 Gene Set 619 : REACTOME_RIP_MEDIATED_NFKB_ACTIVATION_VIA_DAI ES = −0.701 NES = −1.57 Nom. p−val= 0.0152 FWER= 0.987 FDR= 0.0857
 Gene Set 627 : REACTOME_RORA_ACTIVATES_CIRCADIAN_EXPRESSION ES = −0.442 NES = −1.25 Nom. p−val= 0.26 FWER= 1 FDR= 0.241
 Gene Set 831 : REACTOME_SEMA4D_IN_SEMAPHORIN_SIGNALING ES = −0.574 NES = −1.65 Nom. p−val= 0.0118 FWER= 0.924 FDR= 0.0726
 : REACTOME_SEMA4D_INDUCED_CELL_MIGRATION_AND_GROWTH_CONE_COLLAPSE ES = −0.51 NES = −1.67 Nom. p−val= 0.0359 FWER= 0.896 FDR= 0.072
 Gene Set 832 : REACTOME_SEMAPHORIN_INTERACTIONS ES = −0.577 NES = −1.76 Nom. p−val= 0.00193 FWER= 0.709 FDR= 0.0728
 Gene Set 895 : REACTOME_SHC_MEDIATED_CASCADE ES = −0.622 NES = −1.46 Nom. p−val= 0.0273 FWER= 0.999 FDR= 0.117
 Gene Set 858 : REACTOME_SIGNAL_AMPLIFICATION ES = −0.575 NES = −1.59 Nom. p−val= 0.0113 FWER= 0.979 FDR= 0.0798
 Gene Set 911 : REACTOME_SIGNAL_TRANSDUCTION_BY_L1 ES = −0.54 NES = −1.69 Nom. p−val= 0.012 FWER= 0.867 FDR= 0.0757
 Gene Set 642 : REACTOME_SIGNALING_BY_BMP ES = −0.51 NES = −1.39 Nom. p−val= 0.102 FWER= 1 FDR= 0.151
 Gene Set 610 : REACTOME_SIGNALING_BY_EGFR_IN_CANCER ES = −0.393 NES = −1.74 Nom. p−val= 0.00594 FWER= 0.748 FDR= 0.0736
 Gene Set 604 : REACTOME_SIGNALING_BY_ERBB2 ES = −0.386 NES = −1.54 Nom. p−val= 0.0394 FWER= 0.993 FDR= 0.0931
 Gene Set 599 : REACTOME_SIGNALING_BY_ERBB4 ES = −0.382 NES = −1.46 Nom. p−val= 0.0717 FWER= 0.999 FDR= 0.118
 Gene Set 650 : REACTOME_SIGNALING_BY_FGFR_IN_DISEASE ES = −0.471 NES = −1.79 Nom. p−val= 0 FWER= 0.625 FDR= 0.0793 Y
 Gene Set 681 : REACTOME_SIGNALING_BY_FGFR_MUTANTS ES = −0.53 NES = −1.5 Nom. p−val= 0.0305 FWER= 0.998 FDR= 0.108
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 Gene Set 722 : REACTOME_PHASE1_FUNCTIONALIZATION_OF_COMPOUNDS ES = −0.564 NES = −1.42 Nom. p−val= 0.0466 FWER= 1 FDR= 0.134
 Gene Set 888 : REACTOME_PHOSPHOLIPASE_C_MEDIATED_CASCADE ES = −0.602 NES = −1.6 Nom. p−val= 0.00951 FWER= 0.971 FDR= 0.0781
 Gene Set 659 : REACTOME_PHOSPHOLIPID_METABOLISM ES = −0.401 NES = −1.65 Nom. p−val= 0.00194 FWER= 0.927 FDR= 0.0734
Gene Set 699 : REACTOME_PHOSPHORYLATION_OF_CD3_AND_TCR_ZETA_CHAINS ES = −0.826 NES = −1.45 Nom. p−val= 0.0265 FWER= 0.999 FDR= 0.124
 Gene Set 881 : REACTOME_PI_3K_CASCADE ES = −0.505 NES = −1.55 Nom. p−val= 0.0215 FWER= 0.99 FDR= 0.0895
 Gene Set 670 : REACTOME_PI_METABOLISM ES = −0.431 NES = −1.45 Nom. p−val= 0.0824 FWER= 0.999 FDR= 0.121
 Gene Set 689 : REACTOME_PI3K_AKT_ACTIVATION ES = −0.345 NES = −1.36 Nom. p−val= 0.157 FWER= 1 FDR= 0.167
 Gene Set 1060 : REACTOME_PI3K_CASCADE ES = −0.438 NES = −1.45 Nom. p−val= 0.0494 FWER= 0.999 FDR= 0.124
 Gene Set 761 : REACTOME_PKA_MEDIATED_PHOSPHORYLATION_OF_CREB ES = −0.595 NES = −1.47 Nom. p−val= 0.0574 FWER= 0.999 FDR= 0.115
 Gene Set 1043 : REACTOME_PLATELET_ACTIVATION_SIGNALING_AND_AGGREGATION ES = −0.598 NES = −1.83 Nom. p−val= 0 FWER= 0.537 FDR= 0.0825 Y
 Gene Set 972 : REACTOME_PLATELET_AGGREGATION_PLUG_FORMATION ES = −0.591 NES = −1.54 Nom. p−val= 0.0208 FWER= 0.991 FDR= 0.0907
 Gene Set 933 : REACTOME_PLATELET_CALCIUM_HOMEOSTASIS ES = −0.637 NES = −1.39 Nom. p−val= 0.0806 FWER= 1 FDR= 0.152
 Gene Set 928 : REACTOME_PLATELET_HOMEOSTASIS ES = −0.584 NES = −1.67 Nom. p−val= 0 FWER= 0.909 FDR= 0.0737
 Gene Set 929 : REACTOME_PLATELET_SENSITIZATION_BY_LDL ES = −0.636 NES = −1.78 Nom. p−val= 0.00197 FWER= 0.67 FDR= 0.0746
 Gene Set 752 : REACTOME_PLC_BETA_MEDIATED_EVENTS ES = −0.588 NES = −1.65 Nom. p−val= 0.00965 FWER= 0.924 FDR= 0.0724
 Gene Set 867 : REACTOME_POST_NMDA_RECEPTOR_ACTIVATION_EVENTS ES = −0.516 NES = −1.46 Nom. p−val= 0.0322 FWER= 0.999 FDR= 0.119
 REACTOME_POST_TRANSLATIONAL_MODIFICATION_SYNTHESIS_OF_GPI_ANCHORED_PROTEINS ES = −0.336 NES = −1.34 Nom. p−val= 0.123 FWER= 1 FDR= 0.18
 Gene Set 903 : REACTOME_POST_TRANSLATIONAL_PROTEIN_MODIFICATION ES = −0.371 NES = −1.38 Nom. p−val= 0.0812 FWER= 1 FDR= 0.157
 Gene Set 1037 : REACTOME_POTASSIUM_CHANNELS ES = −0.573 NES = −1.5 Nom. p−val= 0.00763 FWER= 0.996 FDR= 0.105
 Gene Set 618 : REACTOME_PPARA_ACTIVATES_GENE_EXPRESSION ES = −0.446 NES = −1.68 Nom. p−val= 0.00395 FWER= 0.892 FDR= 0.0726
 Gene Set 630 : REACTOME_PRE_NOTCH_EXPRESSION_AND_PROCESSING ES = −0.346 NES = −1.3 Nom. p−val= 0.156 FWER= 1 FDR= 0.209
 Gene Set 620 : REACTOME_PRE_NOTCH_TRANSCRIPTION_AND_TRANSLATION ES = −0.404 NES = −1.27 Nom. p−val= 0.241 FWER= 1 FDR= 0.232
 Gene Set 640 : REACTOME_PROLONGED_ERK_ACTIVATION_EVENTS ES = −0.599 NES = −1.79 Nom. p−val= 0.00811 FWER= 0.648 FDR= 0.0776
Gene Set 934 : REACTOME_PROSTACYCLIN_SIGNALLING_THROUGH_PROSTACYCLIN_RECEPTOR ES = −0.687 NES = −1.57 Nom. p−val= 0.0135 FWER= 0.988 FDR= 0.0861
Gene Set 596 : REACTOME_PROTEOLYTIC_CLEAVAGE_OF_SNARE_COMPLEX_PROTEINS ES = −0.686 NES = −1.68 Nom. p−val= 0.00577 FWER= 0.892 FDR= 0.0723
 REACTOME_PTM_GAMMA_CARBOXYLATION_HYPUSINE_FORMATION_AND_ARYLSULFATASE_ACTIVATION ES = −0.493 NES = −1.3 Nom. p−val= 0.125 FWER= 1 FDR= 0.208
 Gene Set 982 : REACTOME_PURINE_METABOLISM ES = −0.474 NES = −1.67 Nom. p−val= 0.0184 FWER= 0.906 FDR= 0.073
 Gene Set 1058 : REACTOME_PYRIMIDINE_METABOLISM ES = −0.62 NES = −1.61 Nom. p−val= 0.00759 FWER= 0.963 FDR= 0.0756
 Gene Set 932 : REACTOME_RAP1_SIGNALLING ES = −0.514 NES = −1.27 Nom. p−val= 0.2 FWER= 1 FDR= 0.226
Gene Set 861 : REACTOME_RAS_ACTIVATION_UOPN_CA2_INFUX_THROUGH_NMDA_RECEPTOR ES = −0.66 NES = −1.5 Nom. p−val= 0.0398 FWER= 0.996 FDR= 0.106
 Gene Set 915 : REACTOME_RECYCLING_PATHWAY_OF_L1 ES = −0.544 NES = −1.68 Nom. p−val= 0.00615 FWER= 0.889 FDR= 0.0737
 Gene Set 718 : REACTOME_REGULATION_OF_APOPTOSIS ES = −0.334 NES = −1.34 Nom. p−val= 0.182 FWER= 1 FDR= 0.184
 REACTOME_REGULATION_OF_GLUCOKINASE_BY_GLUCOKINASE_REGULATORY_PROTEIN ES = −0.361 NES = −1.28 Nom. p−val= 0.191 FWER= 1 FDR= 0.225
 Gene Set 654 : REACTOME_REGULATION_OF_HYPOXIA_INDUCIBLE_FACTOR_HIF_BY_OXYGEN ES = −0.45 NES = −1.52 Nom. p−val= 0.0558 FWER= 0.994 FDR= 0.0976
REACTOME_REGULATION_ OF_INSULIN_LIKE_GROWTH_FACTOR_IGF_ACTIVITY_BY_INSULIN_LIKE_GROWTH_FACTOR_BINDING_PROTEINS_IGFBPS ES = −0.684 NES = −1.53 Nom. p−val= 0.0153 FWER= 0.993 FDR= 0.0952
 : REACTOME_REGULATION_OF_INSULIN_SECRETION_BY_GLUCAGON_LIKE_PEPTIDE1 ES = −0.509 NES = −1.52 Nom. p−val= 0.0101 FWER= 0.995 FDR= 0.0999
 Gene Set 805 : REACTOME_REGULATION_OF_INSULIN_SECRETION ES = −0.44 NES = −1.45 Nom. p−val= 0.014 FWER= 0.999 FDR= 0.122
 Gene Set 588 : REACTOME_REGULATION_OF_KIT_SIGNALING ES = −0.667 NES = −1.59 Nom. p−val= 0.0134 FWER= 0.976 FDR= 0.0792
 Gene Set 923 : REACTOME_REGULATION_OF_SIGNALING_BY_CBL ES = −0.588 NES = −1.39 Nom. p−val= 0.107 FWER= 1 FDR= 0.151
 Gene Set 938 : REACTOME_REGULATION_OF_WATER_BALANCE_BY_RENAL_AQUAPORINS ES = −0.598 NES = −1.7 Nom. p−val= 0.00188 FWER= 0.841 FDR= 0.0746
 Gene Set 705 : REACTOME_RESPONSE_TO_ELEVATED_PLATELET_CYTOSOLIC_CA2_ ES = −0.623 NES = −1.75 Nom. p−val= 0 FWER= 0.721 FDR= 0.0726
 : REACTOME_RIG_I_MDA5_MEDIATED_INDUCTION_OF_IFN_ALPHA_BETA_PATHWAYS ES = −0.423 NES = −1.62 Nom. p−val= 0.0296 FWER= 0.955 FDR= 0.0765
 Gene Set 619 : REACTOME_RIP_MEDIATED_NFKB_ACTIVATION_VIA_DAI ES = −0.701 NES = −1.57 Nom. p−val= 0.0152 FWER= 0.987 FDR= 0.0857
 Gene Set 627 : REACTOME_RORA_ACTIVATES_CIRCADIAN_EXPRESSION ES = −0.442 NES = −1.25 Nom. p−val= 0.26 FWER= 1 FDR= 0.241
 Gene Set 831 : REACTOME_SEMA4D_IN_SEMAPHORIN_SIGNALING ES = −0.574 NES = −1.65 Nom. p−val= 0.0118 FWER= 0.924 FDR= 0.0726
 : REACTOME_SEMA4D_INDUCED_CELL_MIGRATION_AND_GROWTH_CONE_COLLAPSE ES = −0.51 NES = −1.67 Nom. p−val= 0.0359 FWER= 0.896 FDR= 0.072
 Gene Set 832 : REACTOME_SEMAPHORIN_INTERACTIONS ES = −0.577 NES = −1.76 Nom. p−val= 0.00193 FWER= 0.709 FDR= 0.0728
 Gene Set 895 : REACTOME_SHC_MEDIATED_CASCADE ES = −0.622 NES = −1.46 Nom. p−val= 0.0273 FWER= 0.999 FDR= 0.117
 Gene Set 858 : REACTOME_SIGNAL_AMPLIFICATION ES = −0.575 NES = −1.59 Nom. p−val= 0.0113 FWER= 0.979 FDR= 0.0798
 Gene Set 911 : REACTOME_SIGNAL_TRANSDUCTION_BY_L1 ES = −0.54 NES = −1.69 Nom. p−val= 0.012 FWER= 0.867 FDR= 0.0757
 Gene Set 642 : REACTOME_SIGNALING_BY_BMP ES = −0.51 NES = −1.39 Nom. p−val= 0.102 FWER= 1 FDR= 0.151
 Gene Set 610 : REACTOME_SIGNALING_BY_EGFR_IN_CANCER ES = −0.393 NES = −1.74 Nom. p−val= 0.00594 FWER= 0.748 FDR= 0.0736
 Gene Set 604 : REACTOME_SIGNALING_BY_ERBB2 ES = −0.386 NES = −1.54 Nom. p−val= 0.0394 FWER= 0.993 FDR= 0.0931
 Gene Set 599 : REACTOME_SIGNALING_BY_ERBB4 ES = −0.382 NES = −1.46 Nom. p−val= 0.0717 FWER= 0.999 FDR= 0.118
 Gene Set 650 : REACTOME_SIGNALING_BY_FGFR_IN_DISEASE ES = −0.471 NES = −1.79 Nom. p−val= 0 FWER= 0.625 FDR= 0.0793 Y
 Gene Set 681 : REACTOME_SIGNALING_BY_FGFR_MUTANTS ES = −0.53 NES = −1.5 Nom. p−val= 0.0305 FWER= 0.998 FDR= 0.108
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 Gene Set 1054 : REACTOME_SIGNALING_BY_FGFR ES = −0.492 NES = −1.79 Nom. p−val= 0 FWER= 0.625 FDR= 0.0782 Y
 Gene Set 669 : REACTOME_SIGNALING_BY_FGFR1_FUSION_MUTANTS ES = −0.412 NES = −1.28 Nom. p−val= 0.199 FWER= 1 FDR= 0.224
 Gene Set 664 : REACTOME_SIGNALING_BY_FGFR1_MUTANTS ES = −0.526 NES = −1.41 Nom. p−val= 0.0787 FWER= 1 FDR= 0.14
 Gene Set 907 : REACTOME_SIGNALING_BY_ILS ES = −0.596 NES = −1.71 Nom. p−val= 0.00786 FWER= 0.81 FDR= 0.0755
 Gene Set 981 : REACTOME_SIGNALING_BY_INSULIN_RECEPTOR ES = −0.394 NES = −1.47 Nom. p−val= 0.0426 FWER= 0.999 FDR= 0.116
 Gene Set 575 : REACTOME_SIGNALING_BY_NODAL ES = −0.539 NES = −1.38 Nom. p−val= 0.0668 FWER= 1 FDR= 0.157
 Gene Set 973 : REACTOME_SIGNALING_BY_NOTCH ES = −0.356 NES = −1.56 Nom. p−val= 0.0276 FWER= 0.989 FDR= 0.0873
 Gene Set 636 : REACTOME_SIGNALING_BY_NOTCH1 ES = −0.397 NES = −1.58 Nom. p−val= 0.0217 FWER= 0.983 FDR= 0.0811
 Gene Set 775 : REACTOME_SIGNALING_BY_PDGF ES = −0.53 NES = −1.94 Nom. p−val= 0 FWER= 0.282 FDR= 0.114 Y
 Gene Set 564 : REACTOME_SIGNALING_BY_RHO_GTPASES ES = −0.568 NES = −1.78 Nom. p−val= 0 FWER= 0.669 FDR= 0.0754
 Gene Set 843 : REACTOME_SIGNALING_BY_ROBO_RECEPTOR ES = −0.49 NES = −1.46 Nom. p−val= 0.0827 FWER= 0.999 FDR= 0.117
 Gene Set 572 : REACTOME_SIGNALING_BY_SCF_KIT ES = −0.487 NES = −1.82 Nom. p−val= 0.00385 FWER= 0.56 FDR= 0.0724
 Gene Set 1016 : REACTOME_SIGNALING_BY_TGF_BETA_RECEPTOR_COMPLEX ES = −0.335 NES = −1.34 Nom. p−val= 0.198 FWER= 1 FDR= 0.185
 Gene Set 631 : REACTOME_SIGNALING_BY_THE_B_CELL_RECEPTOR_BCR ES = −0.519 NES = −2.11 Nom. p−val= 0.00384 FWER= 0.06 FDR= 0.0433
 Gene Set 569 : REACTOME_SIGNALLING_BY_NGF ES = −0.455 NES = −1.92 Nom. p−val= 0 FWER= 0.315 FDR= 0.102 Y
 Gene Set 645 : REACTOME_SIGNALLING_TO_ERKS ES = −0.432 NES = −1.59 Nom. p−val= 0.0464 FWER= 0.978 FDR= 0.0793
 Gene Set 652 : REACTOME_SIGNALLING_TO_P38_VIA_RIT_AND_RIN ES = −0.69 NES = −1.77 Nom. p−val= 0.00407 FWER= 0.681 FDR= 0.0733
 Gene Set 641 : REACTOME_SIGNALLING_TO_RAS ES = −0.524 NES = −1.79 Nom. p−val= 0.0118 FWER= 0.633 FDR= 0.0775
 Gene Set 823 : REACTOME_SLC_MEDIATED_TRANSMEMBRANE_TRANSPORT ES = −0.431 NES = −1.45 Nom. p−val= 0.0181 FWER= 0.999 FDR= 0.121
 : REACTOME_SMAD2_SMAD3_SMAD4_HETEROTRIMER_REGULATES_TRANSCRIPTION ES = −0.458 NES = −1.34 Nom. p−val= 0.19 FWER= 1 FDR= 0.184
 Gene Set 864 : REACTOME_SMOOTH_MUSCLE_CONTRACTION ES = −0.643 NES = −1.41 Nom. p−val= 0.104 FWER= 1 FDR= 0.142
 Gene Set 760 : REACTOME_STEROID_HORMONES ES = −0.559 NES = −1.37 Nom. p−val= 0.0571 FWER= 1 FDR= 0.165
 Gene Set 783 : REACTOME_STRIATED_MUSCLE_CONTRACTION ES = −0.754 NES = −1.33 Nom. p−val= 0.156 FWER= 1 FDR= 0.184
 Gene Set 567 : REACTOME_SYNTHESIS_OF_BILE_ACIDS_AND_BILE_SALTS ES = −0.496 NES = −1.24 Nom. p−val= 0.155 FWER= 1 FDR= 0.247
 Gene Set 660 : REACTOME_SYNTHESIS_OF_PA ES = −0.63 NES = −1.67 Nom. p−val= 0.0057 FWER= 0.91 FDR= 0.0738
 Gene Set 673 : REACTOME_SYNTHESIS_OF_PC ES = −0.46 NES = −1.26 Nom. p−val= 0.194 FWER= 1 FDR= 0.236
 Gene Set 665 : REACTOME_SYNTHESIS_OF_PIPS_AT_THE_PLASMA_MEMBRANE ES = −0.502 NES = −1.4 Nom. p−val= 0.11 FWER= 1 FDR= 0.144
 REACTOME_TAK1_ACTIVATES_NFKB_BY_PHOSPHORYLATION_AND_ACTIVATION_OF_IKKS_COMPLEX ES = −0.552 NES = −1.53 Nom. p−val= 0.0313 FWER= 0.993 FDR= 0.0931
 Gene Set 693 : REACTOME_TCR_SIGNALING ES = −0.738 NES = −1.66 Nom. p−val= 0.00581 FWER= 0.913 FDR= 0.0734
 Gene Set 606 : REACTOME_TERMINATION_OF_O_GLYCAN_BIOSYNTHESIS ES = −0.589 NES = −1.24 Nom. p−val= 0.195 FWER= 1 FDR= 0.248
 Set 657 : REACTOME_TGF_BETA_RECEPTOR_SIGNALING_ACTIVATES_SMADS ES = −0.442 NES = −1.82 Nom. p−val= 0.00416 FWER= 0.548 FDR= 0.0763
 REACTOME_THE_ROLE_OF_NEF_IN_HIV1_REPLICATION_AND_DISEASE_PATHOGENESIS ES = −0.716 NES = −1.76 Nom. p−val= 0.00572 FWER= 0.701 FDR= 0.0715
 REACTOME_THROMBIN_SIGNALLING_THROUGH_PROTEINASE_ACTIVATED_RECEPTORS_PARS ES = −0.6 NES = −1.71 Nom. p−val= 0 FWER= 0.817 FDR= 0.0762
 Gene Set 872 : REACTOME_THROMBOXANE_SIGNALLING_THROUGH_TP_RECEPTOR ES = −0.633 NES = −1.55 Nom. p−val= 0.0288 FWER= 0.99 FDR= 0.0898
 Gene Set 702 : REACTOME_TIE2_SIGNALING ES = −0.632 NES = −1.58 Nom. p−val= 0.0116 FWER= 0.983 FDR= 0.0812
 Gene Set 845 : REACTOME_TIGHT_JUNCTION_INTERACTIONS ES = −0.467 NES = −1.25 Nom. p−val= 0.187 FWER= 1 FDR= 0.247
 Gene Set 1023 : REACTOME_TOLL_RECEPTOR_CASCADES ES = −0.577 NES = −1.85 Nom. p−val= 0 FWER= 0.473 FDR= 0.0913 Y
 REACTOME_TRAF6_MEDIATED_INDUCTION_OF_NFKB_AND_MAP_KINASES_UPON_TLR7_8_OR_9_ACTIVATION ES = −0.406 NES = −1.55 Nom. p−val= 0.0316 FWER= 0.99 FDR= 0.0892
 Gene Set 942 : REACTOME_TRAF6_MEDIATED_NFKB_ACTIVATION ES = −0.457 NES = −1.31 Nom. p−val= 0.171 FWER= 1 FDR= 0.203
 Gene Set 803 : REACTOME_TRAFFICKING_OF_AMPA_RECEPTORS ES = −0.547 NES = −1.39 Nom. p−val= 0.0916 FWER= 1 FDR= 0.15
 Set 817 : REACTOME_TRAFFICKING_OF_GLUR2_CONTAINING_AMPA_RECEPTORS ES = −0.669 NES = −1.41 Nom. p−val= 0.0881 FWER= 1 FDR= 0.142
 REACTOME_TRANSCRIPTIONAL_ACTIVITY_OF_SMAD2_SMAD3_SMAD4_HETEROTRIMER ES = −0.405 NES = −1.27 Nom. p−val= 0.247 FWER= 1 FDR= 0.229
 REACTOME_TRANSCRIPTIONAL_REGULATION_OF_WHITE_ADIPOCYTE_DIFFERENTIATION ES = −0.52 NES = −1.85 Nom. p−val= 0 FWER= 0.48 FDR= 0.0864 Y
 Gene Set 962 : REACTOME_TRANSFERRIN_ENDOCYTOSIS_AND_RECYCLING ES = −0.49 NES = −1.3 Nom. p−val= 0.211 FWER= 1 FDR= 0.209
 Gene Set 763 : REACTOME_TRANSMEMBRANE_TRANSPORT_OF_SMALL_MOLECULES ES = −0.46 NES = −1.57 Nom. p−val= 0 FWER= 0.987 FDR= 0.0858
 Gene Set 711 : REACTOME_TRANSMISSION_ACROSS_CHEMICAL_SYNAPSES ES = −0.542 NES = −1.58 Nom. p−val= 0.00558 FWER= 0.984 FDR= 0.0829
 REACTOME_TRANSPORT_OF_GLUCOSE_AND_OTHER_SUGARS_BILE_SALTS_AND_ORGANIC_ACIDS_METAL_IONS_AND_AMINE_COMPOUNDS ES = −0.478 NES = −1.38 Nom. p−val= 0.033 FWER= 1 FDR= 0.157
 REACTOME_TRANSPORT_OF_INORGANIC_CATIONS_ANIONS_AND_AMINO_ACIDS_OLIGOPEPTIDES ES = −0.458 NES = −1.38 Nom. p−val= 0.0342 FWER= 1 FDR= 0.156
 Gene Set 581 : REACTOME_TRIF_MEDIATED_TLR3_SIGNALING ES = −0.435 NES = −1.61 Nom. p−val= 0.00994 FWER= 0.964 FDR= 0.0756
 Gene Set 637 : REACTOME_TRIGLYCERIDE_BIOSYNTHESIS ES = −0.429 NES = −1.44 Nom. p−val= 0.0568 FWER= 0.999 FDR= 0.127
 REACTOME_UNBLOCKING_OF_NMDA_RECEPTOR_GLUTAMATE_BINDING_AND_ACTIVATION ES = −0.631 NES = −1.34 Nom. p−val= 0.111 FWER= 1 FDR= 0.184
 Gene Set 1027 : REACTOME_VOLTAGE_GATED_POTASSIUM_CHANNELS ES = −0.635 NES = −1.5 Nom. p−val= 0.0152 FWER= 0.996 FDR= 0.105
 Gene Set 629 : REACTOME_YAP1_AND_WWTR1_TAZ_STIMULATED_GENE_EXPRESSION ES = −0.581 NES = −1.68 Nom. p−val= 0.0058 FWER= 0.895 FDR= 0.0722
 Gene Set 331 : SA_B_CELL_RECEPTOR_COMPLEXES ES = −0.539 NES = −1.58 Nom. p−val= 0.0365 FWER= 0.984 FDR= 0.0825
 Gene Set 335 : SA_CASPASE_CASCADE ES = −0.631 NES = −1.57 Nom. p−val= 0.041 FWER= 0.986 FDR= 0.086
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ES: enrichment score; Nom. p-val: nominal P value; FWER: family-wise error rate; FDR: false discovery rate. 
 
 
 
 Gene Set 357 : SA_MMP_CYTOKINE_CONNECTION ES = −0.765 NES = −1.44 Nom. p−val= 0.0373 FWER= 0.999 FDR= 0.126
 Gene Set 361 : SA_PTEN_PATHWAY ES = −0.443 NES = −1.26 Nom. p−val= 0.225 FWER= 1 FDR= 0.233
 Gene Set 362 : SA_TRKA_RECEPTOR ES = −0.671 NES = −1.69 Nom. p−val= 0.0155 FWER= 0.867 FDR= 0.076
 Gene Set 353 : SIG_BCR_SIGNALING_PATHWAY ES = −0.605 NES = −1.62 Nom. p−val= 0.0386 FWER= 0.948 FDR= 0.076
 Gene Set 333 : SIG_CD40PATHWAYMAP ES = −0.414 NES = −1.47 Nom. p−val= 0.061 FWER= 0.999 FDR= 0.116
 Gene Set 339 : SIG_CHEMOTAXIS ES = −0.558 NES = −1.63 Nom. p−val= 0.00994 FWER= 0.941 FDR= 0.0753
 Gene Set 341 : SIG_IL4RECEPTOR_IN_B_LYPHOCYTES ES = −0.55 NES = −1.56 Nom. p−val= 0.0383 FWER= 0.989 FDR= 0.0876
 Gene Set 350 : SIG_INSULIN_RECEPTOR_PATHWAY_IN_CARDIAC_MYOCYTES ES = −0.377 NES = −1.43 Nom. p−val= 0.0943 FWER= 1 FDR= 0.134
 Gene Set 352 : SIG_PIP3_SIGNALING_IN_B_LYMPHOCYTES ES = −0.611 NES = −1.59 Nom. p−val= 0.01 FWER= 0.978 FDR= 0.08
 Gene Set 334 : SIG_PIP3_SIGNALING_IN_CARDIAC_MYOCTES ES = −0.47 NES = −1.73 Nom. p−val= 0.0039 FWER= 0.768 FDR= 0.0731
 Gene Set 343 : SIG_REGULATION_OF_THE_ACTIN_CYTOSKELETON_BY_RHO_GTPASES ES = −0.605 NES = −1.73 Nom. p−val= 0.00385 FWER= 0.762 FDR= 0.0737
 Gene Set 345 : ST_ADRENERGIC ES = −0.551 NES = −1.52 Nom. p−val= 0.0191 FWER= 0.995 FDR= 0.0979
 Gene Set 354 : ST_B_CELL_ANTIGEN_RECEPTOR ES = −0.536 NES = −1.6 Nom. p−val= 0.0475 FWER= 0.971 FDR= 0.0778
 Gene Set 329 : ST_DIFFERENTIATION_PATHWAY_IN_PC12_CELLS ES = −0.541 NES = −1.6 Nom. p−val= 0.0224 FWER= 0.97 FDR= 0.0767
 Gene Set 332 : ST_ERK1_ERK2_MAPK_PATHWAY ES = −0.465 NES = −1.64 Nom. p−val= 0.0294 FWER= 0.94 FDR= 0.0743
 Gene Set 359 : ST_FAS_SIGNALING_PATHWAY ES = −0.478 NES = −1.85 Nom. p−val= 0 FWER= 0.476 FDR= 0.0899 Y
 Gene Set 338 : ST_G_ALPHA_I_PATHWAY ES = −0.525 NES = −1.53 Nom. p−val= 0.0205 FWER= 0.993 FDR= 0.094
 Gene Set 337 : ST_G_ALPHA_S_PATHWAY ES = −0.676 NES = −1.75 Nom. p−val= 0.00571 FWER= 0.733 FDR= 0.0741
 Gene Set 336 : ST_GA12_PATHWAY ES = −0.701 NES = −1.74 Nom. p−val= 0.00592 FWER= 0.743 FDR= 0.073
 Gene Set 348 : ST_GA13_PATHWAY ES = −0.445 NES = −1.42 Nom. p−val= 0.0733 FWER= 1 FDR= 0.135
 Gene Set 347 : ST_GAQ_PATHWAY ES = −0.384 NES = −1.3 Nom. p−val= 0.18 FWER= 1 FDR= 0.212
 Gene Set 344 : ST_GRANULE_CELL_SURVIVAL_PATHWAY ES = −0.507 NES = −1.47 Nom. p−val= 0.0484 FWER= 0.999 FDR= 0.114
 Gene Set 346 : ST_INTEGRIN_SIGNALING_PATHWAY ES = −0.585 NES = −1.9 Nom. p−val= 0 FWER= 0.346 FDR= 0.0887 Y
 Gene Set 355 : ST_INTERLEUKIN_4_PATHWAY ES = −0.563 NES = −1.55 Nom. p−val= 0.0301 FWER= 0.99 FDR= 0.0893
 Gene Set 358 : ST_JNK_MAPK_PATHWAY ES = −0.431 NES = −1.34 Nom. p−val= 0.174 FWER= 1 FDR= 0.183
 Gene Set 360 : ST_MYOCYTE_AD_PATHWAY ES = −0.602 NES = −1.52 Nom. p−val= 0.0281 FWER= 0.995 FDR= 0.098
 Gene Set 363 : ST_PHOSPHOINOSITIDE_3_KINASE_PATHWAY ES = −0.55 NES = −1.81 Nom. p−val= 0.00199 FWER= 0.571 FDR= 0.0744
 Gene Set 351 : ST_T_CELL_SIGNAL_TRANSDUCTION ES = −0.716 NES = −1.64 Nom. p−val= 0.0117 FWER= 0.935 FDR= 0.074
 Gene Set 330 : ST_TUMOR_NECROSIS_FACTOR_PATHWAY ES = −0.467 NES = −1.49 Nom. p−val= 0.0822 FWER= 0.998 FDR= 0.109
 Gene Set 356 : ST_WNT_BETA_CATENIN_PATHWAY ES = −0.603 NES = −1.66 Nom. p−val= 0.0172 FWER= 0.918 FDR= 0.0738
 Gene Set 342 : WNT_SIGNALING ES = −0.584 NES = −1.85 Nom. p−val= 0 FWER= 0.48 FDR= 0.0886 Y
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